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LIPID-BASED PACLITAXEL AND DOXORUBICIN NANOPARTICLES TO 
OVERCOME P-GP-MEDIATED DRUG RESISTANCE IN SOLID TUMORS 
 
Multidrug resistance (MDR) is a major obstacle limiting chemotherapeutic 
efficacy. The purpose of these studies was to investigate the potential application of 
injectable paclitaxel (PX) and doxorubicin (Dox)-loaded nanoparticles (NPs) engineered 
from oil-in-water microemulsion precursors for overcoming P-glycoprotein (P-gp)-
mediated drug resistance in solid tumors. 
An in-vitro study was performed to test whether the oil (stearyl alcohol and cetyl 
alcohol) used to make lipid nanoparticles could be metabolized. The results showed that 
the concentrations of the fatty alcohols within nanoparticles, which were quantitatively 
determined over time by gas chromatography, decreased to only 10-20% of the initial 
concentration after 15-24 h of incubation with horse liver dehydrogenase (HLADH) and 
NAD+ at 37ºC. Moreover, the surfactant Brij 78 (polyoxyethylene 20-sterayl ether) in the 
nanoparticles influenced the activity of the enzyme. 
Novel Cremophor EL-free paclitaxel-loaded nanoparticles were developed using 
experimental design combining Taguchi array and sequential simplex optimization. The 
resulting PX G78 and PX BTM NPs were stable at 4ºC over five months and in PBS at 
37ºC over 102 h. Release of PX from PX NPs was slow and sustained without initial burst 
release. Interestingly, PX BTM NPs could be lyophilized without cryoprotectants and 
without changing any physiochemical properties and bioactivities. Cytotoxicity studies in 
breast cancer MDA-MB-231 cells showed that PX NPs have similar anti-cancer activities 
compared to Taxol. Optimized Dox-loaded NPs were prepared using an ion-pair agent, 
sodium tetradecyl sulfate (STS), to mask Dox charge and to enhance its entrapment in 
NPs.  
In-vitro cytotoxicity studies were carried out in both sensitive and resistant human 
cancer cells treated with PX and Dox-loaded NPs. All of drug-loaded NPs decreased IC50 
values by 6-13-fold in resistant cells compared to free drugs. A series of in-vitro assays 
were used to understand the underlying mechanisms. The results, in part, showed that the 
NPs inhibited P-gp and transiently depleted ATP, leading to enhanced uptake and 
prolonged retention of the drugs in P-gp-overexpressing cancer cells. 
Finally, in-vivo anti-cancer efficacy studies were performed using pegylated PX 
BTM NPs after intravenous (i.v.) injection and showed marked anti-cancer efficacy in 
nude mice bearing resistant NCI/ADR-RES tumors versus all control groups. These results 
 
suggest that NPs may be used to both target drug and biological mechanisms to overcome 
MDR. 
 
  
KEYWORDS: Nanoparticles, Cancer, Enhanced permeability and retention (EPR) effect, 
Experimental design, ATP 
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Chapter 1 
 
Introduction and statement of problem 
 
Cancer is a leading cause of death worldwide. The disease accounted for 7.9 
million deaths (or around 13% of all deaths worldwide) in 2007 [1]. Over 85% of human 
cancers are solid tumors. Surgery and irradiation are the initial treatments for most cancers. 
However, when tumor becomes metastatic, chemotherapy plays a major role, especially for 
the management of recurrent disease.  
There are a number of agents with established single-agent activity against cancer, 
with the anthracyclines [2] and taxanes [3] generally considered the most active. Selection 
of agents for treatment is a process relied on the patient. The relative benefits and toxicities 
of individual anti-cancer agent or combinations must be considered as well as the treatment 
history and clinical status of the patient. Toxicity is one of the most critical issues in 
chemotherapy since most anti-cancer agents lack selective efficacy in cancer tissue. For 
example, the process of development of chemotherapy in endometrial cancer is slow 
probably because of the toxicity of anti-cancer agents. Another problem with conventional 
chemotherapy pertains to the challenge of delivery. The effectiveness of cancer 
chemotherapy in solid tumors depends on adequate delivery of therapeutic agents to tumor 
cells. The biological properties of the solid tumor, which limit the penetration of drugs into 
neoplastic cells distant from tumor vessels, include abnormal and heterogeneous tumor 
vasculature, interstitium, interstitial fluid pressure (IFP), and cell density. However, even if 
anti-cancer drugs are located in the tumor interstitium, they can turn out to be of limited 
efficacy because cancer cells are able to develop mechanisms of resistance. Drug 
resistance has emerged as a major obstacle limiting the therapeutic efficacy of 
chemotherapeutic agents. These mechanisms allow tumors to evade chemotherapy. For 
example, multidrug resistance is one of the most important problems in chemotherapy. 
MDR could be due to the overexpression of the plasma membrane P-glycoprotein, which 
is capable of effluxing various anti-cancer drugs, such as doxorubicin and paclitaxel, out of 
the cells. P-gp inhibitors, e.g. verapamil or cyclosporin A, have been developed to 
overcome P-gp-mediated MDR. However, P-gp inhibitors do not have good selectivity and 
also block normal cell function of P-gp, for example, intestines and the blood-brain barrier, 
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and therefore increase toxicity. A refinement of this concept is the incorporation of both 
the therapeutic drug and the P-gp inhibiting agent into the same drug carriers, e.g. 
nanoparticles, for simultaneous delivery into the cell. 
Nanoparticles have been developed to enhance the intracellular concentration of 
drugs in cancer cells while avoiding toxicity in normal cells using both passive and active 
targeting. The basic rational of nanoparticle delivery is attributed to their nanometer size 
ranges. The nano-size particles can pass through leaky and hyperpermeable tumor 
vasculature and accumulate in the tumor vicinity utilizing the ‘enhanced permeability and 
retention effect’ (EPR effect). The tumor interstitium is also characterized by the absence 
of an anatomically well-defined functioning lymphatic network. Therefore, the clearance 
of nanoparticles via lymphatics is generally seriously compromised in neoplastic tissues so 
that an additional retention of nanoparticles in the tumor interstitium has been observed. 
This particular concept known as the “EPR effect” results in intratumoral drug 
accumulation which is even higher than that observed in plasma and other tissues. In 
addition to passive targeting by the EPR effect, active targeting may also be pursued by 
targeting nanoparticles with a tumor-cell specific ligand. More importantly, it has been 
suggested that nanoparticles may be able to circumvent P-gp-mediated resistance. The 
mechanisms of carriers to overcome P-gp have been proposed based on various drug 
delivery systems, including N-(2-hydroxypropyl)methacrylamide (pHPMA) drug 
conjugate, Pluronic micelles, hybrid lipid nanoparticles, liposomes and cyanoacrylate type 
nanoparticles. Reported mechanisms included enhancement of cellular uptake of drug via 
endocytosis and ion-pair formation, influence of function and expression of P-gp, and 
change of P-gp down-stream signaling pathways. 
Nanoparticles prepared in our lab from oil-in-water microemulsion precursors have 
been used to formulate anti-cancer drugs. Paclitaxel was entrapped into nanoparticles 
composed of emulsifying wax (E. wax) and Brij 78. These NPs were referred to as “PX 
E78 NPs”. These PX E78 NPs were shown to overcome P-gp-mediated drug resistance in-
vitro in a human colon adenocarcinoma cell line (HCT-15) and in-vivo in a nude mouse 
HCT-15 xenograft model. However, the entrapment of paclitaxel was low, about 50%, and 
also paclitaxel was quickly released from PX E78 NPs, about 100% release after 8 h at 
37oC. Intratumoral injection was used, instead of intravenous injection, for the in-vivo anti-
cancer efficacy studies mentioned above. The present research was focused on, 1) 
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developing new PX and Dox NPs suitable for i.v. injection to overcome P-gp-mediated 
drug resistance, 2) investigating the underlying mechanisms, and 3) performing in-vivo 
anti-cancer efficacy studies in nude mice bearing P-gp+ resistance tumors after i.v. 
injection. These studies are considered to be important as they could lead to a novel 
therapeutic strategy to overcome P-gp-mediated drug resistance and provide benefit to 
patients that otherwise may have limited therapeutic options.   
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Chapter 2 
 
Plan of research and research hypotheses 
 
The overall goal of this project is to investigate drug-loaded nanoparticles to 
overcome P-gp-mediated drug resistance in solid tumors in-vivo after intravenous 
injection. This research was guided by five main hypotheses: 
 
Hypothesis #1:  The lipids used to form lipid nanoparticles could be metabolized in-
vitro by horse liver alcohol dehydrogenase. 
Hypothesis #2:  Nanoparticles prepared from oil-in-water microemulsion precursors 
can be efficiently used to formulate paclitaxel and doxorubicin. 
Hypothesis #3:  Optimized nano-based paclitaxel and doxorubicin formulations will 
overcome P-gp-mediated tumor resistance in-vitro. 
Hypothesis #4:  Paclitaxel nanoparticles will have improved anti-tumor efficacy after 
intravenous injection compared to free PX solution in a nude mouse 
xenograft model bearing P-gp-overexpressing cancer cells.  
Hypothesis #5:  Epidermal growth factor receptor (EGFR)-targeted paclitaxel 
nanoparticles will increase the intracellular concentration of paclitaxel 
in cancer cells. 
 
To evaluate these hypotheses, the research plan described in Sections 2.1 to 2.5 was 
carried out. 
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2.1 Metabolism of fatty alcohols in lipid-based nanoparticles by horse liver alcohol 
dehydrogenase  
The main goal of this section was to investigate the metabolism of fatty alcohols in 
E78 NPs by horse liver alcohol dehydrogenase, a NAD-dependent enzyme. E78 NPs in 
this study were prepared from o/w microemulsion precursors using E. wax as the oil phase 
and Brij 78 as the surfactant. E. wax is composed of cetyl alcohol, stearyl alcohol and 
polysorbate 60. Hexadecanal and octadecanal, the intermediate products of cetyl and 
stearyl alcohols, were synthesized and used as the standard for the corresponding 
metabolic products of NPs. The metabolism of cetyl and stearyl alcohols in NPs was 
monitored by observing the increase in fluorescence intensity of NADH and by measuring 
the metabolized products using a quantitative gas chromatographic method using 
nonadecanoic acid as an internal standard. In parallel, NP size and turbidity were measured 
over time. Moreover, the influence of Brij 78 on the activity of the enzyme was tested.  
 
2.2 Formulations of paclitaxel and doxorubicin-loaded nanoparticles for i.v. 
injection 
The aims of this section were to, 1) develop PX-loaded NPs by combination of 
Taguchi approach and sequential simplex optimization, 2) develop Dox-loaded NPs by an 
ion-pair strategy, and 3) evaluate the cytotoxicity of PX-loaded NPs in sensitive cancer 
cells compared to Taxol. Experimental design by combining Taguchi approach and 
sequential simplex optimization was used to find new NP composition to entrap PX using 
Miglyol 812 or glyceryl tridodecanoate as the oil phase. Different ion-pair agents were 
tested to form a stable ion-pair complex with Dox. All developed PX and Dox-loaded NPs 
were fully characterized by particle size, zeta potential and stability. Entrapment 
efficiencies, drug loading and release profiles were also investigated. Cytotoxicity studies 
in breast cancer MDA-MB-231 cells were performed to evaluate the biological activity of 
PX NPs compared to Taxol®. 
 
2.3 In-vitro assessment of paclitaxel and doxorubicin nanoparticles to overcome 
P-gp-mediated resistance and possible mechanisms 
The main objective of  this section was to test  the potential abilities of PX NPs and 
Dox  NPs  to overcome P-gp-mediated  drug  resistance  in-vitro and  to elucidate  possible 
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mechanisms. To address P-gp-mediated drug resistance, in-vitro cytotoxicity studies were 
carried out based on PX and Dox-loaded NPs in two pairs of parental and MDR tumor cell 
lines. To understand the mechanism of inhibition of P-gp, a resistant cell line, NCI/ADR-
RES, was used for quantitative measurement of uptake and efflux studies with Dox NPs. 
Fluorescence microscopy was also used to observe the uptake of Dox NPs. In addition, the 
effects of blank NPs and excipients used to prepare NPs on both calcein AM uptake and 
ATP levels were studied. In parallel, membrane integrity and cell apoptosis were tested for 
cells treated with NPs and excipients. MTT assay, mitochondrial membrane potential and 
TEM analysis were performed to understand the influence of NPs on cell mitochondria.  
 
2.4 In-vivo anti-cancer efficacy of paclitaxel-loaded nanoparticles in mice bearing 
P-gp + resistant tumor 
The goal of this section was to evaluate the anti-cancer efficacy of PX NPs in mice 
bearing NCI/ADR-RES resistant tumors. New PX BTM NPs composed of Miglyol 812 as 
the oil phase and Brij 78 and D-alpha-tocopheryl polyethylene glycol 1000 succinate 
(TPGS) as the surfactants were used for these studies. P-gp+ resistant NCI/ADR-RES cells 
were implanted into female nude mice by subcutaneous injection. When tumors reached a 
defined size range, 4.5 or 2.25 mg PX/kg was administered by i.v. injection via the tail 
vain every 7 days for three weeks. Tumor size and mice weight were monitored over time.  
 
2.5 Formulation of transforming growth factor-α (TGF-α)-coated nanoparticles 
and in-vitro assessment for active targeting delivery 
The main objective of this section was to develop TGF-α-coated nanoparticles for 
EGFR-targeted delivery. TGF-α was conjugated to polyoxyethylene 100-stearyl ether (Brij 
700) and then the Brij 700-TGF-α conjugate was coated on the surface of nanoparticles. 
The coating efficiency of the Brij 700-TGF-α conjugate was measured after membrane 
separation of coated NPs with the free conjugate. To confirm the binding activity of Brij 
700-TGF-α conjugate, a competition binding assay of the conjugate was performed in 
A431 cells and compared to that of the free TGF-α. TGF-α-coated NPs were fluorescently 
labeled with BODIPY 558/568 C12 to determine the cellular uptake of TGF-α-coated NPs 
in EGFR-overexpressing ovarian NCI/ADR-RES cells.  
Copyright © Xiaowei Dong 2009 
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Chapter 3 
 
Background and significance 
 
3.1 Cancer chemotherapy 
Cancer remains one of the leading killers of humans in the world with the number 
of global cancer deaths projected to increase 45% from 2007 to 2030 in spite of the great 
efforts in the oncology field over the past two decades [1]. The majority of cancer-related 
deaths are a result of complications from recurrent or metastatic disease. When patients are 
diagnosed with cancer, they want to know whether their disease is local or has spread to 
other locations – metastasis, the process whereby cancer cells penetrate into lymphatic and 
blood vessels, circulate through the bloodstream, and then invade and grow in the 
secondary sites elsewhere. Once cancer becomes metastatic, chemotherapy as a systemic 
therapy is a major option for many patients. Moreover, chemotherapy may be the only 
systemically therapeutic option for some types of cancer, for example, for women with 
ER- and HER-2-negative, endocrine-resistant disease [4, 5]. The most active anti-cancer 
drugs are the taxanes and anthracyclines. However, cancer can generate drug resistance 
induced by chemotherapy. One of mechanisms for drug resistance is overexpression of a 
transmembrane protein P-gp. Paclitaxel and doxorubicin are well known to be P-gp 
substrates. In this present research, paclitaxel and doxorubicin were chosen as model drugs 
for the studies. 
 
3.1.1 Paclitaxel and its formulations 
Paclitaxel is one of the most effective anti-cancer agents against a broad spectrum 
of human cancer, including breast, lung, and ovarian caner. Paclitaxel is a natural taxane 
originally extracted from the bark of the Pacific yew tree, Taxus brevifolia [6]. The 
development of paclitaxel was suspended for over a decade because of problems in drug 
formulation, drug supply and controversies regarding the mechanism of action. A semi-
synthesis method was developed to provide the quantities needed for commercialization. In 
this method, a precursor of paclitaxel, 10-deacetyl-baccation III, from the common yew 
Taxus baccata was converted to paclitaxel by chemical synthesis. Horwtiz first
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reported the mechanism of action for paclitaxel in 1979 [7]. It is known that paclitaxel 
interferes with microtubule depolymerization in tumor cells [7-11] resulting in an arrest of 
the cell cycle in mitosis [12, 13] as well as induction of cell death by apoptosis [14, 15]. 
Interestingly, in addition to exerting its more widely accepted anti-cancer effects, 
paclitaxel has also been shown to lower tumor interstitial fluid pressure, decompress blood 
vessels and improve oxygenation in patients [16, 17]. The ability of paclitaxel to lower 
interstitial fluid pressure is a bonus effect of this chemotherapy agent as it has a potential 
to improve penetration of drugs into the interior tumor mass. However, as will be 
discussed in the next paragraph, the physical/chemical properties of paclitaxel present 
many challenges for formulations and advanced drug delivery systems.  
Currently, only two commercial dosage forms of injectable paclitaxel, Taxol® and 
Abraxane®, are available. The high lipophilicity and the high lattice energy of paclitaxel 
result in very limited aqueous solubility. The chemical structure of paclitaxel is shown in 
Figure 3.1. The solubility of paclitaxel has been reported as 0.7 μg/ml and 30 μg/ml [18, 
19]. It is difficult to formulate paclitaxel into a delivery system acceptable for human 
administration. After investigation of a large variety of excipients to enable parenteral 
administration of paclitaxel, the formulation approach using the polyoxyethylated castor 
oil derivative Cremophor EL represented the most viable option [20]. The first commercial 
formulation of paclitaxel was Taxol which contains a solvent system of Cremophor EL and 
dehydrated ethanol in a ratio of 50:50 (v/v) for intravenous infusion. A number of 
pharmacological, pharmacokinetic and pharmaceutical drawbacks are associated with this 
formulation. The pseudo-non-linear pharmacokinetic behavior of paclitaxel and serious 
side effects, such as hypersensitivity reactions, attributable to Cremophor EL have been 
reported [21-26]. In clinical therapy, high doses of anti-histamines and gluococorticoids 
are co-administered to manage these adverse effects, but this strategy has raised the 
possibility of additional pharmacokinetic and pharmacodynamic interactions with 
paclitaxel. The possible precipitation of paclitaxel after dilution in infusion fluids requires 
the presence of a 0.22 micron in-line filter in the administration set. The drawbacks 
presented by the presence of Cremophor EL in Taxol stimulated extensive research to 
develop alternative Cremophor EL-free formulations of paclitaxel.  
Several strategies were used to develop Cremophor EL-free paclitaxel 
formulations, including oral administration of paclitaxel [27], prodrugs and modified 
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taxoids, and various formulation techniques. To avoid vehicle-related adverse effects, 
Cremophor EL-free dosage forms of paclitaxel have been taken by using alternative 
cosolvent/surfactant systems, emulsion systems, microparticles, nanoparticles, 
cyclodextrins, and liposomes [28, 29]. The summary of alternative formulations of 
paclitaxel and their status in clinical development is presented in Table 3.1. Among them, 
Abraxane is the first Cremophor EL-free paclitaxel product approved by the FDA for the 
treatment of relapsed breast cancer or as second-line therapy in metastatic breast cancer in 
2005. This novel formulation is prepared by high-pressure homogenization of paclitaxel in 
the presence of human serum albumin at a concentration of 4.5%, similar to that of 
albumin concentration in the blood, resulting in a nanoparticle colloidal suspension with a 
mean particle diameter of 130-150 nm [30]. The results of a multicenter phase II trial of 
Abraxane at a maximum tolerated dose of 300 mg/m2/week on metastatic breast cancer 
patients showed no severe hypersensitivity reactions without premedication [31]. Another 
phase III trial on patients with metastatic breast cancer demonstrated that Abraxane 
significantly improved response rates compared with Taxol [32]. However, in this phase 
III trial, Abraxane did not show a statistically significant difference on median survival 
compared to Taxol for the patients with metastatic breast cancer receiving first-line 
therapy. Thus, it is true that Cremophor EL-free formulation of paclitaxel do have certain 
advantages in cancer therapy in that the side effect caused by Cremophor EL was 
eliminated; however, it is still unknown as to whether this formulation will improve the 
life-span of patients [28]. It is also worthy to be noted that Abraxane costs over $4200 per 
dose. Therefore, alternative and cost-effective formulations of paclitaxel are still needed 
for novel therapeutic opportunities in cancer.  
 
3.1.2 Doxorubicin and its formulations 
Doxorubicin is one of the first identified anthracyclines and was isolated from the 
pigment-producing Streptomyces peucetius in the 1960s. It is also known as Adriamycin 
and hyrdoxydaunorubicin. The structure of doxorubicin is shown in Figure 3.2. 
Doxorubicin is an essential component in the treatment of a wide variety of cancers, 
including hematological malignancies, many types of carcinoma and soft tissue sarcomas. 
The exact mechanisms of action of doxorubicin in cancer cells remain a matter of 
controversy despite extensive clinical utilization. In general, it is thought that intercalation 
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of doxorubicin into DNA base pairs inhibits the progression of the enzyme, topoisomerase 
II, to stabilize topoisomerase II complex and eventually impedes DNA resealing. The 
resulting DNA fragmentation leads to cell death [33-35]. However, the clinical use of 
doxorubicin soon proved to be hampered by such serous problems as the development of 
resistance in tumor cells or toxicity in healthy tissues. Notably, the main limitation of 
doxorubicin is chronic cardiotoxicity, leading to congestive heart failure.   
The development of effective approaches to limit cardiac toxicity while 
maintaining anti-cancer efficacy of doxorubicin has become a focus in recent years. 
Basically, the efforts were made to either develop tumor-targeted formulations and/or 
develop new analogs. The rationale to use the formulation strategy to reduce cardiac 
toxicity is based on the study of the mechanism by which doxorubicin induces 
cardiotoxicity. Studies have shown that cardiomyocytes are more susceptible than other 
tissues to apoptosis induced by doxorubicin because cardiomyocytes exhibit different 
enzyme expression and antioxidant properties [36-38]. For example, cardiomyocytes 
expresses low levels of catalase and undergo inactivation of selenium-dependent 
glutathione (GSH)-peroxidase-1 after exposing to doxorubicin. This inactivation could 
eliminate an important defense against doxorubicin [37, 38]. Doxorubicin itself dose not 
have tumor-targeting properties. Tumor-targeting delivery could be achieved by putting 
tumor-specific ligands on colloidal carriers such as nanoparticles or liposomes containing 
doxorubicin to achieve active targeting delivery, or by using such carriers themselves 
which have been shown under optimized conditions to preferentially distribute to tumors 
(passive targeting delivery). Currently, there are several doxorubicin formulations based on 
targeting delivery on the market or in clinical trials. Two main liposomal formulations of 
doxorubicin have been marketed: a sterically stabilized polyethyleneglycol (PEG)-coated 
liposomal formulation, Doxil® (Caelyx® in Europe) and a non-pegylated liposomal 
formulation, Lipodox®. In a clinical phase III trial in first-line treatment of women with 
metastatic breast cancer, the liposomal formulation Caelyx showed comparable efficacy 
and significantly reduced cardiac toxicity as compared with free doxorubicin [39]. Ten 
patients of the 254 patients received Caelyx 50 mg/m2 (every 4 weeks) developed 
cardiotoxicity versus 48 patients of the 255 patients received doxorubicin 60 mg/m2 (every 
3 weeks). The success of Caelyx may depend on passive targeting delivery of liposomes by 
taking advantage of the EPR effect. This effect will be discussed in greater details in the 
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sections below. Another interesting approach is active targeting delivery. Although this 
approach is attractive, so far only one such formulation of doxorubicin, N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin-galactosamine (PK2, 
FCE28069), has progressed into a phase I trial designed to treat hepatocellular carcinoma 
or secondary liver disease. PK2, bearing a galactosamine residue as a ligand that is 
recognized by the hepatic asialoglycoprotein receptor, showed evidence of clinical activity 
and induced no or considerably less severe cardiotoxicity than equivalent doses of free 
doxorubicin in rats [40, 41]. To date, no doxorubicin analogs have been shown to have 
clearly superior activity compared with doxorubicin. Liposomal formulations of 
doxorubicin are currently the best known alternative to improve the therapeutic index and 
spectrum of activity of doxorubicin with less cardiotoxicity in clinical practice.  
 
3.2 Barriers in chemotherapy for the treatment of solid tumors 
The development of therapeutic drugs against cancer has been focused on finding 
innovative approaches to selectively deliver anti-cancer drugs to solid tumors, while 
minimizing injury to healthy tissues. However, the efforts are confronted by physiological 
barriers at the tumor level and drug resistance at the cellular level. 
 
3.2.1 Tumor Physiological - tumor-level barriers for drug delivery in solid tumors 
Physiological characteristics of solid tumors related to drug delivery include, 1) 
abnormal blood vessel architecture and function, 2) interstitial fluid pressure, also known 
as interstitial hypertension, and 3) lack of lymphatics [42, 43]. Unlike normal 
microvessels, tumor vessels resulting from angiogenesis are dilated, tortuous and 
heterogeneous in their spatial distribution [44-46]. The flow of blood through tumor 
vessels varies according to tumor types and microenvironment so that the penetration of 
drugs in solid tumors is difficult. The disorganized structure of solid tumors causes poor 
drug delivery to the central region in large tumors. Nonetheless, large inter-endothelial 
junctions, increased numbers of fenestrations and abnormal basement membrane are often 
found in tumor vessels. The “leakiness” of tumor vessels generates gap openings that are 
significantly larger than those observed in normal tissues [47-50]. This vascular 
permeability in solid tumors leads one to develop tumor targeted-carriers that are small 
enough to enter through tumor vascular openings without passing through those in normal 
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tissues. The abnormal structure and function of blood and lymphatic vessels in solid 
tumors cause IFP elevation whereas IFP in normal tissues is around zero mmHg. An 
increase in tumor IFP reduces the transcapillary pressure gradient from the vascular 
compartment to interstitial space of tumors [51]. Furthermore, uniform elevation of IFP 
results in a negligible flow inside tumors [52]. Thus, the uniformly elevated IFP impedes 
the delivery of therapeutic drugs both across the blood vessel wall and interstitium in solid 
tumors. Studies have shown that there are no functional lymphatic vessels inside solid 
tumors [53-55]. Functional lymphatic vessels are present in the tumor margin and the peri-
tumoral tissue to mediate tumor growth and metastases. The lack of lymphatics in tumors 
reduces the effective outflow of interstitial fluid, partially contributing to the increase of 
tumor IFP. However, the positive aspect of the absence of lymphatics for drug delivery is 
that drugs can not be drained out of tumors via the lymphatic system once they locate 
inside tumors. Moreover, since a blood supply is crucial for growth, tumor cells have the 
ability to recruit new blood vessels in various ways through a process called angiogenesis. 
The fact that a survival of tumor critically depends on its blood supply provides a common 
opportunity for the destruction of solid tumors if drug concentrations in the bloodstream 
remain high for an appropriate period.  
 
3.2.2 Multidrug resistance – cell-level barriers for drug delivery in solid tumors 
Therapeutic drugs will face another big barrier, drug resistance, after they penetrate 
in tumors. Multidrug resistance remains the main cause of the failure of the use of 
conventional chemotherapy to treat common solid tumors [56]. Frequently, resistance is 
intrinsic to the cancer, but as therapy becomes more and more effective, acquired 
resistance has also become common. A variety of mechanisms contribute to acquired drug 
resistance to a broad range of anti-cancer drugs including, 1) expressing one or more 
energy-dependent transporters that bind to and efflux anti-cancer drugs from cells, leading 
to insensitivity to drug-induced apoptosis [57], 2) altered targets, and 3) induction of drug-
detoxifying mechanisms [58]. A summary on the reported mechanisms of drug resistance 
is presented in Figure 3.3.  Among them, overexpression of drug transporters is the most 
common reason. P-glycoprotein is the important and best-known membrane transporter 
involved in MDR. The focus of this research is P-gp-mediated MDR.  
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3.2.2.1 P-glycoprotein 
The initial MDR was reported in the late 1960s and early 1970s. Drug-resistant 
mammalian cell lines were then established for studying this phenomenon. A common 
feature of these drug resistant cell lines was the overexpression of P-gp when compared to 
the drug sensitive parent cell lines [59, 60]. In humans, two closely related genes, MDR1 
and MDR2 or MDR3, encode highly homologous P-gp. However, only the MDR1 gene 
has been linked to the MDR. The MDR1 gene is highly expressed in many clinically 
resistant tumors. In some cases its expression at diagnosis has been proven to be an 
adverse prognostic factor. In other cases, MDR1 appeared after relapse from remission, 
suggesting that P-gp was a survival mechanism in a subclone of cancer cells that 
eventually regrew [61-66]. Studies in leukemias, myelomas and some childhood cancers 
showed that P-gp expression correlated with poor response to chemotherapy. Moreover, 
the early clinical trials testing P-gp modulation in acute leukemia in the presence of P-gp 
modulators resulted in clinical relapse and reduction of P-gp expression [67, 68]. These 
clinical evidences demonstrated that P-gp plays a significant role in clinical drug 
resistance.  
P-gp is an ATP-dependent transmembrane transporter which can transport a broad 
range of structurally unrelated compounds out of the cells. The human P-gp is a 170 kDa 
protein containing 1280 amino acids. The topology of P-gp was proposed to contain 12 
transmembrane domains with 6 extracellular loops and 2 hydrophilic regions (ATP-
binding domains) containing nucleotide-binding domains which are characteristics of the 
ATP-binding cassette (ABC) family of transporters (Figure 3.4.) [69-72]. P-gp is expressed 
at significant levels in human normal tissues, such as the biliary canaliculi of the liver, the 
proximal tubules of the kidneys, the small intestine, colon and adrenal cortex [73, 74]. The 
activity of P-gp in normal tissues suggested an important role in transepithelial transport to 
prevent cytotoxic compounds in the environment and diet from entering the body, although 
the physiological role of P-gp still is a subject of speculation. The studies on P-gp 
knockout mice showed that P-gp had no essential physiological function on fertility. The 
mice grew and developed into adulthood normally. However, these mice were very 
sensitive to MDR-related anti-cancer drugs. Moreover, more of these drugs accumulated in 
the central nervous systems of the mice, indicating a major role of P-gp at the blood-brain 
barrier [75-77].  
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P-gp can remove many different hydrophobic drugs from cells to decrease 
intracellular accumulation of anti-cancer drugs. Drugs may be pumped out by P-gp as they 
enter the plasma membrane, or even as they are inside the cells. These drugs include many 
of the commonly used natural-product anti-cancer drugs such as doxorubicin, vinblastine, 
etoposide and paclitaxel, as well as many commonly used pharmaceuticals ranging from 
anti-arrhythmics and anti-histamines to cholesterol-lowering statins and HIV protease 
inhibitors [78]. Although the detailed mechanism of drug efflux by P-gp is unknown, the 
predicted transport cycle of P-gp involves the change of structure of ATP-binding domains 
after binding of drug substrates, stimulation of ATP hydrolysis, and rearrangement of P-gp 
shape caused by ATP binding and hydrolysis. The final step involving the conformational 
change of P-gp results in the release of the drug into the extracellular space. ATP 
hydrolysis is necessary for resetting of P-gp [79].  
 
3.2.2.2 Strategies to overcome P-gp-mediated drug resistance 
The strategies to overcome P-gp-mediated resistance can be summarized as 
follows: 1) modification of chemotherapy regimens. Non-cross-resistant chemotherapeutic 
regimens utilize the largest number of active agents at the highest doses possible, assuming 
that mutations conferring drug resistance will not convey resistance to all of the agents in 
the regimen, and, also, high-dose chemotherapy regimens could be given to cancer 
patients. This approach assumes that despite resistance to standard doses of anti-cancer 
drugs, a dose-response relationship still exists for these tumors and that high doses of 
chemotherapy might overcome this resistance; 2) protein and gene-directed therapy. The 
aim of this strategy is to specifically target overexpressing cells with anti-MDR1 antisense 
oligonucleotides, anti-MDR1 ribozymes or anti-MDR1 monoclonal antibodies. One of the 
most recent developments in cancer gene therapy is the transduction of small interfering 
RNA (siRNA). Some issues are associated with these approaches. For example, anti-
MDR1 antibodies, such as MRK-16, also may target MDR1-expressiong cells in normal 
tissues although it is specific for human P-gp. Thus, the potential to lead to unacceptable 
toxicities could be missed in a murine model. Moreover, anti-MDR1 antibody and anti-
MDR1 ribozymes encountered the problems related to effective delivery to tumors; 3) 
development of new anti-cancer drugs which are not substrates of P-gp. The modified 
drug analogues can affect the binding of analogues to P-gp and consequently P-gp can not 
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recognize the analogues. Two taxane analogues, DJ-927 (phase I) [80, 81] and Ortataxel 
(phase II) [82, 83], designed to overcome drug resistance have been evaluated in clinical 
trials. Other new taxane analogues such as BMS-184476 (phase I) [84, 85] and RPR 
109881A (phase II) [86, 87] also were claimed to have a broad spectrum of activity both in 
sensitive and resistant tumor cell lines; 4) the use of inhibitors of P-gp to reverse P-gp-
mediated drug resistance. This is an approach receiving the most attention. The inhibitors 
of P-gp can be classified into two groups. Some inhibitors can transport themselves, and 
then act as competitive antagonists. The others are not transported but affect P-gp function. 
The mechanism of reversal of P-gp by these agents is not fully understood at the moment; 
5) the use of drug carrier moieties and delivery systems to overcome P-gp-mediated drug 
resistance. Currently, several different formulations encapsulating anti-cancer drugs which 
are P-gp substrates are being developed. Paclitaxel vitamin E emulsion (TOCOSOL) 
containing a P-gp inhibitor TPGS in excipients was evaluated in a clinical phase II trial for 
drug resistance. The results showed promising efficacy when TOCOSOL was 
administrated weekly in patients with refractory cancers [28]. Partial reversal of drug 
resistance has been observed also when liposomal Dox was given to cell cultures [88]. A 
detailed discussion on this approach will be given in the sections below; 6) inhibition of P-
gp-mediated drug resistance using monoclonal antibodies or peptides [89-91]. Synthetic 
P-gp-derived peptides corresponding to fragments from the extracellular loops of the 
murine P-g were coupled to PEG and inserted into liposomes. These peptides have been 
shown to reverse MDR. After immunization with these peptide-loaded liposomes and 
treatment with Dox, an increase of 83% survival time was observed in mice inoculated 
with P388R cells. No auto-immune responses were detected in immunized mice. However, 
complete eradication of tumors did not occur. These results indicate a new approach to 
break immune tolerance towards MDR1 protein and consequently modulate sensitivity of 
resistant tumors to chemotherapy [89].  
The clinical success has been limited in the attempts to overcome P-gp-mediated 
drug resistance. A large number of new generations of drug analogues were developed as 
non P-gp substrates. However, most taxane analogues can not demonstrate greater 
therapeutic indexes in-vivo, or showed toxicity to normal tissues although they were 
proposed to be not P-gp substrates [85]. Another means to overcome P-gp-mediated drug 
resistance is to develop P-gp inhibitors. The study on the compounds including the calcium 
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channel blocker verapamil to reverse vincristine resistance in murine leukemia cells 
opened the door for the development of inhibitors of P-gp to overcome P-gp-mediated drug 
resistance [92, 93]. To date, clinical trials with the third generation inhibitors are ongoing, 
including trials with compounds LY335979, R101933 and XR9576. However, the 
therapeutic results from previous clinical trials using first- and second-generation 
inhibitors of P-gp have been generally negative or only modestly positive and have not 
fulfilled the promise of the preclinical data. There are probably two major reasons for the 
failure of many of these P-gp inhibitors to show beneficial effects. One of the reasons is 
that they are weak and nonspecific inhibitors. The requirement on high dose of inhibitors, 
e.g. > 10 µg verapamil, was not achievable in clinical trials. Additional toxicities of anti-
cancer drugs due to the inhibition of P-gp in normal tissues remain a concern for the more 
potent P-gp inhibitors. The other reason is a programmed pharmacokinetic drug interaction 
resulting from co-administration of P-gp inhibitors and anti-cancer drugs. A modest 
pharmacokinetic interaction between verapamil and doxorubicin in humans was observed 
[94]. Also, one clinical trail reported excessive vincristine neuropathy associated with the 
use of cyclosporin A to inhibit P-gp [95]. Increased toxicity of the anti-cancer drugs may 
occur due to both pharmacokinetic effects and inhibition of a protective function of P-gp in 
normal tissues. Certain third generation of P-gp inhibitors as mentioned above showed 
minimal pharmacokinetic interactions with anti-cancer drugs. However, the contribution of 
these inhibitors to reverse clinical drug resistance needs to be defined in clinical trials.  
 
3.3 Nano-based drug delivery systems for cancer 
Nanotechnology has a long history. The first description of nanoparticles, in 
scientific terms, is back to 1857 in a paper about the optical properties of nanometer-scale 
metals [96]. In pharmaceutical field, the development of the first nanocarrier dates back 
approximately 40 years, when the first example of a liposome was described [97]. 
However, the most important scientific advancements on development of nanoscale 
vehicles with distinct physical and biochemical properties for drug delivery applications 
have only taken place with the last two decades. In its strictest definition from the National 
Nanotechnology Initiative, nanotechnology refers to structures roughly in the 1 to 100 nm 
size in at least on dimension. Nanoparticles for the purpose of drug delivery are more 
commonly defined as submicron (<1 µm) particles. The most common examples of these 
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nanoparticles include polymeric nanoparticles, dendrimers, nanoshells, liposomes, lipid-
based nanoparticles, magnetic nanoparticles and virus nanoparticles. One of the most 
appealing properties of nanoparticles is their sizes, resulting in distinct properties that are 
not available from individual molecule alone or equivalent materials as a larger scale. 
Nanoparticles have the potential to improve the therapeutic index of currently available 
drugs by increasing drug efficacy, lowering drug toxicity, and achieving steady state 
therapeutic levels of drugs over an extended period of time. Nanoparticles can also 
improve drug solubility and drug stability, allowing the development of potentially 
effective new chemical entities that have been stalled during the preclinical or clinical 
development because of suboptimal pharmacokinetic or biochemical properties. Finally, 
nanoparticles may also facilitate the development of multifunctional systems for active 
targeting drug delivery. Nanoparticles are expected to benefit all branches of medicine. 
The focus of the remaining chapter will be to review the applications of nanoparticles for 
cancer chemotherapy.  
 
3.3.1 Nanoparticles for solid tumor delivery 
The effectiveness of cancer therapy in solid tumors depends on adequate delivery 
of the therapeutic agent to tumor cells. Many anti-cancer drugs have a marginal selectivity 
for malignant cells because they target the reproductive apparatus in cells having high 
proliferation rates. However, anti-cancer drugs having this mechanism of action result in 
high toxicities against rapidly dividing normal cells such as hair follicles, germ cells and 
hematopoietic cells. Other anti-cancer drugs are distributed non-specifically in the body 
where they affect cancer and normal cells. Therefore, the side effects associated with 
chemotherapy limit the dose achievable with the tumor and also result in suboptimal 
treatment due to excessive toxicities. Delivery of drugs to solid tumors also remains 
difficult because of the physiological barriers in solid tumors, as described in Section 3.2.1. 
Nanoparticles have emerged as one approach to overcome the lack of specificity of 
conventional drugs and delivery barriers in solid tumors [98-101]. The small physical 
dimensions of nanoparticles enable them to partially penetrate through biological and 
physiological barriers of tumors that are unique to tumors and normally impermeable for 
larger particles. By this way, passive targeting delivery to tumors could be achieved due to 
the physicochemical properties of a carrier and the pathophysiological condition of a 
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target. The flexible surface chemistry of nanoparticles also allows the ability to conjugate 
targeting ligands for active targeting delivery. Then ligand-coated nanoparticles may be 
specifically taken up by cancer cells by receptor-mediated endocytosis. A schematic 
representation for different mechanisms by which nanoparticles enhance drug delivery to 
solid tumors is shown in Figure 3.5. [101].  
 
3.3.1.1 Passive targeting delivery by EPR effect 
The role of tumor vasculature as a potential target for solid tumors has been 
elucidated since the late 1970’s. The studies exploited the ability of nanosize polymeric 
anti-cancer agents selectively to target tumor tissues due to extensive vascular leakage or 
permeability in tumor capillaries. Moreover, vascular permeability enhancing factors, such 
as bradykimin, nitric oxide and vascular endothelial growth factor, facilitate extravasation 
of macromolecular drugs within tumor tissues as well as surrounding normal tissues. 
Furthermore, an impaired lymphatic system in solid tumors leads to prolonged retention of 
macromolecules in tumor tissues. Thus, this enhanced permeability and retention effect of 
macromolecules in tumor tissues has been termed the EPR effect. Later, other nanosize 
anti-cancer drugs, such as the copolymer HPMA-doxorubicin conjugate [102], pegylated 
liposomal doxorubicin [103], and SMA-doxorubicin micelles [104, 105], showed selective 
accumulation of anti-cancer drugs in solid tumors. Treatment of solid tumors has 
undoubtedly been the main research area for nanoparticles because of the targeting 
advantage offered by EPR effect. In nanoparticle delivery research, the EPR effect 
becomes a hallmark concept that differentiates a tumor from normal tissue to make passive 
targeting delivery possible to solid tumors. 
For such a passive targeting mechanism to take place, physiochemical parameters 
of nanoparticles including particle size and surface properties are crucial. The desirable 
nanoparticles should have a certain particle size with long circulation. The leaky 
vasculature at the solid tumor site is a critical advantage in treating solid tumors with 
nanoparticles despite other impeding factors as described in Section 3.2.1. The pore cutoff 
size of extravasation through transvascular gaps in most experimental tumors is in the 
range between 380 nm and 780 nm depending on the tumor types, whereas the tight 
endothelial junctions of normal vessels typically are between 1 to 10 nm [47, 106]. It was 
proposed that transvascular transport of the particles in the tumors resulted from 
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interendothelial or transendothelial open junctions rather than by endothelial phagocytosis 
or vesicles. To achieve this extravasation in solid tumors, average particle size less than 
300 nm was suggested [47].  
Another important prerequisite for the passive targeting delivery is that the plasma 
concentration of the drug must remain high and long; that means, drug-coated 
nanoparticles must be sustained in the bloodstream long enough to reach or recognize solid 
tumors. Nanoparticles, unlike microspheres (> 1µm), are small enough to be dosed via i.v. 
administration. In the bloodstream, the major defense system of the body, 
reticuloendothelial system (RES), also known as mononuclear phagocytes system (MPS), 
could rapidly remove nanoparticles and becomes a major obstacle to long circulation of 
nanoparticles. The first step of clearance of nanoparticles by RES is opsonization in which 
nanoparticles recognized as foreign particles are coated with opsonin proteins to make 
them more visible to phagocytic cells. After opsonization, phagocytosis occurs to destruct 
or remove foreign materials from the bloodstream. Phagocytic cells mainly include 
Kupffer cells of the liver and macrophages of the spleen. A large number of researchers 
were motivated to develop “stealth” nanoparticles to avoid uptake of nanoparticles by the 
RES. It has been repeatedly demonstrated that the opsonization of hydrophobic particles 
occur more quickly than that of hydrophilic nanoparticles owing to the enhanced 
absorbability of blood serum proteins on hydrophobic surfaces [107, 108]. Modification of 
the nanoparticle surface with chains of hydrophilic and flexible polymers can shield 
nanoparticles from the opsonins and therefore prevent elimination by the cells of the RES. 
The polymer chains create a barrier layer to block the adhesion of opsonins and make the 
nanoparticles ‘invisible’ to phagocytic cells. The most commonly used polymers are PEG 
types, such as poly(ethylene oxide) and poly(propylene oxide). Polymers could be put on 
the nanoparticle surface by covalently grafting, entrapping, and adsorption. However, there 
are no absolute rules or methods available to completely and effectively block the 
opsonization of nanoparticles although research in this area has been on-going for over 30 
years. Modification of nanoparticle surface is complicated and case-dependent. For 
example, the study on biodegradable albumin nanoparticles showed that neutrally charged 
albumin nanoparticles reduced phagocytic uptake by macrophages in-vitro in comparison 
with charged particles, especially those with a positive charge. A further study on the in-
vivo distribution of albumin nanoparticles in rats indicated that blood circulation times and 
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organ accumulation was not influenced by surface charges of nanoparticles. Thus, the in-
vivo fate of albumin nanoparticles did not correlate with the in-vitro cell culture model 
[109]. Moreover, Polymer chains here create a barrier layer to block the adhesion of 
opsonins. The thickness of the layer is crucial but hard to control and varies within 
different types of nanoparticles and coating strategies. However, it is noteworthy that the 
effective stealth properties provided by these barrier layers depend largely on the PEG 
molecular weight, surface chain density and conformation [110]. For example, PEG chains 
are incorporated into liposomes using a PEG-lipid, a highly asymmetric amphiphile. 
However, generally, less than 10% of PEG2000-lipid can be incorporated in liposome 
without inducing vesicle micellularization [111]. The configuration of PEG layers changed 
from “mushroom” to “brush” depending on the density of PEG chains on the surface. It is 
considered that the optimal configuration for stealth nanoparticles is to create a PEG 
coating configuration that is somewhere between the mushroom and brush. A general 
guide for liposomes is to coat the liposomes with 3-5% (w/w) of PEG.  However, this 
guide may not apply in the case for other delivery systems as the configuration of PEG 
layers primarily depends on the surface properties of the colloidal delivery system. For 
example, “soft” surface nanoparticles, such as hydrogel nanoparticles and nanocapsules, 
make the PEG coating layers less effective [110]. Therefore, for different nanoparticles, 
the effective modification method needs to be developed individually based on the 
physicochemical properties of the nanoparticles.  
In addition to clearance of nanoparticles by phagocytosis, nanoparticles are also 
subjected to splenic filtration, a non-phagocytic uptake. The width of interendothelial cell 
slits of the spleen is about 200 nm to 500 nm [112]. A study of the biodistribution of 
polystyrene nanospheres (60 to 250 nm) coated or uncoated with hydrophilic polymers was 
carried out in rats. In this study, coating of nanospheres with hydrophilic polymers 
dramatically reduced uptake of particles by liver, regardless of particle sizes. However, 
coated nanospheres were sequestered by the spleen apparently depending on the particle 
size. The size and deformability of nanoparticles play critical roles in their clearance by 
this mechanism in human spleens. For rigid nanoparticles, the size to achieve long 
circulation should not exceed 200 nm. Otherwise, nanoparticles should be deformable 
enough to pass splenic filtration [113, 114].  
 21
Surface modification of nanoparticles using conventional chemicals could alter and 
tune their pharmacokinetic or pharmacodynamic properties, such as to increase the 
circulation time within the body. 
 
3.3.1.2 Active targeting delivery 
The basic principle of active targeting delivery is that the delivery of drugs to 
cancer cells or cancer-associated tissues can be selectively increased by associating the 
drugs with targeting ligands that bind to surface antigens or receptors that are either 
uniquely expressed or overexpressed in the target cells relative to normal tissues. Unlike 
passive targeting delivery discussed above which is due to the nature of the nanoparticles 
and the pathophysiology of solid tumors, active targeting delivery is based on specifically 
molecular recognition. When nanoparticles are targeted to the extracellular portion of 
transmembrane tumor antigens or receptors, they may be specifically taken up by cancer 
cells through receptor-mediated endocytosis. Nanoparticles are able to selectively carry 
higher payloads of anti-cancer drugs with fewer ligands to target cancer cells compared to 
other delivery systems such as active targeting drug-conjugate. The target receptor is an 
important key for targeting delivery. The receptor should be either selectively expressed or 
over-expressed in cancer cells compared to normal cells. The internalization of the ligand-
receptor binding complex and availability of the receptor after the first association with the 
ligands are also important selection criterions for the receptor. Overexpression of the 
receptor in normal tissues is an obstacle for targeting to cancer. For example, folic acid is a 
small molecule popularly used to target folic acid receptors in cancer cells. However, it 
was demonstrated that folic acid receptors are also expressed in normal tissues like 
placenta and kidneys. The clinical translation of this targeting delivery was impeded 
although folate-targeted nanoparticles showed effectiveness in several tumor models [115, 
116]. Thus, the search for new ligands for cancer targeting concentrates around specific 
receptors.   
To choose a ligand, it is now well accepted that the binding affinity, stability, the 
size of the ligand, and the density of the ligand on the surface of nanoparticles play a 
critical role for successful targeting [98, 117]. Antibodies [118], aptamer [119], peptide 
and small molecules [120] have been reported as targeting ligands for selective targeting 
delivery. The ligand could be attached to the surface of nanoparticles by covalent binding 
 22
or non-covalent binding [121]. Covalent binding is the general method in which ligands 
are bound to the surface of nanoparticles through hydrophobic anchors. To avoid steric 
barriers on the nanoparticle surface and to retain the binding activity of ligands, the 
hydrophobic anchors contain PEG moiety with high molecular weight and the ligands are 
coupled to the PEG terminus. One approach, via pre-insertion, is to functionalize 
nanoparticles by entrapping functionalized lipid-PEG into nanoparticles, and then the 
ligands are coupled to the surface of nanoparticles by a covalent bond. The other approach, 
via post-insertion, is to first conjugate functionalized lipid-PEG and the ligands, and then 
the conjugate is post-inserted into nanoparticles to form ligand-coated nanoparticles. 
Obviously, the final coupling reaction in the pre-insertion approach introduces a chance to 
alter the drug loading if components of nanoparticles are not stable during the reaction. 
However, the purification of the conjugate of lipid-PEG-ligand may be an issue in the post-
insertion, especially when using small molecules as the ligands, since the conjugate may 
have similar molecular weight and properties as with the lipid-PEG. Thus, the choice of 
method depends on the properties of nanoparticles and the ligands. However, there are 
several requirements for the coupling. In general, the desirable coupling approach should 
be simple, efficient and reproducible. The method should also not alter the binding affinity 
of the ligands, and not alter the drug entrapment efficiency and drug release profiles in a 
negative manner. Moreover, ligand-coated nanoparticles should be able to circulate a long 
time in the bloodstream to achieve appropriate targeting.   
Active drug targeting delivery is attractive but has not been extensively 
investigated in human clinical trials. There are very few clinical trials in this area although 
the proof of concept is established. Most of studies on active targeting delivery were 
performed using liposomes. In-vivo outcomes are quite dependent on all criteria as 
discussed above. Anti-MUG-1 immunoliposomal doxorubicin targeted to human MUC-1 
gene did not show improved efficacy in solid tumors compared to non-targeted liposomes 
although they were more effective in treating early lesions in both the pseudometastatic 
and metastatic models [122]. Other controversial results in this area are related to the 
question: Dose active targeting delivery increases tumor localization (accumulation)? 
Enhancement of tumor accumulation has been demonstrated in some studies, for example, 
liposomes coated with vasoactive intestinal peptide to target breast cancer [123], folate-
coated polyelectrolyte complex micelles to target folic acid receptors in solid tumors [124], 
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and peptide-coated liposomes to target EFGR [125]. However, in other studies, tumor 
accumulation was not different between targeted and non-targeted liposomes even though 
enhanced therapeutic efficacy was observed using the targeted liposomes. The explanation 
for the enhanced therapeutic efficacy includes the alteration of target caused by the active 
targeting of angiogenic homing peptide coated liposomes [126], the acceleration of cellular 
uptake of antibody-modified liposomes [118, 127] and effective penetration of sigma 
receptor-targeted siRNA nanoparticles in tumors [128]. In this research, TGF-α was chosen 
as a ligand to coat on the surface of nanoparticles to target EGFR in solid tumor cells.  
 
3.3.1.2.1 EGF receptor 
Overexpression of EGFR has been detected in more than 90% of human head and 
neck squamous cell carcinomas [129], and also is frequently detected in other major 
cancers of epithelial origin, including carcinomas of the lung, breast, prostate, ovary and 
bladder [130-132]. Increased expression of EGFR and its ligands in cancers often 
correlates with poor prognosis stemming from advanced disease [133]. EGFR has been a 
molecular target for cancer therapy as it is overexpressed in cancer cells and is a central 
element for cell proliferation, differentiation and apoptosis [134]. There are two general 
strategies to inhibit EGFR: antagonistic antibodies targeting the extracellular domains and 
small soluble tyrosine kinase inhibitors competing with ATP for binding to the catalytic 
domain [135].  
The EGFR is a 170 kDa cell surface transmembrane receptor with receptor tyrosine 
kinase activity. EGFR is one of the members in ErbB family which includes four closely 
related members: EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/HER3, and 
ErbB4/HER4. EGFR is characterized by a modular structure consisting of an extracellular 
ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular 
part harboring the highly conserved tyrosine kinase domain. Ligand binding induces 
homodimerization or heterodimerization and subsequently conformational change which 
triggers autophosphorylation of C-terminal tyrosines. It is phosphorylation of tyrosine 
residues that leads to a series of intracellular signaling events [130, 136]. After binding of 
the ligand to EGFR, the ligand-receptor complex enters cells by receptor-mediated 
endocytosis [137]. Activation of EGFR initiates to a multitude of signaling pathways such 
as the highly conserved MAP kinase pathway, phosphatidylionsitol-2-kinase pathway and 
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cytoplasmic tyrosine kinase c-Src signaling. These diverse cellular pathways lead to 
proliferation, migration, gene transcription, cell cycle progression and cell survival.  
EGFR-targeted drug delivery systems have been investigated for active targeting 
delivery because of the overexpression of EGFR in cancers. Radiopharmaceutical 111In-
labeled-EGF exhibited strong anti-cancer effects against MDA-MB-468 (EGFR+) breast 
cancer xenografts, and had modest inhibition of tumor growth against MCF-7 (EGFR-) 
breast cancer xenografts in comparison. The highest tumor localization and growth 
inhibition were achieved for small, nonestablished tumors [138]. Also, EGF was 
conjugated on copolymer micelles for active targeting delivery [139]. Confocal laser 
scanning microscopy revealed that EGF-conjugated micelles, labeled by the fluorescent 
probe CM-Dil, accumulated intracellularly in MDA-MB-468 cells after incubation for 2 h, 
whereas no detectable cell uptake was observed for the non-targeted micelles. It suggests 
that EGFR-targeted delivery formulation could enhance cellular uptake by the endocytosis 
pathway. EGFR-targeted liposomes have been developed using EGF [140], monoclonal 
antibody fragment of C225 [141], or a peptide ligand [125]. The antibody-conjugated 
drug-loaded liposomes showed greater cytotoxicity than the corresponding non-targeted 
liposomal drugs in EGFR-overexpressing cancer cells while equivalent potency was 
observed in cells that lacked EGFR overexpression. The biodistribution of peptide ligand-
mediated liposomes performed by using fluorescence imaging techniques demonstrated 
preferential accumulation of the liposomes in the tumor site, suggesting active targeting 
delivery in-vivo.  
 
3.3.1.2.2 TGF-α as a targeting ligand 
TGF-α is a biological active polypeptide containing 50 amino acids with a 
molecular weight of 5616 Da. TGF-α was first isolated from retrovirus-transformed cells 
[142] and specifically binds to the EGFR. The structure of TGF-α is represented in Figure 
3.6. The three disulfide bonds separate the amino acid sequence to three loops: A, B and C 
loops. The data from NMR analysis suggested that A and C loops and the C-terminal tail 
of TGF-α contain residues that form the major binding interface with the EGFR and that 
the N-terminal amino acids outside the A loop remain flexible in the receptor-bound 
species that make the N-terminal not play an important role in the receptor-ligand 
interaction [143, 144].   
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After TGF-α binding, ligand-occupied EGFR is rapidly internalized in a process 
termed ligand-induced endocytosis. TGF-α dissociates from EGFR in the early endosomes 
(pH= 5.9-6.0) very shortly after internalization, which favors receptor recycling and results 
in more potent mitogenic signaling. The recycling of EGFR to the cell surface will sustain 
the original ligand-binding ability of the cells [8]. Unlike TGF-α, EGF-EGFR complex 
remains stable in the mildly acidic early endosomes. Most of EGF is degraded in 
lysosomal compartment (pH= 5.0-6.0) thus reducing the cell surface content of the 
receptor and its signal capacity. This pH-dependent stability difference is attributed to the 
fate of EGFR during endocytosis. TGF-a may dissociate from EGFR at pH 7 whereas EGF 
may dissociate from EGFR at pH 5.5, according to the isoelectric point (pI) values of both 
ligands. Comparing TGF-α and EGF as the ligand for active targeting delivery, the use of 
TGF-α as a ligand will theoretically allow for retention of EGFR on the cell surface for 
targeting. The aberrant expression of TGF-α was associated with a highly aggressive 
phenotype in human colon cancer cell lines. In addition, TGF-α could be an autocrine for 
EGFR network [145, 146]. Thus, the possibility to stimulate proliferation of tumor cells by 
TGF-α is a concern. 
TGF-α levels in cancer patients are higher than those in healthy individuals. The 
concentration of TGF-α ranged from 210 to 740 pg/ml in 83 breast cancer patients as 
compared to a range from 120 to 207 pg/ml in 74 healthy individuals [147]. The 
endogenous TGF-α may not interfere with TGF-α-coated nanoparticles to bind with the 
receptors. In a study, human placental membranes were pre-incubated with human EGF or 
human TGF-α. The results indicated that the presence of these ligands in a membrane 
preparation did not affect the apparent number of binding sites, but only resulted in an 
increase in the apparent dissociation constant for EGFR [148]. Therefore, exogenous TGF-
α, like TGF-α coated on nanoparticles, could be able to bind with EGFR even in the 
presence of endogenous TGF-α.   
TGF-α has been used to target toxins to cancer cells overexpressing EGFR. In-vitro 
and in-vivo studies demonstrated that TGF-α-Pseudomonas exotoxin (PE40) exhibited 
cytotoxicity that correlated to the expression of EGF. The exotoxin caused only minimal 
damage to normal tissues despite the presence of EGFR on many normal cell types [149, 
150]. However, there are no reports in literatures examining the utilization of TGF-α for 
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targeting delivery of nanoparticles. Thus, we propose to deliver paclitaxel nanoparticles to 
breast tumors using TGF-α as a ligand to target cell surface EGFR. 
 
3.3.2 Lipid-based nanoparticles to formulate anti-cancer drugs 
Nanomedicine is based on nanotechnology to aim at developing effective clinical 
treatments. In cancer research, nanomedicine covers diagnostics, biosensors and drug 
delivery. There are many reviews written on nanoparticles used for drug delivery. Here, the 
following section will focus on the lipid-based nanoparticles and present some of their 
potential applications for anti-cancer drug delivery. The term lipid is taken in the general 
sense to include wax, glycerides and phospholipids.  
The innovations in combinatorial chemistry and high throughput screening focused 
on potency and high activity of small molecule anti-cancer drugs are leading to a shift of 
the properties of new chemical entities towards more lipophilic and poorly water-soluble 
molecules. As a result, about 40% of potential drug candidates never enter further 
development including a formulation development stage due to their poorly water 
solubility [151]. An urgent need has always existed for the safe and effective delivery of 
poorly soluble drugs. Water insolubility can be defined as more than 10,000 parts of water 
needed to dissolve one part of solute, corresponding to a solubility of <0.1 mg/ml. Drug 
insolubility is caused by either hydrophobicity impeding the drug to form hydrogen bonds 
with water or by a high lattice energy of the drug resulting in the ability to reduce 
intermolecular drug interactions in the solid state. Typically, hydrophobicity and crystal 
lattice energy are indicated by the octanol-water partition coefficient (P) and melting point 
(MP), respectively. The conventional formulation strategies for water-insoluble drugs 
include the conversion of a water-insoluble drug to a more soluble salt form, pH 
adjustment, the use of co-solvents, and inclusion complexation, i.e. the use of cyclodextrin 
[152]. However, for drugs with high P and/or MP, or if a high dose is required, the 
conventional approaches mentioned above are limited. In addition to insolubility, drug 
candidates may have additional problems pertaining to stability, acute toxicity and side 
effects. When taken together, all of these become a bottleneck in the drug development 
process. The advances of lipid-based nanoparticle systems for improved drug delivery 
offer a great potential for the administration of anti-cancer drugs. The main advantages of 
this system include low toxicity of carriers themselves, solubilization of poorly water-
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soluble drugs, high drug loading, protection of drugs against chemical and biological 
degradation related to the administration route, prolonged circulation, targeting delivery, 
and controlled release. In addition, more than one anti-cancer drug may be co-encapsulated 
into colloidal carriers for combined cancer chemotherapy [153]. Lipid-based nanoparticles 
are generally comprised of biocompatible and biodegradable lipids and therefore may be 
less toxic than many types of polymeric nanoparticles prepared from synthetic polymers. 
Once the particle size is reduced to submicron levels, the surface area of the nanoparticles 
increases substantially, and also the saturation solubility increases with the reduction of 
particle size, leading to an increase in the dissolution rate. The encapsulation of drugs into 
the carriers provides protection of the drugs from the influence of physiological conditions. 
Also, the carrier may have prolonged circulation; thus, the required therapeutic levels of 
the drugs in the blood for the extended time interval and a better targeting effect may be 
more readily achieved. Additionally, by choosing the excipients and compositions of the 
nanoparticles, controlled release can be explored to further reduce acute toxicity. As 
described above, nanoparticles could perform passive targeting delivery to solid tumors by 
the EPR effect or even active targeting by placing the ligand on the surface of 
nanoparticles. Lipid-based nanoparticles have become an increasingly important field of 
research for delivering anti-cancer drugs in terms of these potential benefits. The primary 
types of lipid-based nanoparticles investigated are micelles, liposomes, nanoemulsions, 
nanocapsules, and solid lipid nanoparticles. These systems will be discussed in the 
following sections. All of them are potential drug carriers administered by different routes 
including oral [154, 155], topical [156, 157] and parenteral [158, 159].  
 
3.3.2.1 Micelles 
Micelles are the most basic colloidal drug delivery systems and are formed 
spontaneously in nature. In the body, colloidal micellar species comprising endogenous 
surfactants and lipid digestion products, i.e. bile salt mixtures, facilitate the absorption of 
highly insoluble fatty acids and fat soluble vitamins. Micelles with particle size normally 
within 5 to 100 nm range are thermodynamically stable and form spontaneously by 
association of amphiphilic molecules such as surfactants under defined concentrations and 
temperatures. The concentration of a monomeric amphiphile at which micelles appear is 
called the critical micelle concentration (CMC). The formation of micelles is driven by the 
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decrease of free energy in the system because of the removal of hydrophobic fragments 
from the aqueous environment and the re-establishment of the hydrogen bond network in 
water. Hydrophobic fragments of the amphiphilic molecules form the core of a micelle, 
while hydrophilic moieties form the shell of the micelle. When used as drug carriers in 
aqueous media, micelles solubilize molecules of poorly soluble nonpolar drugs within the 
micelle core, while polar drugs could be adsorbed on the micelle surface and substances 
with intermediate polarity distribute along surfactant molecules in intermediate positions. 
One limitation of micellar systems is the relatively low hydrophobic volume of the interior 
of micelles, leading to limited drug loading. Consequently micellar formulations may often 
comprise a surfactant and solvent mixture, such as the formulation of the injection Taxol 
consisting of Cremophor EL and ethanol at a 1:1 ratio. Another limitation of conventional 
micellar systems is the danger of drug precipitation upon the dilution of the solubilized 
drug with physiological fluids after parenteral administration. The dilution of the 
formulation by physiological fluids may cause the disassociation of the micelles as the 
concentration of the surfactants used to solubilize the drugs may be lower than their CMC.  
More recently, polymer micelles prepared from amphiphilic copolymers for 
solubilization of poorly soluble drugs as an alternative to lipid-based surfactant systems 
have attracted much attention. Polymer micelles offer a more versatile structure, 
biodegradability, and lower CMC that may lead to better in-vivo stability and more 
conjugation chemistries for linking ligands to the surface of the colloidal system. Polymer 
micelles are self-assembled from block copolymers comprising a hydrophobic block such 
as poly-lactic acid with a hydrophilic block. As a result of a common progression of 
development of ‘stealth’ systems for intravenous administration, pegylation approaches 
were used to form stealth micelles to enhance circulation time. Also, the PEG corona can 
act as a diffusion barrier for hydrophobic drugs to reduce burst release characteristic of 
micelles [160]. Thus, the hydrophilic block on the copolymer typically contains PEG 
segments with a molecular weight from 1 to 15 kDa. Similar to micelles formed with 
conventional surfactants, polymeric micelles comprise the core of the hydrophobic blocks 
stabilized by the corona of hydrophilic chains in water. However, compared to the 
conventional micelles, polymeric micelles are more stable upon the relatively high dilution 
conditions experienced in-vivo. For example, some amphiphilic copolymers have CMC 
values as low as 10-6 M [161]. PEG-phosphatidylethanolamine (PEG-PE) conjugates were 
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used to self-assemble the micelles with the particle size of 7 to 35 nm [162, 163]. Two 
long-chain fatty acyl groups of phospholipids provided greater hydrophobic cores 
compared to the conventional polymeric micelles. CMC and the particle size of the 
micelles formed from lipid-polymer conjugates depend on the length of the polymers. 
These lipid-core micelles are hybrid between polymeric micelles and lipid-based micelles. 
The hydrophobic block can represent a hyperbranched backbone chain to which 
hydrophilic PEG chains were attached to make a water-soluble polymer exhibiting micellar 
properties [164]. To further reduce the clearance by RES system and perform active 
targeting delivery, multifunctional micelles either through conjugation of targeting ligands 
on the micelle surface or through a triggered release mechanism (pH-sensitive polymeric 
micelles) were developed [163, 165, 166]. Antibody, peptide, transferrin and folate 
residues have been attached to the micelle surface. The drug loading efficiency apparently 
correlates with the hydrophobicity of a drug and is usually in the range from 1.5 to 50% by 
weight. Although many drug-loaded polymeric micelles have been developed, most of the 
results have described in-vitro studies. Such in-vitro results do not necessarily imply that 
these systems will be efficacious in-vivo. For example, recently, methoxy poly(ethylene 
glycol)-block-poly(caprolactone) (MePEG-b-PCL) amphiphilic diblock copolymers were 
synthesized as a water-soluble form or a water-insoluble form based on the lengths of PCL 
block. Water-insoluble copolymers were used to make nanoparticles while water-soluble 
copolymers were used to make micelles. It was demonstrated that the polymeric 
nanoparticles possessed a higher core microviscosity than the polymeric micelles. 
Interestingly, although the in-vitro release of paclitaxel from both paclitaxel-loaded 
polymeric nanoparticles and micelles in PBS were similar and slow, in-vivo biodistribution 
showed that the association of paclitaxel solubilized by micelles with the lipoprotein 
deficient plasma caused a similar plasma distribution as with free paclitaxel, resulting in a 
rapid release of the micellar drug during the in-vivo study, whereas nanoparticles retained 
more of paclitaxel with less association with the lipoprotein deficient plasma [167].  
 
3.3.2.2 Liposomes 
Liposomes have been and continue to be the most intensively researched colloidal 
drug delivery systems even four decades after their discovery. There are some excellent 
reviews and books covering all aspects of liposome technology. Liposomes are normally 
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composed of phospholipids that spontaneously form multilamellar, concentric bilayer 
vesicles with layers of aqueous media separating the lipid layers. The particle size of small 
unilamellar vesicles which are comprised of a single, lipid outer layer with an aqueous core 
is in the range 20 – 80 nm. The surface of liposomes may be charged or uncharged based 
on the selection of different phospholipids. There are many methods to prepare liposomes 
including precipitation [168]. Liposomes may be used to load both hydrophobic and 
hydrophilic drugs. Hydrophilic drugs reside in the aqueous core whereas hydrophobic 
drugs tend to remain in the lipid layers. Hydrophobic drugs are added during the formation 
of liposomes. Hydrophilic drugs may also be loaded during formation, but for charged 
drugs the pH-gradient method may be used wherein a pH gradient between the internal and 
external aqueous domains drives the drug into the interior of the liposomes by partitioning 
through the membrane. Liposomes have poor loading capacity for hydrophobic drugs that 
can not be dissolved in sufficient amounts in the phospholipid bilayer or sequestered in the 
liposome core. Furthermore, after i.v. administration, such drugs often rapidly partition 
from the bilayers into cells or bind to serum proteins preventing accumulation at the target 
site. Several liposomal drugs are now marketed including Ambisome® (amphotericin B), 
Doxil® (doxorubicin hydrochloride) and Visudyne® (verteporfin) to name a few. As 
discussed previously pegylation using a PEG conjugated lipid is routine to sterically 
stabilize liposomes for escaping the RES and altering pharmacokinetics. Pegylation is 
described in details in Section 3.3.1.1. However, based on the recent studies, a potential 
limitation of pegylated liposomes is the complement activation that can lead to 
anaphylactic response, causing hypersensitivity reactions in patients receiving pegylated 
liposomes. Another recent finding on pegylated liposomal drugs reported the accelerated 
blood clearance (ABC) phenomenon, resulting in pegylated liposomes to be cleared very 
rapidly from the circulation upon repeated injection [169]. IgM was secreted into the 
bloodstream after the first dose. The abundant binding of IgM to liposomes was 
responsible for the induction of the ABC phenomenon, and it appeared that the spleen may 
play an important role in this phenomenon. As was described in Section 3.3.1.2, various 
ligands, such as folate, peptides and antibodies have also been conjugated to liposomes to 
achieve active targeting delivery to solid tumors. On-going limitations of liposomes relate 
to stability and the ease and cost of manufacturing liposomal products 
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3.3.2.3 Nanoemulsions 
Emulsions with particle size in the nanometer scale (typically between 50 nm and 
200 nm) are often referred to nanoemulsions. To prepare an emulsion, oil, water, surfactant 
and energy are required. The total free energy of formation of an emulsion, ∆G, can be 
represented as the following: 
∆G = ∆Aγ - T∆S     Ref. [170] 
where ∆A is the increase in interfacial area, γ is the interfacial tension, T is temperature 
and ∆S is the increase of entropy. When the bulk oil produces a large number of droplets, 
the interfacial area greatly increases. The small energy term, T∆S, can not compensate for 
the energy change from ∆Aγ and consequently ∆G is positive. Thus, nanoemulsions cannot 
form spontaneously and the energy is required. In contrast to microemulsions, 
nanoemulsions are thermodynamically unstable. The methods used to produce 
nanoemulsions mainly include high-energy processes, low-energy emulsification and the 
phase inversion temperature (PIT) method [158, 159, 171]. High-energy methods include 
high-pressure homogenization and microfluidization which can be used at both the 
laboratory and industrial scale, as well as ultrasonification which is primarily used at the 
laboratory scale. The low-energy emulsification method was developed in a study of the 
phase behavior of water/oil/surfactant systems. Three different methods were studies based 
on the various emulsification processes: method (1) addition of oil to aqueous surfactant 
dispersion, method (2) addition of water to a surfactant solution in oil, and method (3) 
mixing preequilibrated samples of the components [172]. Only method 2 generated 
nanoemulsions with sizes about 50 nm. It appeared that the formation of nanoemulsions 
depended not only on the thermodynamic conditions but also on preparation methods and 
the order of addition of the components. The PIT method is the most widely used in the 
industry among all methods. It is based on the changes of the hydrophilic lipophilic 
balance (HLB) of the system by modifying factors such as temperatures, electrolyte 
concentrations, and using mixtures of surfactants which influence HLB [173]. It was 
thought that the key to nanoemulsion formation using low-energy emulsification and PIT 
methods could be attributed to the phase transitions occurring during the emulsification 
process. In addition to the three common methods mentioned above, a ‘spontaneous’ 
emulsification method named the Ouzo method also was reported to form nanoemulsions. 
The limitation of this method is the low oil content (typically 1%) and requirement for 
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using water-miscible solvents resulting in systems with somewhat limited utility for drug 
delivery [174]. 
Nanoemulsions are transparent or translucent systems and possess stability against 
sedimentation or creaming since the Brownian motion and the diffusion rate are greater 
than the sedimentation rate induced. The major mechanism for nanoemulsion 
destabilization is Ostwald ripening, an observed phenomenon in solid (or liquid) solutions 
which describes the evolution of an inhomogeneous structure over time and results from 
the difference in solubility between small and large droplets. Ostwald ripening can be 
quantitatively assessed from the Lifshitz-Slezov and Wagner (LSW) theory. According to 
this theory, the Ostwald ripening rate in oil-in-water emulsions is directly proportional to 
the solubility of the oil in the aqueous phase. However, experimental Ostwald ripening 
rates have been reported to be about three orders of magnitude higher than those 
calculated. Therefore, it is debatable to use LSW theory to predict Ostwald ripening rates 
[175]. Ostwald ripening can be reduced by the addition of the second oil with a low 
solubility in the aqueous phase and modification of the interfacial film at the oil/water 
interface using a second surfactant [170]. Nanoemulsions have been used as drug delivery 
systems for various routes of administration including parenteral [159, 176] and oral [177]. 
The anti-HER2 monoclonal antibody (Herceptin) was covalently linked to paclitaxel-
palmitate-loaded cationic immunoemulsion to target HER2 receptors on prostate cancer 
cells [178]. The improved anti-cancer efficacy of this immunoemulsion was observed at 
day 56 after three treatments (once weekly for 3 weeks) at dose of 10 mg/kg compared to 
non-targeted paclitaxel-palmitate-loaded cationic emulsion and paclitaxel-palmitate 
solution in mice bearing orthotopic prostate tumors. A vitamin E-based nanoemulsion of 
paclitaxel (TOCOSOL) is currently in phase III clinical development. TOCOSOL is 
produced by a high-shear homogenization method. Tumor growth over time was 
monitored using TOCOSOL at 20, 40 and 60 mg/kg and Taxol at its MTD of 20 mg/kg. 
TOCOSOL had improved anti-tumor activity compared to Taxol in mice implanted with 
B16 murine melanoma [179].  
 
3.3.2.4 Nanocapsules 
Nanocapsules are ultrafine particles with a diameter of less than 1 µm with a liquid 
core (generally an oil) surrounded by a polymeric membrane structured by polymers or a 
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combination of hydrophilic/lipophilic surfactants. The structural feature and concept of 
nanocapsules are different form nanoemulsions which have surfaces stabilized by the 
adsorption of some surfactants [180-182]. Vegetable oils and triglycerides with medium- 
and long- chain fatty acids are the common components for the lipid cores. The drugs are 
confined to the lipid core which serves as a reservoir to allow a high drug loading for 
hydrophobic drugs and a slow release profile. Thus, nanocapsules are pharmaceutically 
attractive for water-insoluble drugs. Four techniques have been reported to prepare 
nanocapsules to date and include (1) interfacial polymerization of monomers [183], (2) 
interfacial deposition of preformed polymers [184], (3) an emulsification-diffusion 
technique [180], and (4) a phase inversion-based process [185]. Only the phase inversion-
based process did not require the use of organic solvents for preparation of the 
nanocapsules. Although nanocapsules have been studied over the last 20 years, progress 
toward the use of nanocapsules for delivering anti-cancer drugs has been slow. Very few 
reports of in-vivo studies can be found in literature. A possible reason for this is that, as 
mentioned above, many of the processes used to prepare nanocapsules requires the use of 
organic solvents which may present toxicity issues. Paclitaxel-loaded nanocapsules were 
proved to be toxic in mice bearing P388 leukemia. The toxicity was apparently due to the 
composition of the nanocapsules which were comprised of poly(lactic acid), benzyl 
benzoate and Pluronic F68 [186]. Another problem that has been reported for nanocapsules 
is their stability in an aqueous environment. Drug leakage out of the nanocapsules can 
happen. Lyophilization, also known as freeze drying, has been investigated to extend the 
shelf-life of nanocapsules. However, lyophilization of nanocapsules is not easy as 
nanocapsules have a very thin and fragile envelop that may not withstand the mechanical 
stress of freezing [187, 188]. Etoposide and paclitaxel were encapsulated into nanocapsules 
and relatively high drug loadings and sustained drug release were achieved over a period of 
several days for etoposide and up to a few weeks for paclitaxel [189]. Lipophilic 
derivatives of gemcitabine, which is an anti-cancer drug and suffers from a rapid plasmatic 
metabolism, were incorporated into polycyanoacrylate nanocapsules in order to physically 
and chemically protect gemcitabine [190]. PEG was used to form a hydrophilic layer on 
the surface of nanocapsules to escape the RES system [191, 192]. Pegylated lipid 
nanocapsules exhibited long circulating properties. A promising in-vivo study was carried 
out using paclitaxel-loaded nanocapsules prepared from a phase inversion-based process in 
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a chemically induced hepatocellular carcinoma model in Wistar rats. Groups treated with 
paclitaxel and with PX-loaded nanocapsules showed significant increases in mean survival 
times compared to control, demonstrating an equivalent therapeutic efficiency of paclitaxel 
and paclitaxel-load nanocapsules that avoided the use of Cremophor EL in the formulation. 
Paclitaxel-loaded nanocapsules formulated using the phase inversion-based process also 
showed reversal of multidrug resistance in glioma cells in-vitro and reduction of tumor 
progression in rats bearing F98 glioma cells [193].  
 
3.3.2.5 Solid lipid nanoparticles 
Solid lipid nanoparticles made from biodegradable or biocompatible solid lipids 
were developed in the beginning of 1990s as an alternative colloidal carrier system for 
controlled drug delivery. Solid lipid nanoparticles are matrix systems in which the drug is 
physically and uniformly dispersed. The release of a drug incorporated in the lipid matrix 
occurs due to degradation of the particles by lipases present at the site of injection, leading 
to a prolonged release of drugs from the solid lipid nanoparticles [194]. A comprehensive 
review on solid lipid nanoparticles can be found in the literature [195]. As with other lipid 
colloidal systems, solid lipid nanoparticles have advantages including good tolerability due 
to the use of relatively safe lipids, protection of drugs against chemical degradation, and 
manageable issues with respect to large scale production by high pressure homogenization. 
Different water-insoluble drugs have been incorporated into solid lipid nanoparticles by 
choosing appropriate lipids for the drugs [196, 197]. However, the high temperatures used 
in the process of high pressure homogenization may increase the degradation rate of the 
drug and the carriers. Also, solid lipid nanoparticles have shown somewhat limited drug 
loading capacity and drug expulsion during storage. Moreover, the majority of lipophilic 
spin probes were found to be located not in the core of solid lipid nanoparticles but at the 
interface between the lipid layers and the core [198]. This may be the reason for the burst 
release of the drug which often happens for drug-loaded solid lipid nanoparticles. Selection 
of lipids is important for development of solid lipid nanoparticles. Lipids containing less 
ordered crystal lattices favor high drug loading capacity, slow release and prevention of 
drug leakage during the storage. For example, paclitaxel nanoparticles (PX E78 NPs) were 
previously developed in our lab. The nanoparticles were composed of emulsifying wax and 
Brij 78. Low drug entrapment efficiency (<50%) and a fast release profile (100% release 
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within 8 h) were associated with these PX E78 NPs. To solve this problem, nanostructured 
lipid carriers (NLC) have been developed as a new generation of solid lipid nanoparticles 
[199]. The lipid core of NLC was composed of a mixture of solid and liquid lipids in order 
to obtain a reduced crystal lattice. The choice of the lipids forming the core of NLC was 
considered as the most important factor determining drug incorporation efficiency. The 
solid lipid and the liquid lipid may not be very miscible, possibly resulting in a separate 
compartment in the core. In this case, the core is no longer a viscous semisolid and the 
drug will be excluded. For example, lipophilic drugs including bupivacaine base, 
bupivacaine stearate or indomethacin were incorporated into NLC with a lipid core 
composed of a mixture of triglycerides containing Precirol (solid) and Miglyol 812 (liquid) 
at a 4:1 ratio. None of the studied drugs were successfully incorporated in the lipid core. 
Moreover, the choice of lipids can not be based on the solubility of drugs in the bulk lipids 
since the exclusion effect did not correlate with the solubility [200].  
 
3.3.3 Experimental design to optimize nanoparticle composition 
To achieve targeting delivery to tumors, the preparation of nanoparticles is a 
critical step. In general, the components of the nanoparticles including lipids and 
surfactants are selected based on the physical and chemical properties of the model drug. A 
scientist then faces the challenge of finding the right composition of nanoparticles that will 
have the optimal properties for that specific drug. The basic goal is to develop 
nanoparticles of required stability, particle size range and uniform distribution and to 
ensure robust parameters for production. The classical approach used to optimize 
nanoparticle formulations is one-factor-at-a-time which is to vary the levels of one factor 
while keeping the others constant. This approach generally leads to a large number of 
experiments and ignores the possibility of factor interactions whereby the optimum for one 
variable may depend on the particular level of other variables.   
Experimental design can be defined as the strategy for setting experiments in such a 
manner that the information required is obtained as efficiently and precisely as possible. 
The objective of experimental design is to plan and conduct experiments in order to extract 
the maximum amount of information from the collected data in the smallest number of 
experimental runs [201]. The optimization, which is a process to choose the best 
alternative from a set of possibilities, is facilitated based on experimental design. In the 
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search for the best nanoparticle formulation, the excipients are the independent variables or 
factors which are controllable and the dependent variables or responses are the factors to 
be optimized. When optimization includes different excipients and various responses, the 
combined response optimization is preferable. Desirability function is a way to combine 
multiple responses into one function for the simultaneous evaluation [200, 201]. In this 
function, each response is transformed to a d value. The overall contribution of all 
responses (d values) is combined to a D value which is used as an overall response to 
evaluate the outputs of the experiments.  
Optimization methods could be considered as two different groups [202]. The first 
group is called the simultaneous approach and depends on mathematical models. The 
setting of all the variables in the mathematical models is preselected and consequently the 
number of experiments to be performed is known beforehand. Factorial design belongs to 
this group and has been used in the development of formulations [203-207]. A full factorial 
experimental design which studies the effect of all factors at various levels includes a large 
number of experiments. For example, for a study involving five factors at two levels of 
each factor, the number of experiments is 25. To reduce the number of experiments, 
fractional factorial design is developed using only a fraction of the experiments specified 
by the full factorial design. Various strategies are used to ensure an appropriate choice of 
experiments which could cover all possibilities in a full factorial design. Taguchi approach 
is based on fractional factorial designs, combining mathematical and statistical techniques. 
Orthogonal arrays are chosen for experimental design in this approach [208]. This 
approach was used to optimize solid lipid nanoparticles in which camptothecin was 
incorporated. The solid lipid nanoparticles were prepared by high pressure 
homogenization. Four independent variables including drug concentration, types and 
concentrations of emulsifiers, and homogenization pressure at three levels of each variable 
were studied for their influence on nanoparticle sizes. After nine experiments, the 
optimized condition resulted in monodispersed camptothecin-loaded nanoparticles with 
particle size about 200 nm. The carboxylate form of camptothecin was found to be 
significantly less potent than the lactone form in in-vivo tumor models. The resultant 
camptothecin-loaded nanoparticles greatly increased the stability of camptothecin toward 
hydrolysis and retention of the active lactone form [197].  
 37
The second group of optimization methods is model independent. The optimization 
is completed via a “searching” process. Sequential simplex optimization is the common 
approach in this group of optimization. The sequential simplex optimization was original 
developed in 1965 [209]. A simplex is a geometric figure with k + 1 corners, where k is 
equal to the number of independent variables. In this method, the optimum is tracked by 
evaluating the responses from the experiments at a set of points forming a simplex in the 
factor-space. New simplices are continually formed by reflecting one point in the 
hyperplane of the remaining points. The setting is not known beforehand. Thus, the current 
experiment is based on previous experiments. Each movement of the simplex involves 
changing all factor levels but factor interaction is accommodated in this scheme. This 
method has been demonstrated to be an efficient strategy for rapid optimization of multi-
factor systems in chemistry and biochemistry [210-212]. In pharmaceutical product 
development, it is worthy to note that this search method allows setting up the range of 
independent variables and restricting the responses, e.g. particle size, in a very simple way 
besides the optimization. However, very few studies in literature have reported on the use 
of this method to optimize formulations. Essentially there are no reports on optimization of 
nanoparticle formulations using simplex optimization. The few use of simplex 
optimization may result from the unexpected number of experiments to reach an optimum 
because the number of experiments to be performed is unknown before the optimization in 
this method. When the starting simplex is far away from the optimum, optimization needs 
a long way to search for the best case. Therefore, the optimization process may be longer 
compared to simultaneous methods. A relevant study used a genetic algorithm and a 
downhill simplex technique to optimize a dry powder blend comprised of six 
lubricant/glidant agents and containing 500 mg of alpha methyl dopa to fill into hard 
gelatin capsules [213].  
 
3.3.4 Safety issue for nanoparticles including their fate and metabolism  
While targeted drug-loaded nanoparticle formulations have been shown to greatly 
improve anti-cancer efficacy of anti-cancer drugs in-vivo or in the clinic, there have been 
increasing concerns regarding the risks that nanoparticles may pose [214, 215]. To avoid 
risks, biodegradable and biocompatible excipients are commonly selected to produce 
nanoparticles for medical uses. These relatively safe materials includes lipids, 
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polysaccharides and biodegradable aliphatic polyesters, such as poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA) and poly(ε-caprolactone) (PCL) [216]. Still, the properties of 
nanoparticles are different from those of bulk excipients. A decrease in the size of particles 
results in an increase in the total surface area of particles while keeping the mass 
unchanged. Although these intrinsic properties of nanoparticles may help improve drug 
delivery as discussed above, chemical alternations on the surface of the nanoparticles may 
occur. The nano-scale size of nanoparticles may lead to additional physicochemical and 
biological activities which are lacking in large, micron-sized particles. Moreover, the 
entrapment of bulk excipients into the matrix of nanoparticles may change their properties. 
For example, the surfactants are generally used to make lipid-based nanoparticles. It is 
known that the surfactants as surface active agents can affect membrane integrity [217]. To 
understand the blood compatibility of E78 nanoparticles composed of emulsifying wax 
(oil) and Brij 78 (surfactant), the hemocompatibility of E78 NPs was evaluated including 
hemolytic activity, platelet function and blood coagulation [218]. E78 NPs showed 
potential blood compatibility at clinically relevant doses. In addition, the platelet function 
was not affected up to 1 mg/ml of E78 NPs. Moreover, whereas Brij 78 alone led to a 
significant dose-dependent and time-dependent red blood cell lyses at the tested 
concentration range from 0-4 mM, E78 NPs made with 4 mM Brij 78 did not cause red 
blood cell lyses.  
The metabolism of excipients in nanoparticles or the metabolism of nanoparticles 
themselves has not been studied in detail. A few in-vitro studies have been carried out to 
understand the degradation of solid lipid nanoparticles [219, 220]. During storage time and 
in in-vivo conditions, drug release from solid lipid nanoparticles could take place by 
diffusion and by matrix degradation. Thus, the main purpose of these studies was to 
optimize the compositions of solid lipid nanoparticles by choosing different lipids based on 
degradation velocity by enzymes and surfactants which influenced the biodegradation 
process. The results showed that the longer the fatty acid chains in the glycerides, the 
slower the degradation rate. Also, some surfactants, e.g. Poloxamer 407, slowed down the 
degradation due to steric stabilization whereas others, e.g. Tween 80, did not. There are 
very few studies on the metabolism of nanoparticles in-vivo. It is possible that insoluble 
nanoparticles accumulate in the body. The biological effect will depend on the properties 
and dose of nanoparticles. Nanoparticles also may interact with biological molecules [221]. 
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Therefore, there remains the need to study metabolism of excipients in nanoparticles and 
the nanoparticles themselves to understand the potential issues pertaining to the fate and 
safety of nanoparticles for drug delivery.  
 
3.4 Drug delivery systems to overcome P-gp-mediated drug resistance and their 
possible mechanisms 
Multidrug resistance is a major impediment to the success of cancer chemotherapy. 
P-glycoprotein is the first discovered multidrug transporter and best characterized and most 
clinically relevant. P-gp is the product of the MDR1 gene and effluxes drugs without 
chemically modify. Approximately 50% of the anti-cancer drugs used clinically today are 
substrates of P-gp [222]. The emergence of drug resistance has made many of the 
chemotherapy drugs ineffective. Different strategies attempting to overcome P-gp-
mediated drug resistance have been developed as described above. This section focuses on 
overcoming P-gp-mediated drug resistance using drug delivery systems. Unlike the 
potentially more serious effects of the active P-gp inhibitors, drug delivery systems may be 
inhibitors of P-gp with low pharmacological activity and reduced side-affects. The 
formulations discussed below to overcome MDR are summarized in Table 3.2. 
 
3.4.1 P-gp inhibition by lipid formulations 
In 1972, the study showed that Tween 80 enhanced the effect of actinomycin D and 
daunomycin in Chinese hamster resistant cells [223]. Since this report, a number of lipid 
and polymeric excipients present in pharmaceutical formulations have been reported to 
modulate the activity of P-gp. P-gp as an efflux pump located in the apical membranes of 
intestinal absorptive cells can reduce the absorption of drugs and consequently decrease the 
oral bioavailability. Thus, the lipid formulation strategy for enhancing absorption of drugs 
which are P-gp substrates become an attractive topic and has been extensively reviewed for 
oral delivery [222, 224-226]. Caco-2 and MDCK cells expressing P-gp are the most widely 
used cell models to study the oral absorption. Most of surfactants inhibiting P-gp are non-
ionic. They can be divided into two classes according to the chemical structure [224]. The 
first class of surfactants exhibit a hydrophobic tail responsible for membrane anchoring 
and a hydrophilic head-group, including triglycerides, Cremophor EL, Solutol HS-15, 
TPGS, Tween 80, and Brij 35. The second class of surfactants, which lack a typical 
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membrane anchor, includes polyethylene glycol (PEG) and poly(ethylene oxide) (EO)-
poly(propylene oxide) (PO) block copolymers (Pluronics or poloxamers). All surfactant 
inhibitors contain a unit which comprises hydrogen bond acceptor groups such as ester 
groups and polyoxyethylene sequences that could form hydrogen bonds with the 
transmembrane sequences of P-gp which are rich in hydrogen bond donor groups. 
Provided that the binding affinity of surfactants is higher than that of the drug, the 
surfactants become P-gp inhibitors and enhance the absorption. The inhibitory effects of 
surfactants on P-gp efflux are related to the structure of surfactants such as the length 
hydrophilic chain and hydrophilic lipophilic balance. TPGS 1000 has been reported to 
influence drug efflux well below its reported CMC of 0.02 wt. % [227]. A structure-
activity relationship (SAR) study was carried out to understand the influence of PEG chain 
length on apical efflux transporters in Caco-2 cell monolayers [228]. TPGS analogs 
containing different PEG chain length (MW from 200-6000 Da) were synthesized. The 
results suggested that PEG chain length was essential to influence Rhodamine 123 efflux 
in-vitro. Commercial TPGS 1000 turned out to be one of the most potent analogs to inhibit 
P-gp efflux. The effect of HLB values of excipients on P-gp modulation was also studied 
for uptake of epirubicin in Caco-2 cells [229]. Surfactants with optimal net efficacy in this 
study including Tween 20, Tween 80, Brij 30 and Myrj 52 consist of a polyethylene and 
intermediate hydrocarbon chain. The characteristics of the surfactants allow them to 
partition between lipid bilayers and P-gp domains. The optimal HLB value to enhance 
epirubicin uptake was in the range of 10 to 17. A relative study on Pluronic block 
copolymers with varying length of EO and PO segments was performed in bovine brain 
microvessel endothelial cells (BBMEC) cells [230]. The most efficacious block 
copolymers exhibited intermediate length of 30 to 60 PO blocks and a relatively 
hydrophobic structure (HLB < 20), e.g. Pluronic P85 with 40 PO blocks and an HLB of 16. 
The common mechanisms of surfactants to inhibit P-gp may include binding competition 
of drugs with surfactants resulting from an interaction between surfactants and P-gp, and 
membrane fluidization leading to an indirect protein destabilization [230-233]. However, 
the latter mechanism may not be the case for some surfactants. For example, TPGS tends 
to rigidify lipid bilayers, not fluidizes them. [232].  
 
3.4.2 Liposomes to address P-gp 
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Liposomal delivery systems have been shown to inhibit P-gp efflux [88, 234-238]. 
The proposed mechanisms included escaping P-gp through an endocytosis pathway [238] 
and direct interaction with P-gp. The interaction of liposomes with P-gp was proved by 
completely inhibition of photoaffinity labeling of P-gp by azidopine [235]. However, other 
studies showed that liposomes had limited effectiveness in addressing P-gp-mediated 
resistance in laboratory in-vitro models of cellular resistance and in clinical studies [239-
242]. Liposome formulations containing both an anti-cancer drug and a P-gp inhibitor have 
been studied recently. The results showed that liposomal co-encapsulated drugs had better 
responses in both in-vitro and in-vivo resistant models compared to a single drug [243-
245]. Moreover, liposomal targeting delivery systems have been investigated to overcome 
P-gp-mediated drug resistance [244]. For example, doxorubicin and verapamil were co-
encapsulated into liposomes with 95% and 70% loading efficiency, respectively. To 
achieve targeting, human transferring (Tf) targeted to the Tf receptors which are 
overexpressed in leukemia cells was further conjugated to the liposomes. In resistant 
leukemia K562 cells (Tf receptor +), Tf-conjugated co-loaded liposomes showed 5.2 and 
2.8 times greater cytotoxicity than non-targeted co-loaded liposomes and Tf-conjugated 
Dox liposomes, respectively. It was concluded that TfR-targeted liposomes co-loaded with 
Dox and verapamil were effective in selective targeting and reversal of drug resistance in 
cells [244].  
 
3.4.3 Polymer and lipid nanoparticles (or nanocapsules) to address P-gp 
A number of studies have investigated encapsulation of anti-cancer drugs into 
polymer nanoparticles and lipid nanoparticles (or nanocapsules) to overcome P-gp-
mediated drug resistance [246-251]. Among them, polyalkylcyanoacrylate nanoparticles 
were the earliest ones investigated in resistant cell lines [249]. The results showed that 
non-biodegradable polymethacrylate nanoparticles can be internalized by an endocytosis 
process and reverse P-gp-mediated drug resistance in-vitro [252]. For in-vivo studies, 
biodegradable Dox-loaded polyisohexylcyanoacrylate (PIHCA) nanoparticles were 
developed. These PIHCA nanoparticles showed more cytotoxicity than free Dox in Dox-
resistant C6 cells. Later on, more rapidly biodegradable PIBCA NPs were formulated to 
load Dox. Dox uptake from PIBCA NPs was different with that from PIHCA NPs as Dox-
loaded PIBCA NPs caused higher cellular Dox uptake than free Dox. Also, it was 
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demonstrated that PIBCA NPs did not enter cells via an endocytosis pathway and efflux of 
Dox in NPs had a similar profile with free Dox. Mechanistic studies found that, 1) 
nanoparticles could deliver high concentration of Dox close to or adhered to the cell 
membrane, resulting in saturation of P-gp, and 2) the formation of an ion-pair between 
cyanoacrylic acid (a nanoparticle degradation product) and Dox could mask the positive 
charge of Dox and facilitate diffusion of Dox across cell membranes [253, 254]. However, 
in-vivo studies using MDR tumors showed that these nanoparticles were not efficacious in-
vivo perhaps due to poor delivery to the tumors [255]. A new polymer-lipid hybrid 
nanoparticle (PLN) system was used to increase the cytotoxicity of Dox in resistant cells 
[251]. Dox uptake and retention from Dox-loaded NPs were significantly enhanced 
compared to free Dox. Blank PLNs did not improve Dox uptake and retention in resistant 
MDA-MB-435/LCC6MDR1 cells. These results indicated that the PLNs did not influence 
P-gp activity by themselves. The results also revealed that phagocytosis was an important 
pathway for PLN to enter the cells. Based on this pathway, Dox-loaded PLNs could bypass 
P-gp, leading to enhanced Dox uptake in resistant cells [256]. Recently, AerosolOT 
(AOT)-alginate nanoparticles were evaluated for their potential to overcome P-gp-
mediated drug resistance. Dox-loaded AOT-alginate NPs enhanced cytotoxicity of Dox in 
resistant NCI/ADR-RES cells. It was observed that: 1) the uptake of rhodamine was 
significantly increased using rhodamine-entrapped nanoparticles in resistant cells, 2) blank 
NPs also improved rhodamine accumulation in a dose-dependant manner in resistant cells, 
and 3) the enhancement in rhodamine accumulation was not due to membrane 
permeabilization. However, the mechanism of AOT-alginate NPs to overcome P-gp-
mediated drug resistance has not been established [248]. As mentioned above, the 
surfactant Solutol HS15, a mixture of free PEG 660 and PEG 660 hydroxystearate, could 
inhibit P-gp. Solutol HS-15-based lipid nanocapsules (LNC) containing paclitaxel or 
etoposide were studied for their potential to overcome MDR [193, 257]. PX-loaded LNCs 
were shown to significantly reduce cancer cell survival in comparison with Taxol in 9L 
cells and F98 cells. Solutol HS15 on its own did not improve the effects of paclitaxel. 
Similarly, PX-loaded LNCs significantly reduced tumor mass in-vivo whereas Taxol did 
not have a significant effect in an MDR-expressing F98 s.c. glioma model. The mixture of 
Solutol HS15 and PX did not improve tumor responses in this in-vivo model. This 
indicated that the importance of the nanocarrier itself for the anti-cancer effect on MDR. 
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The study also showed that LNC internalization could not be mediated by clathrin-
dependent endocytosis. It was assumed that LNC endocytosis involves one or both of the 
two known cholesterol enriched membrane microdomains. The consecutive intracellular 
cholesterol movements would constitute the core of the LNC inhibitory effects on MDR. 
Thus, according to these mechanism studies, the investigators proposed that the inhibition 
of MDR efflux pump by LNCs could result from the interaction of the released 
intracellular free Solutol HS15 with MDR efflux pump and redistribution of intracellular 
cholesterol [193]. It is noteworthy that the drugs delivered into MDR cells by PLGA NPs 
are susceptible to efflux by P-gp [258]. PLGA NPs were taken up by cells by endocytosis, 
resulting in an increase of cellular concentration of the drug encapsulated into the NPs. 
Following entry, NPs were retained in the cytoplasm for a sustained period of time and 
slowly released the drug in the cellular cytoplasm. However, PX-loaded PLGA NPs did 
not show significant cytotoxicity in resistant NCI/ADR-RES cells. It was proved that P-gp 
activity did not affect the uptake and retention of NPs themselves. Thus, the inefficiency of 
PX-loaded PLGA NPs could result from the active efflux of the drug in cytoplasm by P-
gp. Therefore, P-gp could not only extract the drug when the drug diffused into the cell 
through the lipid bilayer, but also pump out the drug present in the cytoplasm. 
Consequently, the efficiency of overcoming P-gp based on endocytosis of NPs may be 
limited. 
 
3.4.4 Polymer conjugates to address P-gp  
Poly[N-(2-hydroxypropyl)methacrylamide] (polyHPMA) and HPMA copolymers 
have been proposed by several groups as potential drug delivery systems. HPMA is a 
water-soluble, nonimmunogenic, synthetic polymer. HPMA copolymer-Dox conjugates 
have shown the potential to overcome drug resistance [259-261]. A series of studies on 
HPMA-Dox conjugates addressed multiple mechanisms of MDR in addition to P-gp-
mediated drug resistance. After HPMA-Dox conjugate was internalized by an endocytosis 
pathway, the spacer between the polymer and the drug was cleaved by an enzymatic 
hydrolysis reaction in the lysosomal compartment of the cells, resulting in the release of 
the drug from the conjugate. Chronic exposure of sensitive A2780 cells to HPMA-Dox 
conjugates did not induce MDR as measured by quantification of MDR-1 gene expression, 
the inhibition of MPR gene expression and a decrease of resistance against Taxol [262]. In 
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contrast, repeated exposure to free Dox led to an increased resistance to Dox and Taxol and 
upregulation of the MDR-1 gene. Further in-vitro mechanistic studies on overcoming 
MDR revealed that HMPA-Dox conjugates inhibited drug detoxification systems by 
suppressing the expression of genes encoding glutathione and UDP transferase, cellular 
defensive mechanism by activating apoptosis signaling pathways and down-regulating the 
expression of the bcl-2 protein family and mechanisms of DNA repair, replication and 
synthesis leading to more DNA damage [263, 264]. These results indicated that underlying 
mechanisms triggered by macromolecular carriers can modulate the biological response of 
the cell at a molecular level, resulting in an overall increased cytotoxicity. The ability of 
HMPA-Dox conjugates to overcome MDR in-vivo was demonstrated in solid tumor mouse 
models of sensitive human ovarian carcinoma A2780 and resistant A2780/AD tumors 
[265]. HMPA-Dox conjugates significantly decreased tumor size 28 times in sensitive 
tumors and 18 times in resistant tumors whereas free Dox only reduced tumor size 2.8 
times in sensitive tumor and had no effect in the resistant tumor model as compared to the 
control. The underlying mechanisms were also investigated for the in-vivo study. An 
enhanced accumulation of HMPA-Dox conjugates in the tumor was observed, and 
attributed to the EPR effect. The permeability of blood vessels decreased concomitantly 
with the downregulation of vascular growth and permeability (VEGF) gene in polymer-
treated tumors. The other mechanisms proposed in-vitro, such as downregulation of the 
expression of genes responsible for the activity of efflux pumps, detoxification and 
apoptosis, were also demonstrated in the in-vivo studies.  
 
3.4.5 Pluronic micelles to address P-gp 
Pluronic is an inert block copolymer comprising of poly(ethylene oxide) (EO) 
(hydrophilic) and poly(propylene oxide) (PO) (hydrophobic). Pluronics are different than 
HMPA copolymers due to their amphiphilic nature. Their surfactant properties allow them 
self-assemble into micelles with a hydrophobic PO inner core and a hydrophilic EO outer 
shell. However, similar with HMPA copolymers, Pluronic block copolymer micelles also 
have been shown to overcome drug resistance. Extensive studies with Pluronic block 
copolymer micelles have been reviewed [266-268]. SP1049C containing Dox in the mixed 
micelles of Pluronic L61 and F127 is in clinical trials to treat metastatic adenocarcinoma of 
the upper gastrointestinal tract. Also, SP1049C showed more efficient accumulation in 
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tumors than free Dox, while distribution of SP1049C in normal tissues is similar to that of 
Dox [269]. Efficacy of SP1049C was confirmed in in-vivo experiments in both sensitive 
and resistant tumor models including P388 and P388/ADR murine leukemia, Sp2/0 and 
Sp2/0-Dnr murine myeloma, 3LL-M27 Lewis lung carcinoma, MCF-7 and MCF-7/ADR 
human breast carcinomas and KBv human oral epidermoid carcinoma [267, 269]. 
However, the toxicity of SP1049C was similar to that of free Dox. This suggested that 
SP1049C did not improve toxicity of free Dox, e.g. cardiotoxicity which is improved by 
liposomal Dox. However, there were no additional side-effects reported for SP1049C. 
Disintegration of micelles in biological fluids upon dilution to a concentration below its 
CMC is one of common concerns about using micelles for drug delivery. The 
biodistribution and pharmacokinetics of Pluronic P85 micelles suggested that the 
elimination of P85 was controlled by the renal elimination of P85 unimers and not by the 
rate of micelle disintegration [270]. However, micelle disintegration had been reported 
with other Pluronic micelles. To further address the potential of micelle disintegration, 
Pluronic L121 and Pluronic P-105 micelles were chemically modified to form a network or 
crosslink. Therefore, the CMC of the micelles was greatly reduced and the stability was 
enhanced while their ability to inhibit P-gp function still remained [271, 272].  
The complex mechanisms associated with the effects of Pluronic block copolymers 
on MDR cells have been thoroughly studied. These mechanisms include, 1) altering 
membrane microviscosity [273, 274]. It was suggested that unimers (single block 
copolymer molecules) are responsible for biological modification as the effect of Pluronic 
copolymer occurred at the concentrations below their CMC. The hydrophobic PO chains of 
Pluronic unimers insert into the hydrophilic regions of the membrane, resulting in 
alterations of the membrane structure, and decrease in its microviscosity (membrane 
fluidization); and 2) inhibiting drug efflux transporters, such as P-gp and MRPs, through 
inhibition of P-gp ATPase activity; and 3) depleting intracellular ATP levels [273, 275]. 
As these pumps are energy dependent, attenuation of these pumps was related to energy 
deprivation and abolishment of pump associated ATPase activity. Thus, it can be surmised 
that Pluronic mediating direct and indirect energy depletion leads to operation cessation of 
efflux pumps and consequently sensitizes resistant cell lines to chemotherapeutic agents. A 
linear correlation between the extent of ATP depletion and chemosensitization elicited was 
established; and 4) influencing cell apoptosis signaling. Dox-loaded Pluronic block 
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copolymer P85 significantly enhanced the pro-apoptotic activity of the drug and prevented 
the activation of the anti-apoptotic cellular defense [276]; and 5) decreasing GSH 
intracellular levels and glutathione-s-transferase (GST) activity, indicating the inhibition of 
the GSH-GST detoxification system [277]. 
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Table 3.1.  Summary of alternative parenteral formulations of paclitaxel in 
clinical development (Adapted from Hennenfent and Govindan [28]) 
Delivery 
strategy Agent 
Development 
stage 
Dose-limiting 
toxicity References 
Nanoparticles 
Paclitaxel protein-
bound particles 
(AbraxaneTM) 
FDA-
approved 
(300)a 
neuropathy, 
stomatitis, 
superficial 
keratopathy 
[30] 
Prodrugs DHA-paclitaxel 
(Taxoprexin®) 
Clinical 
(phase III) 
(1100)a 
neutropenia [278] 
Co-solvents 
Polymeric-micellar 
paclitaxel 
(Genexol-PM®) 
Clinical 
(phase I)a 
(390) 
neuropathy, 
myalgia, 
neutropenia 
[279] 
Liposomes 
Liposome-
encapsulated 
paclitaxel 
Clinical 
(phase I) 
(175)a 
mucositis, 
neutropenia 
[280] 
Emulsions 
Paclitaxel vitamin 
E? emulsion 
(Tocosol/S-8184) 
Clinical 
(phase II) neutropenia 
[281] 
 
a: maximum tolerated dose (mg/m2) 
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Table 3.2.  Formulations to overcome MDR and their proposed mechanisms 
Formulations Proposed mechanisms Status References 
Endocytosis In-vitro [238] 
Interaction of liposomes  
with P-gp In-vitro [235] Liposomes 
Co-encapsulation of a P-gp 
inhibitor (verapamil) In-vitro [244] 
Polymethacrylate NPs Endocytosis In-vitro [252] 
Polyisohexylcyanoacrylate 
NPs 
(1) No endocytosis 
(2) Saturation of P-gp by 
high concentration of the 
drug 
(3) Formation of an ion-pair 
between NP degradation 
product and the drug 
In-vitro 
in-vivo [253-255] 
Polymer-lipid hybrid NPs Phagocytosis In-vitro [251] 
AerosolOT (AOT)-alginate NPs Not established In-vitro [248] 
Solutol HS-15-based lipid 
nanocapsules 
(1) Interaction of the 
released intracellular free 
Solutol HS-15 with MDR 
efflux pump 
(2) Redistribution of 
intracellular cholesterol 
In-vitro 
in-vivo [191, 257] 
HPMA copolymer-Dox 
conjugates 
(1) Endocytosis 
(2) Inhibition of drug 
detoxification systems 
(3) Inhibition of cellular 
defensive mechanisms 
In-vitro 
in-vivo [259-265] 
Pluronic block copolymer 
micelles 
(1) Change in membrane 
microviscosity 
(2) Inhibition of drug efflux 
transporters 
(3) ATP depletion 
(4) Influence of cell 
apoptosis signaling 
(5) Inhibition of the GSH-
GST detoxification system 
In-vitro 
in-vivo 
phase II 
[266-275] 
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Figure 3.1:  The chemical structure of paclitaxel 
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Figure 3.2:  The chemical structure of doxorubicin. 
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Figure 3.3:  The summary of the mechanisms in which cultured cancer cells have 
been shown to become resistant to cytotoxic anti-cancer drugs. The efflux pumps 
shown schematically at the plasma membrane include MDR-1, MRP family members, and 
MXR (ABC G2), which is presumed to function as a dimer (Adapted from Gottesman 
[77]). 
ATP ATP
1. Efflux pump
2. Altered cell cycle checkpoints
3. Alterations in 
membrane lipids
6. Induction of emergency genes
4. Alteration in detoxification system
The increase of repair 
of damage and 
inhibition of apoptosis 
5. Altered drug targets
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Figure 3.4:  Topology model of P-glycoprotein. Each hydrophobic domain is followed 
by a hydrophilic domain (ATP binding domain) containing a nucleotide-binding site that is 
located at the cytoplasmic face of the membrane and couples ATP hydrolysis. 
ATP ATPNH2
COOH
out
in
Cell membrane
 53
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5:  A schematic representation of enhanced drug delivery to solid tumors 
using nanoparticles. (I) Passive targeting delivery. After i.v. injection, nanoparticles 
accumulate in tumors through leaky and permeable tumor vasculature and impaired 
lymphatic system (EPR effect). (II) Active targeting delivery. Ligand-coated nanoparticles 
can bind with the receptor resulting in cell-specific recognition and improved drug delivery 
to solid tumors.  
nucleus
receptor
nanoparticles
i.v. injection
Blood vessel
Normal vessels have 
a tight endothelium 
Angiogenic tumor vessels 
are leaky and permeable
Tumor
I
II
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Figure 3.6:  A schematic representation of the primary and loop structure of TGF-α. 
Te six cysteines form the three disulfide loops. The disulfide bonds are represented as thick 
lines, and the loops formed by these are labeled as A, B, and C. 
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Chapter 4 
 
The metabolism of fatty alcohols in lipid nanoparticles by horse liver alcohol 
dehydrogenase 
 
4.1 Summary 
Fatty alcohols are commonly used in lipid-based drug delivery systems including 
parenteral emulsions and solid lipid nanoparticles. The purpose of these studies was to 
determine whether horse liver alcohol dehydrogenase, a NAD-dependent enzyme, could 
metabolize the fatty alcohols within the NPs and thus serve as a mechanism to degrade 
these NPs in the body. Solid nanoparticles (<100 nm) were engineered from oil-in-water 
microemulsion precursors using emulsifying wax as the oil phase and Brij 78 as the 
surfactant. Emulsifying wax contains both cetyl and stearyl alcohols. NPs were incubated 
with the enzyme and NAD+ at 37°C for up to 48 h, and the concentrations of fatty alcohols 
were quantitatively determined over time by gas chromatography (GC). The concentrations 
of cetyl alcohol and stearyl alcohol within the NPs decreased to only 10-20% remaining 
after 15-24 h of incubation. In parallel, NP size, turbidity and the fluorescent intensity of 
NADH all increased over time. It was concluded that horse liver alcohol 
dehydrogenase/NAD+ was able to metabolize the fatty alcohols within the NPs, suggesting 
that NPs made of fatty alcohols may be metabolized in the body via endogenous alcohol 
dehydrogenase enzyme systems. 
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4.2 Introduction 
Nanoparticles have received considerable attention as potential drug delivery 
systems for over 30 years. There are some general advantages to the use of nanoparticles 
for drug delivery: (1) Due to their small sizes, nanoparticles help to solve many 
challenging problems in drug formulation. For example, nanoparticles are ideal carriers for 
poorly soluble drugs, especially when the drugs lack solubility in both aqueous and non-
aqueous media. Reducing the particle size of poorly soluble drugs may enhance the 
dissolution rate and drug bioavailability since the available surface area per given mass of 
particles is increased [282]; (2) The toxicity and side effects of certain anti-cancer drugs 
such as doxorubicin [283] and cisplatin [284] may be considerably reduced by entrapping 
the drugs in nanoparticles; (3) In addition, nanoparticles have been shown to provide 
benefit in enhancing the circulation time of drugs in the body [285, 286]; (4) Finally, 
nanoparticles have been used to target specific cells and tissues in the body [287] and to 
control the release rate of drugs [288].  
 One of the major considerations in the use of nanoparticles as delivery systems is 
the selection of the composition of the components. Typically, nanoparticles are made 
from either biodegradable and/or biocompatible polymers or lipids [289, 290]. Recently, 
lipids such as fatty alcohols have been used to form colloidal carriers such as microspheres 
[291, 292], liposomes [293, 294] and nanoparticles [295]. However, there are few or no 
reports on the metabolism of fatty alcohols within formed nanoparticles. It was previously 
shown by DeAngelis and Findlay that synthetic 14C-cetyl alcohol was widely distributed in 
the body after intratracheal administration. 14C-cetyl alcohol was oxidized to palmitic acid 
which was then used in the phospholipid biosynthesis pathway [296]. Additionally, another 
report has shown that lipase was able to metabolize fatty acids used to make solid lipid 
nanoparticles [219].  
 Our laboratories have reported on a novel method to engineer stable nanoparticles 
from oil-in-water microemulsion precursors. In this method, melted nonionic emulsifying 
wax which is composed of cetyl alcohol (C16H34O), stearyl alcohol (C18H38O) and 
polysorbate 60 was used to form the oil phase. These nanoparticles have been utilized for 
brain targeting [297], dendritic cell targeting [298, 299] and tumor targeting [300-302]. In 
a recent study, it was demonstrated that these lipid-based nanoparticles did not cause in-
vitro red blood cell lyses at concentrations up to 1 mg/ml [218]. In addition, these 
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nanoparticles did not activate or aggregate platelets; however, the nanoparticles were 
shown to inhibit agonist induced platelet activation and aggregation in a dose-dependent 
manner. Although these NPs appear to have blood compatibility at clinically relevant 
doses, little is known about the metabolism of the NPs. 
The purpose of the present studies was to investigate whether horse liver alcohol 
dehydrogenase (alcohol: AD+ oxidoreductase, EC 1.1.1.1) could metabolize cetyl and stearyl 
alcohols present in the lipid-based nanoparticles. The metabolism of the fatty alcohols in the 
nanoparticles was monitored by the increase in fluorescence intensity of NADH and by 
quantitative measurements of the metabolized products using a quantitative gas 
chromatographic method. 
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4.3 Materials and Methods 
 
Materials 
Cetyl alcohol (1-hexadecanol, 95%) was purchased from Sigma (St. Louis, MO). 
Stearyl alcohol (1-Octadecanol, 99%), stearic acid (99.5%), pyridinium chlorochromate 
(PCC), nonadecanoic acid (98%), diethyl ether, dichloromethane (CH2Cl2), NAD+ (β-
nicotinamide adenine dinucleotide) (99%) and horse liver alcohol dehydrogenase (HLADH) 
(0.89 units/mg lyophilized powder containing sodium phosphate buffer salt and NAD+) were 
purchased from Sigma-Aldrich (St. Louis, MO.). Celite® 545, 1 N hydrochloric acid and 1 N 
sodium hydroxide were obtained from Fisher (Fairlawn, NJ.). Silica gel 60 was obtained 
from Macherey-Nagel (Düren, Germany). Hexane was purchased from EM (Darmstadt, 
Germany). Brij 78 was purchased from Uniqema (New Castle, DE.). Emulsifying wax, 
palmitic acid, monobasic sodium phosphate and dibasic sodium phosphate were purchased 
from Spectrum (New Brunswick, NJ.).  
 
Methods 
Synthesis of hexadecanal and octadecanal 
Hexadecanal and octadecanal were prepared by oxidation of the corresponding 
alcohols using pyridinium chlorochromate (PCC). The initial concentrations of pyridinium 
chlorochromate and fatty alcohols were 0.9 mM and 0.1 mM, respectively. Pyridinium 
chlorochromate was dissolved in 85 ml dichloromethane with Celite 545 (PCC: Celite 545, 
1: 1 w/w). The fatty alcohol dissolved in 15 ml dichloromethane was slowly added to a well 
stirred PCC solution and reacted for 4 h. The reaction mixture was passed through a column 
(3 cm × 8 cm) packed with silica gel 60. The products were eluted with dichloromethane and 
the fraction was evaporated to dryness. The structures of hexadecanal and octadecanal were 
confirmed by GC-MS and NMR.   
 
Preparation and characterization of nanoparticles from microemulsion precursors 
Solid nanoparticles were engineered from oil-in-water microemulsion precursors 
using emulsifying wax as the oil phase and Brij 78 as the surfactant. Twelve (12) milligrams 
of emulsifying wax were accurately weighed into a glass vial and melted together with 20.7 
mg Brij 78 at 60°C. Next, 6 ml of 50 mM phosphate buffer (pH 7.5) were added under 
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magnetic stirring. After 30 min of continuing stirring at 60°C, a homogeneous and clear oil-
in-water microemulsion formed. The warm microemulsion was then cooled to room 
temperature while stirring to form a 6 ml solid nanoparticle suspension. After the 
nanoparticles formed, an additional 4 ml of 50 mM phosphate buffer (pH 7.5) were added to 
dilute the nanoparticles to 10 ml. Nanoparticle size was measured by photon correlation 
spectroscopy (PCS) using a Coulter N4 Plus Submicron Particle Sizer (Coulter, Miami, FL) 
by scattering light at 90° at 25°C for 1 min. Each 1 ml sample for PCS was prepared by 
diluting 100 μl nanoparticle suspension with 900 μl deionized and 0.22 μm filter water. 
 
Incubation of nanoparticles with horse liver alcohol dehydrogenase and NAD+ 
Horse liver alcohol dehydrogenase and NAD+ were added to nanoparticle 
suspensions so that the final concentrations were 1 mg/ml and 5 mg/ml, respectively. The 
amount of alcohol dehydrogenase and NAD+ added was based on a previous reported study 
(Hinson & Neal, 1975.). The samples were incubated with shaking at 37°C for 48 h. 
Nanoparticle suspensions in the absence of alcohol dehydrogenase and NAD+ were used as 
controls. To measure the metabolism of the fatty alcohols, 100 μl and 1000 μl aliquots were 
removed from the samples at different time points during the 48 h incubations. For the 100 
μl aliquots, 900 μl water was immediately added to perform particle size, turbidity, and 
fluorescence intensity measurements (see below). For the 1000 μl aliquots, the enzymatic 
reaction was terminated by adding 100 μl of 1 N HCl. Next, 300 μl of the internal standard, 
nonadecanoic acid (1000 μg/ml), were added to the mixture. The mixture was then heated at 
60°C for 30 min, cooled to room temperature, and then extracted with 1 ml diethyl ether (× 
2) and 1 ml hexane (× 2). The combined extract was dried under N2, and dissolved with 1 ml 
hexane for GC analysis. 
 
Measurement of particle size, turbidity and fluorescence intensity  
The nanoparticle size was measured as described above. The turbidity of the 
nanoparticle suspensions was detected by UV spectroscopy using a Beckman DU 7500i 
Spectrophotometer at 320 nm using water as the blank. The fluorescence intensity of NADH 
was measured using a Hitachi Model F-2000 Fluorometer (excitation wavelength was 350 
nm and emission wavelength was 460 nm). To obtain the corrected fluorescent measurement 
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of each sample, the fluorescent intensity of a fresh mixture of 1 mg/ml alcohol 
dehydrogenase and 5 mg/ml NAD+ was subtracted at each time point. 
 
The influence of Brij 78 on the HLADH/NAD+ enzyme reaction of fatty alcohols  
Cetyl alcohol (1 mg/ml) without Brij 78 and with 1 mM Brij 78 or 3 mM Brij 78 was 
incubated with 1 mg/ml horse liver alcohol dehydrogenase and 5 mg/ml NAD+ at 37°C for 
48 h. The enzymatic reactions were monitored by detecting NADH (as described above). As 
controls, the mixtures of alcohol dehydrogenase and NAD+ in the absence and present of Brij 
78 were used. 
 
Quantitative analysis of cetyl alcohol and stearyl alcohol by gas chromatography  
GC analysis was performed using a Thermoquest Trace 2000 System equipped with a 
flame ionization detector (FID) and AS 2000 Autosampler. Separation of samples was 
carried out on a 30 m column (0.53 mm i.d.) coated with SPB-1 phase (poly 
(dimethylsiloxane), 1.5 µm film thickness) from Supelco (Bellefonte, PA). The injector was 
used in the splitless mode, and the sample injection volume was 1 μl. The injector and 
detector temperatures were kept at 220°C and 270°C, respectively. The initial temperature of 
the column was 80°C and was held for 0.06 min, and then increased at 20°C/min to 250°C. 
The temperature was then held at 250oC for 6 min. The total run time was 14.56 min. Helium 
was used as the carrier gas. Data acquisition and processing were performed with a 
Chromquest (Version 2.53) software for GC system. 
The identification of sample peaks was determined by comparing the relative 
retention time to that of known standards. Quantification was aided using nonadecanoic acid 
as an internal standard. The purity of each standard was determined by GC in triplicate. The 
revised concentration was used for subsequent calculations. The stock solutions of 
hexadecanal, octadecanal, cetyl alcohol, stearyl alcohol, palmitic acid, stearic acid and 
nonadecanoic acid were prepared at a concentration of 1000 µg/ml in n-hexane. From the 
stock solutions of cetyl alcohol and stearyl alcohol, working standards of 600, 400, 300, 100 
and 10 µg/ml containing 300 µg/ml nonadecanoic acid in n-hexane were made. Each sample 
was measured in triplicate, and average areas were used to obtain calibration curves of the 
standards. Consequently, quantitative linear ranges were determined and relative response 
factors (fi) were calculated. The stock solutions of hexadecanal, octadecanal, palmitic acid 
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and stearic acid were used to identify the corresponding peaks. The concentrations of 
samples from the incubations were determined in triplicate and calculated as Wi = (fi ×Ai × 
Ws)/As: where Wi and Ws are the weighed amounts of sample (i) and internal standard (s), 
respectively; Ai is the peak area of sample, As is the peak area of the internal standard, and fi 
is the relative response factor of sample (i). 
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4.4 Results and discussion 
Fatty alcohols present in the body can be incorporated into wax esters and ether lipids 
via the fatty acid-fatty alcohol cycle [303]. Fatty alcohols are oxidized to the corresponding 
fatty acids by fatty alcohol: NAD+ oxidoreductase (FAO, EC 1.1.1.192). FAO is a complex 
enzyme that consists of at least two separate enzymes, fatty alcohol dehydrogenase (FADH) 
and fatty aldehyde dehydrogenase (FALDH). Fatty alcohol dehydrogenase (FADH) 
metabolizes fatty alcohols to fatty aldehydes and fatty aldehyde dehydrogenase (FALDH) 
metabolizes fatty aldehydes to fatty acids [303-305]. Previous literature studies with this 
enzyme system have been performed in a heterogeneous enzyme ‘cocktail’ derived from the 
liver, and thus it was not an isolated enzyme system. However, in these present studies, a 
commercially available purified enzyme, HLADH was utilized. The general reaction of 
HLADH is shown in Figure 4.1 [306]. As a single enzyme, Horse liver alcohol 
dehydrogenase catalyzes the reversible interconversion of fatty alcohols and their 
corresponding aldehyde/ketone products, and also catalyzes the dismutation and oxidation of 
the fatty aldehydes to the corresponding fatty acids. The activity of horse liver alcohol 
dehydrogenase for aldehyde oxidation is low due to the high Km and low Vmax of the reaction 
of fatty alcohols to fatty acids. Thus, alcohol dehydrogenase plays a more important role in 
the oxidation of alcohols to aldehydes. Related, aldehyde dehydrogenase may then convert 
the formed aldehydes to the corresponding acids [306, 307]. 
In order to choose the appropriate operational parameters for the quantitative gas 
chromatographic method, several temperature programs were studied. The optimized 
chromatographic method balanced efficiency, sample capacity, and peak resolution. In initial 
GC method development studies, peaks of palmitic acid and stearyl acid showed some 
tailing. Thus, methods were adapted to increase resolution and resolve tailing. The final 
optimized temperature program was held at 80°C for 0.06 min, then increased to 250°C at a 
rate of 20°C/min and held for 6 min at 250°C. Seven compounds (hexadecanal, cetyl 
alcohol, palmitic acid, octadecanal, stearyl alcohol, stearic acid and nonadecanoic acid) were 
fully separated with good resolution in the optimized operational condition. A representative 
GC chromatogram is shown in Figure 4.2.  
 The purity of cetyl alcohol, stearyl alcohol, and nonadecanoic acid was determined 
by GC and is listed in Table 4.1. Nonadecanoic acid was chosen as the internal standard for 
quantitative measurement by GC. All three compounds had purity in the range of 98.3-
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99.4%. Table 4.2 shows the calibration parameters of both cetyl and stearyl alcohols. A 
minimum of five concentrations were examined for each calibration curve (see Figure 4.3). 
The results demonstrate that the calibration curves for both cetyl and stearyl alcohols were 
linear from 10 µg/ml to 600 µg/ml. The R2 value for cetyl alcohol and stearyl alcohol were 
0.9969 and 0.9941, respectively. 
The in-vitro metabolism of lipid-based NPs is shown in Figure 4.4 as a function of 
time. The GC assay was used to quantify the loss of both cetyl and stearyl alcohols from the 
NP suspension incubated with the HLADH/NAD+ system at 37oC for up to 48 h. The 
concentrations of cetyl alcohol and stearyl alcohol decreased by more than 80% of each 
initial one of fatty alcohols after 15-24 h. However, from 24-40 h, the concentrations of both 
cetyl alcohol and stearyl alcohol increased by 2-3 fold. This phenomenon was very 
reproducible and was repeated in multiple experiments. Most likely, the subsequent increase 
in alcohol concentrations at approximately 24 h could be explained by the unique property of 
the enzyme (see Figure 4.1) whereby the equilibrium supports the regeneration of the 
alcohols from the aldehydes by the reversible reactions [306, 308].  
 Experiments were also performed to quantify the corresponding fatty aldehydes 
(hexadecanal and octadecanal) and fatty acids (palmitic acid and stearic acids). In fact, as 
shown in Figure 4.2, the presence of these metabolic products could be identified by GC. 
However, due to extraction difficulties and stability limitations of the fatty aldehydes, 
additional studies were not performed to develop a quantitative GC method for these 
compounds. 
 
Increase in size, turbidity and fluorescence intensity when NPs are incubated with 
HLADH/NAD+ 
 In addition to quantitative studies assessing the loss of the primary NP components, 
cetyl and stearyl alcohols, evidence to prove NP metabolism was sought. It was 
hypothesized that NPs exposed to HLADH/NAD+ would undergo an expansion in particle 
size coupled with an increase in turbidity due to the presence of metabolic products. As 
shown in Figure 4.5, HLADH/NAD+ caused the NPs to more than double in size over 48 h at 
37oC versus a NP control. In addition, as shown in Figure 4.6, there was a corresponding 
increase in the turbidity of the metabolized NP suspension. It was also noted that the 
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metabolized NP suspension exhibited an increase in foaming likely a result of free Brij 78 
that was liberated from the NPs over time.   
 As shown in Figure 4.1, the conversion of a fatty alcohol by HLADH results in the 
reduction of NAD+ to NADH. NADH is fluorescent and thus its concentration over time 
would be expected to increase upon fatty alcohol metabolism. As shown in Figure 4.7, 
NADH fluorescence in the suspension substantially increased over the first 24 h providing 
additional evidence of the enzymatic reaction. Notably, the rate and extent of NADH 
fluorescence very closely matched the rate and extent of the loss of fatty alcohols as shown 
in Figure 4.4. 
 
Effect of the Brij 78 surfactant on the enzyme reaction 
During the engineering of the nanoparticles, the Brij 78 surfactant was added to form 
the oil-in-water microemulsion at an elevated temperature. It is known that the addition of 
even low concentrations of surfactants influence the structure and activity of enzymes [309, 
310]. No previous literature reports on the effect of Brij-based surfactants on the 
HLADH/NAD+ enzyme system were identified. Thus, studies were undertaken to assess the 
effect of Brij 78 on the activity of this enzyme system. In these studies, cetyl alcohol was 
incubated with HLADH/NAD+ in the presence and absence of Brij 78. The increase of 
NADH fluorescence was monitored over time. As shown in Figure 4.8, the incubation of 
HLADH/NAD+ with or without 2 mM Brij 78 resulted in no increase in NADH fluorescence 
intensity. The fluorescence intensity increased when HLADH/NAD+ was incubated with 1 
mg/ml cetyl alcohol. However, the rate of increase of fluorescence intensity was 
considerably lower than the rate when HLADH/NAD+ was incubated with lipid-based NPs 
(as shown in Figure 4.7). This suggested that Brij 78 may be enhancing the activity of 
HLADH. In fact, when HLADH/NAD+ was incubated with both Brij 78 and cetyl alcohol, 
the fluorescent intensity markedly increased similar to that of the NPs shown in Figure 4.7. 
Moreover, the enhancement of fluorescent intensity was related to the concentration of Brij 
78. These results indicate that the activity of HLADH was enhanced in the presence of Brij 
78 and this enhancement accelerated metabolism of fatty alcohols present as either free fatty 
alcohols (cetyl alcohol alone) or fatty alcohols entrapped in a solid nanoparticle. 
In conclusion, the results of these studies demonstrate that an alcohol dehydrogenase 
enzyme metabolized fatty alcohols present in solid lipid-based nanoparticles. In fact, 
 65
entrapping the fatty alcohols into solid nanoparticles did not hinder the reaction of the fatty 
alcohols with the enzyme. Under the conditions tested, over 80% of cetyl alcohol and stearyl 
alcohol in the NP suspension were metabolized within 15 h. The results also showed that 
Brij 78 increased the activity of the enzyme. These studies suggest that lipid-based systems 
comprised of fatty alcohols are likely to be readily metabolized in the body by endogenous 
fatty alcohol dehydrogenase. 
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Table 4.1.  The average purity of each standard as measured 
by gas chromatography (n=3) 
 
Standard Cetyl Alcohol Stearyl Alcohol Nonadecanoic acid 
Purity (%) 99.37 98.29 98.52 
R.S.D. (%) 0.222 0.031 0.178 
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Table 4.2.  Calibration parameters of cetyl and stearyl alcohols in the 
quantitative gas chromatographic assay 
 
Standard Calibration curve Linear range (µg/ml) R
2 Relative response factor (fi) 
Cetyl Alcohol (n=3) y = 3.2438x – 0.1284 10-600 0.9969 0.30828 
Stearyl Alcohol (n=3) y = 3.4693x – 0.1838 10-600 0.9941 0.28824 
 
Nonadecanoic acid was used as an internal standard. y= Ai/As and x= Ci/Cs; where 
Ai and As are the peak areas of the fatty alcohols and internal standard, respectively, and 
Ci and Cs are the concentrations of the fatty alcohols and internal standard, respectively. 
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Figure 4.1 
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Figure 4.1:  The reaction of fatty alcohol and fatty aldehyde with horse liver alcohol 
dehydrogenase (HLADH)/NAD+ enzyme system. 
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Figure 4.2 
 
 
Figure 4.2:  Gas chromatography (GC) chromatogram of seven standards: (1) 
hexadecanal, (2) cetyl alcohol, (3) palmitic acid, (4) octadecanal, (5) stearyl alcohol, (6) 
stearic acid and (7) nonadecanoic acid. 
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Figure 4.3 
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Figure 4.3:  Calibration curves (Ci/Cs vs Ai/As) of cetyl alcohol and stearyl alcohol as 
measured by gas chromatography. Ai and As are the peak areas of the fatty alcohols and 
internal standard, respectively. Ci and Cs are the concentrations of the fatty alcohols and 
internal standard, respectively. Each point is the mean ± SD (n=3). The internal standard 
was nonadecanoic acid. 
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Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4:  In-vitro metabolism of cetyl alcohol and stearyl alcohol in lipid 
nanoparticles as a function of time when nanoparticles were incubated with horse 
liver alcohol dehydrogenase and NAD+ at 37oC for 48 h. Each point is the mean ± SD 
(n=3). 
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Figure 4.5 
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Figure 4.5:  The change in particle size when lipid nanoparticles were incubated with 
horse liver alcohol dehydrogenase and NAD+ at 37oC for 48 h. Each point is the mean ± 
SD (n=3). 
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Figure 4.6 
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Figure 4.6:  The change in turbidity when lipid nanoparticles were incubated with 
horse liver alcohol dehydrogenase and NAD+ at 37oC for 48 h. Each point is the mean ± 
SD (n=3). 
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Figure 4.7 
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Figure 4.7:  The change in fluorescence intensity when lipid nanoparticles were 
incubated with horse liver alcohol dehydrogenase and NAD+ at 37oC for 48 h. Each 
point is the mean ± SD (n=3). 
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Figure 4.8 
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Figure 4.8:  The effect of Brij 78 on the enzymatic reaction of cetyl alcohol in lipid 
nanoparticles with horse liver alcohol dehydrogenase (HLADH) and NAD+ for 48 h. 
(○) 2 mM Brij 78 + HLADH/NAD+, (▲) HLADH/NAD+, (●) Cetyl alcohol + 
HLADH/NAD+, (□) 1 mM Brij 78 + cetyl alcohol + HLADH/NAD+, (■) 3 mM Brij 78 + 
cetyl alcohol + HLADH/NAD+. For all samples, the concentrations of HLADH, NAD+, 
and cetyl alcohol were 1 mg/ml, 5 mg/ml, and 1 mg/ml, respectively.  Each point is the 
mean ± SD (n=3). 
 
 
 
 
 
 
*The contents of this chapter were published in Drug Development and Industrial 
Pharmacy, 32:973-980, 2006. X. Dong and R. J. Mumper, The metabolism of fatty 
alcohols in lipid nanoparticles by alcohol dehydrogenase. Copyright 2006 with permission 
from Informa.  
 
Copyright © Xiaowei Dong 2009 
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Chapter 5 
 
Development of new lipid-based paclitaxel nanoparticles using  
sequential simplex optimization 
 
5.1 Summary 
The objective of these studies was to develop Cremophor-free lipid-based 
paclitaxel nanoparticle formulations prepared from warm microemulsion precursors. To 
identify and optimize new nanoparticles, experimental design was performed combining 
Taguchi array and sequential simplex optimization. The combination of Taguchi array and 
sequential simplex optimization efficiently directed the design of paclitaxel nanoparticles. 
Two optimized paclitaxel nanoparticles were obtained: G78 NPs composed of glyceryl 
tridodecanoate (GT) and Brij 78, and BTM NPs composed of Miglyol 812, Brij 78 and 
TPGS. Both nanoparticles successfully entrapped paclitaxel at a final concentration of 150 
µg/ml (over 6% drug loading) with particle sizes less than 200 nm and over 85% of 
entrapment efficiencies. These novel paclitaxel nanoparticles were stable at 4ºC over five 
months and in PBS at 37ºC over 102 h as measured by physical stability. Release of 
paclitaxel was slow and sustained without initial burst release. Cytotoxicity studies in 
MDA-MB-231 cancer cells showed that both nanoparticles have similar anti-cancer 
activities compared to Taxol. Interestingly, PX BTM nanocapsules could be lyophilized 
without cryoprotectants. The lyophilized powder comprised only of PX BTM NPs in water 
could be rapidly rehydrated with complete retention of original physicochemical 
properties, in-vitro release properties, and cytotoxicity profile. Sequential simplex 
optimization has been utilized to identify promising new lipid-based paclitaxel 
nanoparticles having useful attributes. 
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5.2 Introduction 
Paclitaxel is one of the most effective anti-cancer agents used in the treatment of 
various tumors. It is a taxane which interferes with microtubule depolymerization in tumor 
cells resulting in an arrest of the cell cycle in mitosis followed by the induction of 
apoptosis. However, the high lattice energy of paclitaxel results in very limited aqueous 
solubility (approximately 0.7-30 µg/ml) [18, 19] contributing to only two commercialized 
dosage forms of injectable paclitaxel, Taxol and Abraxane. Taxol is composed of a 50:50 
(v/v) mixture of Cremophor EL (polyethoxylated castor oil) and dehydrated alcohol. 
Serious side effects, such as hypersensitivity reactions, attributable to Cremophor EL, have 
been reported [26]. In clinical therapy, high doses of anti-histamines and gluococorticoids 
are co-administered to manage these adverse effects, but this strategy has raised the 
possibility of additional pharmacokinetic and pharmacodynamic issues with paclitaxel. To 
eliminate Cremophor EL from the paclitaxel formulation, many alternative Cremophor EL-
free formulations of paclitaxel have been investigated. Abraxane is one of those 
Cremophor EL-free paclitaxel formulations and was registered with the FDA in 2005. 
Despite its improved clinical profile, Abraxane is generally not replacing Taxol in cancer 
chemotherapy, mostly due to its high cost. Therefore, alternative and cost-effective 
parenteral formulations of paclitaxel are still needed.  
Nanoparticles offer an alternative delivery system for cancer therapy that have the 
potential to control the release rate of drug, improve the drug pharmacokinetics and 
biodistribution, and reduce drug toxicity. Due to their small size, nanoparticles with 
entrapped drugs may penetrate tumors due to the discontinuous and leaky nature of the 
microvasculature of tumors [47, 311]. Also, the characteristically poor lymphatic drainage 
of tumors may result in slower clearance of nanoparticles that accumulate in tumors. This 
well-known effect is referred to as the EPR effect [283, 312].  
Lipid-based particulate delivery systems, including liposomes, micelles, 
nanocapsules, and solid lipid nanoparticles, have been developed especially to solubilize 
poorly water-soluble and lipophilic drugs. These lipid-based systems have the advantage 
that comprises bio-derived and/or biocompatible lipids that often result in lower toxicity. 
In general, the lipid-based systems are made from the combination of lipophilic (oil), 
amphiphilic (surfactant) and hydrophilic (water) excipients. Formulation approaches 
typically involve a highly interactive process of experimentally investigating many 
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variables including type and amount of excipients, excipient combinations, and processes 
(i.e., high-pressure homogenization, microfluidization, extrusion, microemulsion 
precursors, etc.). Appropriate type and amount of excipients are critical variables, 
especially in the case of microemulsion precursors to prepare lipid-based systems. 
Typically, phase diagrams with the blends of different excipients are first developed using 
the water titration method. Then, combinations of excipients and the drug substance are 
further optimized for their phase behavior and thermodynamic stability [313, 314]. 
However, when several surfactants and/or oils are used, construction of phase diagrams 
becomes quite tedious, expensive, and time consuming. 
Experimental design is a statistical technique used to simultaneously analyze the 
influence of multiple factors on the properties of the system being studied. The purpose of 
experimental design is to plan and conduct experiments in order to extract the maximum 
amount of information from the collected data in the smallest number of experimental 
runs. Factorial design based on response surface method has been applied to design 
formulations [203, 315]. However, an increase in the number of factors markedly increases 
the number of experiments to be carried out. The so-called Taguchi approach proposes a 
special set of orthogonal arrays to standardize fractional factorial designs [208]. By this 
approach, the size of factorial design is reduced. As shown in Figure 5.1, sequential 
simplex optimization is a step-wise strategy for optimization that can adjust many factors 
simultaneously to rapidly achieve optimal response. The optimization is preceded by 
moving of a geometric figure (the “simplex”). The starting simplex is composed of k + 1 
vertex (experiments) wherein k is the number of variables. Then, the experiments are 
performed one by one. The new simplex is obtained based on the results from the previous 
simplex and the procedure is repeated until the simplex has rotated and optimum is 
encircled. The variable-size simplex algorithm is the modified simplex algorithm which 
allows the simplex to change its size during movement (Figure 5.1). For detailed principles 
and applications, the reader is referred to the specialized literature [316, 317]. Thus, this 
process of sequential simplex optimization allows for simultaneous formulation 
development and optimization.  
Our laboratory has already reported on the engineering of stable solid lipid-based 
nanoparticles from oil-in-water microemulsion precursors. Nanoparticles (E78 NPs) 
composed of E. wax as the lipid matrix and Brij 78 as the surfactant were reproducibly 
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prepared with particle sizes less than 150 nm. These E78 NPs were found to have excellent 
hemocompatibility [218] and were shown to be metabolized in-vitro by HLADH/NAD+ 
[318]. Paclitaxel E78 NPs were shown to overcome Pgp-mediated tumor resistance in-vitro 
in a human HCT-15 colon adenocarcinoma cell line [300] and in-vivo in athymic nude 
mice bearing solid HCT-15 xenograft tumors [319]. However, a shortcoming of the PX 
E78 NPs used in the above studies was that the entrapment efficiency of paclitaxel in the 
NPs was only 50% which resulted in relatively rapid in-vitro release (over 80% in 8 h). 
These shortcomings were directly attributable to the relatively poor solubility of PX in the 
melted E. Wax. 
In light of the above, the objective of these studies was to develop Cremophor-free 
lipid-based paclitaxel nanoparticle formulations that (1) utilized acceptable oil phases 
having improved solvation ability for PX, (2) had PX entrapment efficiency >80% with a 
minimum final concentration of 150 μg/ml with over 5% drug loading, (3) resulted in 
slow(er) release profiles of PX from NPs, and (4) had comparable in-vitro cytotoxicity to 
Taxol. To achieve these objectives, two medium-chain triglycerides, glyceryl 
tridodecanoate and Miglyol 812, were selected as the oil phases to engineer nanoparticles 
from o/w microemulsion precursors. Triglycerides are biocompatible/biodegradable 
excipients [320]. It has been reported that paclitaxel has a high partition coefficient (Kp) in 
medium-chain triglycerides [321]. Glyceryl tridodecanoate is solid at room temperature 
whereas Miglyol 812 is liquid at room temperature. Thus, it was thought that the uses of 
glyceryl tridodecanoate and Miglyol 812 as oil phases may result in the formation of solid 
lipid nanoparticles and nanocapsules, respectively. As discussed above, simplex 
optimization or the combination of Taguchi array and sequential simplex optimization was 
used to identify optimized systems based on initial response variables (criteria) of particle 
size and polydispersity index.  Identified leads were then fully characterized for stability, 
entrapment efficiency, in-vitro release, and cytotoxicity in human MDA-MB-231 breast 
cancer cells.  
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5.3 Materials and Methods 
 
Materials and cell culture 
Paclitaxel, glyceryl tridodecanoate, PBS, and Tween 80 were purchased from 
Sigma-Aldrich (St. Louis, MO). Emulsifying wax and stearyl alcohol were purchased from 
Spectrum Chemicals (Gardena, CA). Brij 78 was obtained from Uniqema (Wilmington, 
DE). TPGS was purchased from Eastman Chemicals (Kingsport, TN). Miglyol 812 is a 
mixed caprylic (C8:0) and capric (C10:0) fatty acid triglyceride and was obtained from Sasol 
(Witten, Germany). Dialyzers with a molecular weight cutoff (MWCO) of 8000 Da were 
obtained from Sigma-Aldrich (St. Louis, MO). Microcon Y-100 with MWCO 100 kDa 
was purchased from Millipore (Bedford, MA). Ethanol USP grade was purchased from 
Pharmco-AAPER (Brookfield, CT). Taxol® was obtained from Mayne Pharma Inc. 
(Paramus, NJ). The human breast cancer cell line, MDA-MB-231, was obtained from 
American Type Culture Collection (ATCC) and was maintained in DMEM supplemented 
with 10% fetal bovine serum (FBS). Cells were cultured at 37ºC in a humidified incubator 
with 5% CO2 and maintained in exponential growth phase by periodic subcultivation. 
 
Methods 
Preparation of nanoparticles from microemulsion precursors 
Nanoparticles were prepared from warm o/w microemulsion precursors as 
previously described with some modification [322]. Defined amounts of oil phases and 
surfactants were weighed into glass vials and heated to 65ºC. One (1) ml of filtered and 
deionized (D.I.) water pre-heated at 65ºC was added into the mixture of melted oils and 
surfactants. The mixture were stirred for 20 min at 65ºC and then cooled to room 
temperature. To prepare PX NPs, 150 µg of PX dissolved in ethanol was added directly to 
the melted oil and surfactant and ethanol was removed by N2 stream prior to initiating the 
process described above. Particle size and size distribution of NPs were measured using a 
N5 Submicron Particle Size Analyzer (Beckman). Ten microliters of nanoparticles were 
diluted with 1 ml of D.I. water to reach within density range required by the instrument, 
and particle size analysis was performed at 90º light scattering at 25ºC. 
 
Development of prototype nanoparticles by sequential simplex optimization 
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(1) BTM Nanoparticles comprised of Miglyol 812, Brij 78 and TPGS 
Miglyol 812 and stearyl alcohol were chosen as oil phases, and Brij 78 and TPGS 
were selected as the surfactants. Taguchi array L-9 (34) was first used to help set up the 
starting simplex for sequential simplex optimization. Particle size and polydispersity index 
(P.I.) were used to evaluate the results. Three levels for each excipient and Taguchi array 
are presented in Table 5.1.A. As directed by the results from Taguchi array, the starting 
simplex was constructed based on the results of trials 3, 5, and 9 with a slight change for 
each component in each trial (Table 5.1.B). Sequential simplex optimization then was 
performed as previously described following the variable-size simplex rules [317]. 
Desirability functions previously developed for the simultaneous optimization of different 
response variables (criteria) [323] were used to transform response variables (particle size 
and P.I.) into a measure d (dsize or dP.I.) that could be adequately compared and combined 
with each other. Then, the d of the individual response variable was combined into an 
aggregated value (D value) by using a weighted geometric average. Definitions of d and D 
value are presented in the equation (1) and equation (2), respectively:  
 
Equation (1) 
 
In Equation (1), i indicates particle size or P.I. The limits were from a = 70 nm to b = 250 
nm for particle size, and from a = 0.05 to b = 1.2 for P.I. As the optimization in Table 
5.1.B was complex, a larger range of P.I. were chosen in order to avoid too many “worst” 
trials in the simplex, which could stop the optimization. In addition, the larger range of P.I. 
also helped to seize all possible compositions in the optimization process. For these 
optimization experiments, particle size and P.I. were given equal importance; thus, the 
constant s = 1. 
The overall contribution of all responses is presented as a single aggregated D 
value as calculated by Equation (2): 
 
Equation (2) 
 
A comparison of each trial in the simplex optimization was based on this aggregated D 
value which contained information from both particle size and P.I.  
D = (dparticle size × dP.I.)1/2
di = 
0
s
i
ab
aY
⎥⎦
⎤
⎢⎣
⎡
−
−
Yi ≤ a  or 
a < Yi < b
Yi ≥ b
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After the sequential simplex optimization, Miglyol 812, Brij 78 and TPGS were 
chosen to form BTM NPs. Four different compositions based on the results from 
sequential simplex optimization were tested (Table 5.1.C) and were prepared to further 
optimize BTM NPs. 
 
(2) G78 nanoparticles comprised of glyceryl tridodecanoate and Brij 78  
G78 nanoparticles were optimized using MultiSimplex software (CambridgeSoft 
Corporation, Cambridge, MA). The variable-size simplex rules were also used in this 
optimization, and response variables included particle size, P.I. and the peak numbers in 
nanoparticle distribution. The starting simplex was based on our previously optimized E78 
NP composition (2 mg E. wax and 4 mg Brij 78 in 1 ml NP suspension). Thus, the limits 
for particle size and P.I. were naturally smaller than those for the sequential simplex 
optimization in Section 2.3.1. The limits were from a = 50 nm to b = 200 nm for particle 
size, and from a = 0.01 to b = 0.4 for P.I., and from a = 1 to b = 2 for peak numbers. Two 
milliliters of NP formulations were prepared for each composition.  
 
Lyophilization of PX NPs  
To determine the effect of lyophilization on the NPs, blank and PX NPs in the 
presence or absence of 5% lactose were lyophilized using a VirTis® lyophilizer (SP 
Industries, Gardiner, NY). Two milliliters of each sample was rapidly frozen at -40ºC and 
then lyophilized using a program of 7.5 h at -10ºC for primary drying and 7.5 h at 25ºC for 
secondary drying at 100 mTorr. The resultant lyophilized products were reconstituted in 2 
ml of D.I. water using a plate shaker for 5 min. The particle sizes of reconstituted 
lyophilized NPs from six different batches were measured as described above. 
 
Characterization of paclitaxel G78 and BTM nanoparticles  
(1) Particle size and zeta potential measurement 
Nanoparticles were analyzed for particle size and size distribution as described 
above. Ten microliters of blank NPs and PX NPs were diluted with 1 ml of D.I. water and 
was added 10 µl of PBS buffer (pH 7.4) for the measurement of zeta potentials using 
Zetasizer Nano Model ZEN2600 (Malvern Instruments, Worcs, U.K). 
 
 83
(2) Determination of drug loading and entrapment efficiency 
The concentration of PX was quantified by HPLC using a Thermo Finnigan 
Surveyer HPLC System and an Inertsil ODS-3 column (4.6 × 150 mm) (GL Sciences Inc.) 
preceded by an Agilent guard column (Zorbax SB-C18, 4.6 × 12.5 mm). The mobile phase 
was water-acetonitrile (40:60, v/v) at a flow rate of 1.0 ml/min with PX detection at 227 
nm. For the paclitaxel standard curve, paclitaxel was dissolved in methanol. To quantify 
PX in NPs, 1 part of PX NPs in water was dissolved in 8 parts of methanol. PX BTM NPs 
containing 30% of 7-epi PX was dissolved in methanol and then serially diluted in 
methanol to prepare the standard curve of 7-epi PX. Drug loading and entrapment 
efficiencies were determined by separating free PX from PX-loaded NPs using a Microcon 
Y-100, and then measuring PX in NP-containing supernatants as described above. To 
ensure mass balance, the filtrates were also assayed for PX. PX loading and PX entrapment 
efficiency were calculated as follows: 
 
% drug loading = [(drug entrapped in NPs) / (weight of oil)] × 100% (w/w)  
% drug entrapment efficiency = [(drug entrapped in NPs) / (total drug added into NP 
preparation)] × 100% (w/w) 
 
(3) Particle size stability of NPs in 4ºC and 37ºC  
The physical stability of G78 and BTM nanoparticle suspensions was assessed over 
storage at 4ºC for five months. Prior to particle size measurement, NP suspensions were 
allowed to equilibrate to room temperature. The stability of all NP suspensions was also 
assessed at 37oC in 10 mM PBS, pH 7.4 by adding 100 µl NP suspensions to 13 ml PBS 
buffer with a water bath shaker mixing at 150 rpm. At each time interval, 1 ml aliquots 
were removed and allowed to equilibrate to room temperature prior to particle size 
measurement.  
 
(4) DSC analysis of G78 NPs 
Differential scanning calorimetry (DSC) analysis was performed to determine the 
physical state of the core lipid (glyceryl tridodecanoate). Blank G78 or PX G78 
nanoparticle suspensions were concentrated about 20-fold using Microcon Y-100 at 4ºC. 
The concentrated NPs were (1) analyzed by DSC immediately or (2) transferred to an 
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aluminum pan and that was placed in a desiccator for two days at room temperature prior 
to DSC analysis. As controls, bulk glyceryl tridodecanoate (5 mg), Brij 78 (5 mg) and the 
bulk mixture of glyceryl tridodecanoate (3.4 mg) and Brij 78 (8 mg) were placed in 
aluminum pans for DSC analysis (PerkinElmer, Norwalk, CT). Heating curves were 
recorded using a scan rate of 1ºC/min from 15ºC to 66ºC. 
 
(5) In-vitro release studies 
PX release studies (n = 4) were completed at 37ºC by the dialysis method using 
PBS with 0.1% Tween 80 as release medium. Before release studies, the solubility of PX 
in release medium was measured. Briefly, extra amounts of paclitaxel were added into 2 ml 
of release medium until saturation was attained. After centrifuge, the concentration of PX 
in the supernatant was determined by HPLC as described above. For release studies, one 
milliliter (1 ml) of PX G78 NPs was purified with a Microcon Y-100 and re-suspended 
into 1 ml D.I. water. The concentration of PX in re-suspended PX G78 NPs was measured 
by HPLC as described above. Eight hundred microliters of purified PX G78 NPs, PX BTM 
NPs and reconstituted lyo PX BTM NPs were placed into a regenerated cellulose dialysis 
membrane (MWCO 8000 Da) submerged in 40 ml PBS with 0.1% Tween 80, respectively, 
and then shaken in a water bath at a speed of 150 rpm at 37ºC. Free PX was also used as a 
control. At predetermined times, 200 μl aliquots were taken from outside of the dialysis 
membrane, and replaced with 200 μl fresh media. PX was measured by HPLC as described 
above. Mass balance was confirmed by measuring PX concentration inside the dialysis 
membranes after 72 h. In addition, the particle sizes of PX NPs inside the dialysis 
membranes were measured when release studies were terminated (at 72 h).  
 
In-vitro cytotoxicity studies 
The cytotoxicity of PX NPs was tested in human MDA-MB-231 breast cancer cells 
using the sulforhodamine B (SRB) assay [324]. Cells were seeded into 96-well plates at 
1.5 × 104 cells/well and cells were allowed to attach overnight. Cells were incubated for 48 
h with drug equivalent concentrations ranging from 10,000 nM to 0.01 nM for Taxol, PX-
loaded NPs and blank NPs. The SRB assay was performed and IC50 values were 
determined. Briefly, the cell lines were fixed with cold 10% trichloroacetic acid and 
stained using 0.4% SRB dissolved in 1% acetic acid. The bound dye was solubilized with 
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10 mM tris base, and the absorbance was measured at 490 nm using a microplate reader. 
IC50 values were calculated based on the percentage of treatment over control. All groups 
included three independent experiments (N = 3) with triplicates (n = 3) for each 
experiment.  
 
Statistical analysis 
Statistical comparisons were made with ANOVA followed by pair-wise 
comparisons using Student’s t-test using GraphPad Prism software. Results were 
considered significant at 95% confidence interval (p < 0.05). 
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5.4 Results 
Development of BTM nanoparticles by Taguchi array and sequential simplex 
optimization 
 It has previously been reported that a combination of liquid and solid lipid oils 
enhances drug loading and stability in nanoparticles as compared to only a solid lipid core 
[195, 199]. In the initial development of NPs, a combination of the oil phase of Miglyol 
812 (liquid oil) and stearyl alcohol (solid oil) was selected, in addition to two potential 
surfactants, Brij 78 and TPGS. Thus, based on these four variables (excipients), Taguchi 
array was carried out to determine the extent of compositions to which the starting simplex 
could be formed efficiently. Taguchi’s orthogonal array for 3 levels 4 variables (L-9 34) is 
shown in Table 5.1.A. As depicted, trials 3, 5 and 9 gave the most promising results. Thus, 
the compositions of these three trials (3, 5, and 9) were used to construct the starting 
simplex in the sequential simplex optimization (Table 5.1.B). As described in the method 
section, there were two basic criteria for current nanoparticle formulation: particle size 
(<200 nm) and P.I. (< 0.35). D value from desirability functions including particle size and 
P.I. as response variables was used to evaluate the result of each experiment. Interestingly, 
the simplex (trial 6 in Table 5.1.B) identified an initial NP formulation that did not contain 
stearyl alcohol (the solid oil component), but comprised of Miglyol 812, Brij 78 and 
TPGS. Thus, as directed by simplex, subsequent experiments focused on these three 
excipients. Four different compositions were used to prepare nanoparticles as shown in 
Table 5.1.C. Among them, trial 2 resulted in optimized NPs having a mean particle size of 
149 nm and P.I. of 0.328. Interestingly, due to the relatively low concentration of the 
resulting NPs, 150 µg/ml of paclitaxel could not be entrapped into these NPs. However, 
when each component was increased by a factor of 2.5, the more concentrated NP 
formulation was able to accommodate the desired concentration of PX without changes in 
particle size and P.I. This final PX BTM NP formulation consisted of 2.5 mg of Miglyol 
812, 1.5 mg of TPGS and 3.5 mg of Brij 78 in 1 ml water with 150 µg/ml of paclitaxel.  
 
Development of G78 nanoparticles by sequential simplex optimization 
A solid lipid, glyceryl tridodecanoate, was selected as an alternative to lipid-based 
NPs. Glyceryl tridodecanoate was selected as a possibly direct replacement of E. Wax in 
the previously described E78 NPs due to the enhanced solubility of PX in glyceryl 
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tridodecanoate. Thus, in this simplex optimization, there were two variables, glyceryl 
tridodecanoate (oil) and Brij 78 (surfactant). The initial simplex was directed by the 
MultiSimplex software based on the reference values of 2 mg for glyceryl tridodecanoate 
and 4 mg for Brij 78 in 1 ml water. Simplex optimization then proceeded as shown in 
Table 5.2. After 8 trials, the optimized composition reached nearly constant values in trials 
9-11 of 1.6-1.9 mg for glyceryl tridodecanoate and 4-4.2 mg for Brij 78 in 1 ml NP 
suspension. Finally, trial 11 was identified as the most optimized composition since the 
composition gave the smallest particle size and the formulation could easily accommodate 
150 µg/ml of paclitaxel. 
 
Lyophilization of BTM and G78 nanoparticles 
The lyophilization of blank BTM NPs and PX BTM NPs in water alone resulted in 
the formation of dry white cakes that were rapidly rehydrated with water within <15 s to 
produce clear NP suspensions wherein the NPs showed complete retention of original 
physicochemical properties and in-vitro release properties (Figure 5.2 and Figure 5.6). In 
contrast, lyophilized blank G78 NPs or PX G78 NPs in the presence or absence of 5% 
lactose as a cryoprotectant could not be rehydrated in water and produced 
aggregates/agglomerates after rehydration. 
 
Particle size and zeta potential 
All tested nanoparticles had mean particle size diameters less than 200 nm with 
zeta potentials of about -6 mV regardless of PX entrapment. The entrapment of paclitaxel 
had no influence on the mean particle size of G78 and BTM nanoparticles (Table 5.3). 
Interestingly, rehydrated lyophilized NPs had smaller particle sizes for both blank BTM 
NPs and PX BTM NPs (Figure 5.2).  
 
Drug loading and entrapment efficiencies of paclitaxel in nanoparticles 
HPLC analysis showed that the 7-epi isomer of PX was present at about 30% when 
PX was formulated in NPs in water. Further analysis showed that the epimerization 
occurred during preparation of the PX NPs [325]. However, epimerization at C7 is 
reversible and can be prevented by forming PX NPs at slightly acidic pH [326]. 7-epi 
isomer of PX did not form when PX BTM NPs were prepared in 10% lactose (pH = 5) or 
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50 mM sodium acetate buffer (pH = 6). The slope of the standard curve for 7-epi PX was 
not statistically different from that for PX (data not shown). Thus, the standard curve for 
PX was used to determine the total PX concentration (PX plus 7-epi PX). 
The entrapment efficiencies for PX G78 NPs and PX BTM NPs were 85% and 
97.5% as shown in Table 5.3. The mass balance of PX was 85.4 ± 3.3 % and 97.5 ± 2.6 % 
(mean ± SD, n = 3) for PX G78 NPs and PX BTM NPs, respectively. The results showed 
that paclitaxel was incorporated into nanoparticles at weight ratio of over 6% of the 
selected lipid core. Finally, rehydrated lyophilized PX BTM NPs showed 93.1% of 
entrapment efficiency, which was not statistically different to that of non-lyophilized PX 
BTM NPs (p > 0.05).  
 
Physical stability of nanoparticles 
The physical stability of paclitaxel nanoparticles was evaluated by monitoring 
changes of particle sizes at 4ºC upon long-term storage as well as short-term stability at 
37ºC in PBS to simulate physiological conditions. The particle sizes of G78 and BTM 
nanoparticles with or without paclitaxel did not significantly change at 4ºC for five months 
(Figure 5.3). To test stability of nanoparticles in physiological conditions, G78 NPs, BTM 
NPs and reconstituted lyophilized BTM NPs were incubated in PBS at 37ºC for 102 h. 
Particle sizes of PX-loaded and blank nanoparticles slightly increased after 72 h 
incubation. The data for PX-loaded NPs are shown in Figure 5.4 whereas the data for blank 
NPs are not shown.  
 
Physical state of the core lipid in G78 nanoparticles 
It has been reported that glyceryl tridodecanoate (also called “trilaurin”) existed as 
super-cooled melts rather than in a solid state in nanoparticles [327, 328]. Thus, in the 
present studies, DSC analysis was used to determine the physical state of glyceryl 
tridodecanoate in G78 nanoparticles. Bulk glyceryl tridodecanoate showed the melting 
peak at 46ºC while Brij 78 had two melting peaks at 35ºC and 40ºC. The concentrated 
blank and PX G78 NPs clearly showed an endothermal peak at 43ºC (Figure 5.5.B). After 
drying of the NPs, two other peaks at 35ºC and 40ºC appeared for blank or PX G78 NPs 
(Figure 5.5.A). The endothermal peaks of Brij 78 intensified after drying suggesting that 
more Brij 78 existed in the solid state. The melting peak of glyceryl tridodecanoate in 
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nanoparticles shifted to lower temperature and broader compared to that of bulk material. 
However, the endothermic peak at 43ºC for glyceryl tridodecanoate indicated that glyceryl 
tridodecanoate retained a solid state in G78 nanoparticles.  
 
In-vitro release of paclitaxel from nanoparticles 
Paclitaxel has been reported to have aqueous solubility of 0.7-30 µg/ml. Therefore, 
to maintain sink conditions, PBS with 0.1% Tween 80 was used as the release medium for 
the in-vitro release studies of paclitaxel. The solubility of paclitaxel in the release medium 
at room temperature was 10.8 ± 0.3 µg/ml (mean ± SD, n = 3) as measured by HPLC. 
Thus, for the release studies, 800 μl of PX NPs containing 150 µg/ml of paclitaxel were 
placed into 40 ml of the release medium. There was no 7-epi PX observed during the 
release study of free paclitaxel. The cumulative release of paclitaxel from PX NPs was 
calculated based on the total PX (PX plus 7-epi PX) released and is shown in Figure 5.6. 
Free PX was released completely within 4 h. For all tested PX NPs, although the initial 
release rates were greater between 0 and 8 h, no initial burst of PX was observed. After 8 
h, the release rates were much lower. The results showed that the mean cumulative release 
of PX after 72 h was 40%, 50% and 53% from PX G78 NPs, PX BTM NPs and 
reconstituted lyophilized PX BTM NPs, respectively. Mass balance analysis for PX G78 
NPs, PX BTM NPs and lyophilized PX NPs showed that 79.2 ± 8.6 %, 98.3 ± 24.2 %, and 
73.4 ± 16.6 % (mean ± SD, n = 4) of the PX was recovered, respectively. There were no 
other PX degradation peaks, except for 7-epi PX, observed by HPLC during the course of 
the studies. Moreover, lyophilized PX BTM NPs showed the same release profile as 
compared to PX BTM NPs (p > 0.05 at each time point). Also, the particle sizes of all 
tested nanoparticles did not change significantly after 72 h.  
 
In-vitro cytotoxicity studies 
The cytotoxicity of PX NPs was tested in human breast cancer MDA-MB-231 cells 
using the SRB assay (Table 5.4). PX NPs showed a clear dose-dependent cytotoxicity in 
MDA-MB-231 cells. There was no statistical significance in the IC50 values of PX BTM 
NPs and lyophilized PX BTM NPs compared to commercial Taxol. However, the IC50 of 
PX G78 NPs had comparable but statistically different IC50 values compared to Taxol. 
Blank NPs showed some cytotoxicity but only at the paclitaxel equivalent dose of 617.3 
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nM and 354.6 nM of PX which corresponds to a total NP concentration of 26.4 µg/ml and 
15.1 µg/ml for blank G78 NPs and BTM NPs, respectively.  
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5.5 Discussion 
Paclitaxel is an important agent in the treatment of metastatic breast cancer. 
However, the optimal clinical use of paclitaxel is limited due to its poor aqueous solubility. 
Commercial paclitaxel formulation, Taxol, is generally associated with hypersensitivity 
reactions which results from the excipient Cremophor EL in Taxol. To overcome the 
problems, numerous lipid-based and Cremophor EL-free paclitaxel formulations have been 
investigated, such as liposomes [329], solid lipid nanoparticles [330, 331], micelles [332, 
333], and emulsions [176, 334].  
In the present study, two median chain triglycerides, glyceryl tridodecanoate and 
Miglyol 812, were used to investigate new lipid-based nanoparticles for paclitaxel. 
Relative to other candidate oil phases, these two oils have high solvation abilities for PX. 
Glyceryl tridodecanoate has a relatively low melting point of 46ºC, which theoretically 
facilitates the preparation of lower crystalline cores which may accommodate a greater 
concentration of drug [195]. Miglyol 812, being a liquid, forms a reservoir-type drug 
delivery system in which poorly water-soluble drugs remain dissolved inside the liquid oil 
core and consequently a high payload and reduced release profile may be achieved [184, 
335]. As expected, the final optimized nanoparticles, G78 NPs and BTM NPs, successfully 
entrapped paclitaxel with high loading and entrapment efficiency (Table 5.3). However, 
the selection of these two alternative oil phases required the development of optimized NP 
formulations. To facilitate, we used a methodology that combined Taguchi array and 
sequential simplex optimization. The simplex is made of k + 1 vertex. The response of the 
experiment in each vertex is ranked and the “worst” response is replaced by the new set of 
variables for the next experiment. To efficiently move the simplex, there should be limited 
“worst” responses in the staring simplex. As new excipients were investigated and no prior 
composition was used as a reference (Table 5.1), Taguchi array was first performed to 
explore and provide the framework of the starting simplex. The final optimization was then 
completed using sequential simplex optimization. Trial 6 in Table 5.1.B identified a new 
nanoparticle formulation composed of the liquid oil Miglyol 812. After further 
optimization, new BTM nanoparticles were developed. In the case of G78 NPs, it was 
closely resembled with the E78 NPs (Table 5.2). Thus, sequential simplex optimization 
was directly used for the investigation of G78 NPs. The results for both PX NPs indicate 
that this new methodology combining Taguchi array and sequential simplex optimization 
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could efficiently and effectively be used to identify optimized nanoparticles. Finally, a total 
of 19 trials and 11 trials were used to obtain optimized BTM NPs and G79 NPs, 
respectively. In contrast, even for 4 factors and 3 levels design, e.g. optimization in Table 
5.1.A and 5.1.B, complete factorial design would require 34 = 81 experiments. To our best 
knowledge, this is the first report to use the combination of Taguchi array and sequential 
simplex optimization for the development of nanoparticles.  
Choosing appropriate lipids could help increase the entrapment efficiency of drug 
and slow the release rate of the drug from the nanoparticles. As compared with PX E78 
NPs previously developed in our laboratory, the optimal PX BTM and G78 nanoparticles 
were very reproducible with high drug loading and showed much slower release of PX 
achieving about 50% and 40% after 72 h, respectively (Figure 5.6). The slow and sustained 
release of paclitaxel without burst release from PX BTM and PX G78 nanoparticles 
indicated that paclitaxel was likely not present at or near the surface of nanoparticles but 
instead within the core of the NPs as ideally predicted by the enhanced solvation abilities 
of Miglyol 812 and glyceryl tridodecanoate for PX. Moreover, entrapment of paclitaxel 
into nanoparticles did not change the sizes of nanoparticles. All PX NPs had particle sizes 
less than 200 nm, even after 102 h of incubation in PBS at 37ºC. These data indicate 
potential stability of PX NPs in-vivo after intravenous injection (Figure 5.4). Cytotoxicity 
studies showed that both PX G78 and BTM nanoparticles had the same or comparable 
anti-cancer activity compared to commercial Taxol in human MDA-MB-231 breast cancer 
cells. Therefore, both of these identified PX NP formulations may be good candidates for 
ligand-mediated tumor-targeting delivery of PX.  
Several studies have reported that glyceryl tridodecanoate retained in lipid-based 
NPs in a super-cooled liquid state. If true, this semi-stable state of glyceryl tridodecanoate 
will likely affect the stability of nanoparticles due to the predicted phase transition of the 
super-cooled core to the crystalline phase. However, the present studies showed using DSC 
analysis that glyceryl tridodecanoate remained as a solid state in G78 NPs (Figure 5.5), 
suggesting that the phenomenon of super-cooled glyceryl tridodecanoate in nanoparticles 
may be dependent on the process and compositions (i.e., surfactant) used to prepare the 
nanoparticles. Blank and PX G78 nanoparticles stored as liquid suspensions at 4ºC 
remained stable for several months and exhibited no change in particle sizes. There was 
some concern that G78 nanoparticles, made with the lower melting GT, may be adversely 
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affected by body temperature. However, either blank or PX G78 nanoparticles showed no 
change in particle sizes after 102 h of incubation in PBS at 37ºC.  
It is thought that BTM NPs may be a novel liquid reservoir, or nanocapsule-type 
formulation. The liquid reservoir containing paclitaxel dissolved in Miglyol 812 is 
stabilized with the polymeric surfactants Brij 78 and TPGS. Higher drug loading of PX 
BTM nanoparticles indicates the advantage of this nanocapsule-type formulation as 
compared to the solid-core type G78 NP system. The BTM NPs were spontaneously 
formed after cooling from the warm o/w microemulsion precursors. It is thought that the 
BTM NPs are nanocapsules and not nanoemulsions since nanoemulsions are non-
equilibrium and thermodynamically unstable systems that cannot, by definition, form 
spontaneously without agitation or significant mechanical/shear mixing [336]. Another 
very interesting discovery was serendipitously made during the course of the present 
studies. In one attempt to concentrate NP formulations to analyze for entrapped PX, NPs 
were lyophilized in water. The BTM NP formulations produced uniform white cakes that 
could be rapidly rehydrated with complete retention of original physicochemical 
properties, in-vitro release properties, and cytotoxicity profile. Our experience, as well as 
others, is that it is often difficult to freeze-dry colloidal suspensions in the presence of 
cryoprotectants. To our knowledge, there are few or no reports on the successful 
lyophilization of colloidal suspensions without the use of a cryoprotectant which protects 
the nanoparticles from the stresses of the freezing and thawing process. Moreover, the 
lyophilization of nanoemulsions or nanocapsules is thought to be even more challenging 
due to the existence of the very thin and fragile envelope that may not withstand the 
mechanical stress of freezing [187, 188]. Even in the presence of cryoprotectants, an 
increase of particle size is likely to occur [185]. In the present studies, the optimal BTM 
nanoparticles were successfully lyophilized without cryoprotectants. The non-collapsed 
uniform cakes of PX BTM NPs in water alone were rehydrated and spontaneously 
produced particle sizes that were, in fact, slightly smaller than the original particle sizes. In 
addition, there was a complete retention of the in-vitro release properties and cytotoxicity 
profile. 
In conclusion, the combination of Taguchi array and sequential simplex 
optimization efficiently guided the development and optimization of lipid-based 
nanoparticulate formulations for paclitaxel. Injectable paclitaxel nanoparticles, PX G78 
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NPs and PX BTM NPs, were successfully prepared via a warm o/w microemulsion 
precursor engineering method. Both paclitaxel nanoparticle suspensions were physically 
stable at 4ºC over five months, and PX BTM could be lyophilized without cryoprotectants. 
PX G78 and BTM nanoparticles showed comparable or same anti-cancer activity 
compared to Taxol in MDA-MB-231 breast cancer cells. Therefore, these paclitaxel-loaded 
nanoparticles may be candidates for ligand-mediated tumor-targeting delivery of paclitaxel 
after intravenous injection.  
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Table 5.1.A.  Taguchi array for the development of BTM nanoparticles. Listed are 
the compositions per 1 ml nanoparticle suspension. 
 
 
 
 
 
 
 
 
 
 
 
 
 Bold font indicates promising lead formulations 
 
 
Table 5.1.B.  Sequential simplex optimization for the development of BTM 
nanoparticles. Listed are the compositions per 1 ml nanoparticle suspension. 
 
 
 
 
 
 
 
 
 
 Bold font indicates promising lead formulations 
Trial Brij 78 (mg) TPGS (mg) Stearyl alcohol (mg) Miglyol 812 (mg) Particle size (nm) P.I.
1 1.6 1.2 0.6 1.4 35 1.21
2 1.6 0.9 0.4 1.0 193.5 0.978
3 1.6 0.6 0.2 0.6 118.4 0.159
4 1.2 1.2 0.4 0.6 25 1.435
5 1.2 0.9 0.2 1.4 212.9 0.307
6 1.2 0.6 0.6 1.0 282.6 0.897
7 0.7 1.2 0.2 1.0 130.5 0.826
8 0.7 0.9 0.6 0.6 315 1.685
9 0.7 0.6 0.4 1.4 234.6 0.355
Trial movement
Brij 78
(mg)
TPGS 
(mg)
Stearyl 
alcohol (mg)
Miglyol 
812 (mg)
Particle 
size (nm)
P.I. dsize dP.I. D
1 \ 1.6 0.6 0.4 0.6 35.6 0.070 0 0.017 0
2 \ 1.2 0.9 0.4 1.4 197.6 0.449 0.709 0.347 0.496
3 \ 0.7 0.6 0.8 1.4 186.3 0.360 0.646 0.270 0.417
4 \ 1.6 0.9 1.6 1.2 309.2 1.079 0 0.895 0
5 \ 0.7 2.1 1.6 1.2 182.7 1.028 0.626 0.85 0.730
6 R (1, 2, 3, 5) 0.5 1.2 0 1.1 192.4 0.230 0.680 0.157 0.326
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Table 5.1.C.  Development of BTM nanoparticles. Listed are the compositions per 1 
ml nanoparticle suspension. 
 
 
 
 
 
 
 
 Bold font indicates promising lead formulations 
Trial Brij 78 (mg) TPGS (mg) Miglyol 812(mg) Particle size (nm) P.I.
1 0.5 1.2 1.1 192.4 0.23
2 1.4 0.6 1 149 0.328
3 0.9 0.6 1.4 190 0.103
4 1.2 1.5 1.2 309.2 1.079
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Table 5.2.  Simplex optimization for the development of G78 nanoparticles. Listed are 
the compositions per 1 ml nanoparticle suspension 
 
 
 
 
 
 
 
 
 
 
 
 
 
a The peak numbers in nanoparticle distribution 
b Current membership has the same meaning and definition with D value in desirability 
functions. 
c Impossible to form nanoparticles based on this composition 
* indicates the composition of the final simplex 
  Bold font indicates promising lead formulations 
Trial Brij 78 (mg) Glyceryl tridodecanoate (mg) Particle size (nm) P.I. Peak # a Current bmembership
1 3.5 1.5 157.2 0.3 2 0
2 4.5 1.8 153.5 0.36 1 4.77E-02
3 3.8 2.5 194.6 0.275 1 1.73E-02
4 4.8 2.8 195.3 0.25 2 0
5* 3.8 1.8 161.9 0.258 1 0.138
6 4.5 1.1 -- c -- -- --
7 4.0 2.1 199 0.282 1 3.03E-03
8 3.3 2.2 -- -- -- --
9* 4.2 1.9 161.3 0.274 1 0.125
10 4.0 1.6 156.4 0.325 1 8.38E-02
11* 4.0 1.7 143.6 0.369 1 4.48E-02
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Table 5.3.  Physiochemical properties of  
PX G78, PX BTM, and lyo PX BTM nanoparticles (n=3) 
 
 
 
 
 
 
 
a The data are presented as the mean of the mean particle size of nanoparticles in 
different batches ± SD (n = 3).  
# p > 0.05 
Formulations
Theoretical 
loading
(µg/ml)
Mean 
a 
diameter
(nm)
P.I.
Zeta 
potential
(mV)
% Drug 
loading
(w/w, 
drug/oil)
% Drug 
entrapment 
efficiency
PX G78 NPs 150 169.2 ± 8.1 0.302 ± 0.027 -6.6 ± 2.6 7.5 85.4 ± 3.3
PX BTM NPs 150 190.5 ± 7.8 0.279 ± 0.054 -5.9 ± 1.78 6 97.5 ± 2.6#
Lyo PX BTM NPs 150 130.0 ± 7.8 0.284 ± 0.042 -5.1 ± 1.00 6 93.1 ± 4.1#
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Table 5.4.  IC50 values of paclitaxel nanoparticles in MDA-MB-231 cells at 48 h 
 
 
 
 
 
Data are presented as the mean ± SD of three independent experiments (N=3) with 
triplicate (n=3) measurements for each sample/concentration tested. 
 
a Lyo BTM NPs #2 were directly lyophilized from BTM NPs #2. Lyophilized powder 
was stored at 4oC for overnight prior to completing the cytotoxicity studies. 
# p > 0.05 compared to IC50 of Taxol® 
## p > 0.05 within the group 
* p < 0.05 compared to IC50 of Taxol® 
G78 NPs BTM NPs #1 BTM NPs #2
a
Lyo BTM NPs #2
Formulations Taxol ®
PX NPs BL NPs PX NPs BL NPs PX NPs BL NPs PX NPs BL NPs
IC50 (nM) 7.2 ± 2.9 21.0 ± 1.5 617.3 ± 356 7.6 ± 1.2 354.6 ± 59.0 15.1 ± 6.8 342.7 ± 119.6 15.6 ± 10.6 256.1 ± 128.6
* # #### ## ##
a
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Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1:  The principles of sequential simplex optimization for two variables using 
variable-size simplex rules on the response surface [317]. The starting simplex consists 
of vertexes 1, 2 and 3 where 1 gives the worst response. The second simplex consists of 
vertexes 2, 3, and 4 after a reflection and expansion. Finally, the movement of the simplex 
results in the simplex 12, 14, and 15 which indicates the optimum.  
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Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2:  Particle size of BTM nanoparticles before and after lyophilization (and 
rehydration). Six different batches were tested for both blank BTM nanoparticles and PX-
loaded BTM nanoparticles. For all tested NP formulations, P.I. values ranged from 0.03 to 
0.35 indicating uniform, mono-dispersed NPs. Data are presented as the mean particle size 
of three separate measurements of each batch. 
0
50
100
150
200
250
#1 #2 #3 #4 #5 #6 #1 #2 #3 #4 #5 #6
Pa
rt
ic
le
 si
ze
 (n
m
)
Before lyophilization
After lyophilization
BL BTM NPs PX BTM NPs
Pa
rt
ic
le
 si
ze
 (n
m
)
 102
Figure 5.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3:  Long-term stability of paclitaxel nanoparticles stored at 4ºC. Three 
different batches of PX-loaded BTM and G78 nanoparticles were monitored for particle 
sizes over five months. For all tested samples, P.I. <0.35. Data are presented as the mean 
particle size of three separate measurements of each batch. 
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Figure 5.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4:  Stability of paclitaxel nanoparticles in PBS at 37ºC. PX BTM 
nanoparticles, reconstituted lyophilized PX BTM nanoparticles and PX G78 nanoparticles 
were monitored for particle sizes for 102 h. For all tested samples, P.I. <0.35. Data are 
presented as the mean particle size of three separate measurement of each batch. 
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Figure 5.5 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5:  DSC for G78 nanoparticles. (A) The concentrated nanoparticles were dried 
by desiccations for two days prior to DSC analysis (“dry”). (B) DSC analysis of 
nanoparticles was performed immediately after concentrating nanoparticles (“wet”). GT 
means glyceryl tridodecanoate.  
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Figure 5.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6:  Release of PX from PX nanoparticles at 37ºC. Paclitaxel release was 
measured using the dialysis method in PBS (pH 7.4) with 0.1% Tween 80 as described in 
the Method section. Data are presented as the mean ± SD (n = 4). # p > 0.05 as compared 
between PX BTM NPs and lyo PX BTM NPs. 
 
 
 
 
 
 
*The contents of this chapter were published in European Journal of Pharmaceutics and 
Biopharmaceutics, 72:9-17, 2008. X. Dong, C. A. Mattingly, M. T. Tseng, M. Cho, V. R. 
Adams, and R. J. Mumper, Development of new lipid-based paclitaxel nanoparticles using 
sequential simplex optimization. Copyright 2008 with permission from Elsevier. 
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Chapter 6 
 
Development of new solid lipid doxorubicin nanoparticles to treat P-gp-mediated 
resistance in-vitro 
 
6.1 Summary 
Doxorubicin has a wide range of anti-cancer activity. Also, it is a P-gp substrate. 
The purpose of these studies was to develop and characterize a doxorubicin-loaded solid 
lipid nanoparticle delivery system to treat P-gp-mediated drug resistance in-vitro. Solid 
lipid nanoparticles were prepared from microemulsion precursors. An ion-pair strategy was 
used to enhance the loading of doxorubicin into nanoparticles. Different potential ion-pair 
agents were investigated. STS was found to be the best choice for the ion-pair agent. 
Further, drug release and drug entrapment efficiency of Dox NPs were measured. To 
optimize the composition of nanoparticles to get a slow release profile, various 
compositions of nanoparticles were investigated using STS as the ion-pair agent. 
Doxorubicin was released from solid lipid nanoparticles about 65% at 8 h in PBS at 37ºC. 
Dox-loaded solid lipid nanoparticles containing different compositions of oils and 
surfactants provided several promising formulations to test for efficacy in P-gp-
overexpressed resistant cancer cells.  
 107
6.2 Introduction 
Current tumor chemotherapy faces several challenges which include the lack of 
tumor selectivity, and intrinsic or acquired drug resistance, such as overexpression of a 
membrane transporter P-gp on the surface of cancer cells. To improve the therapeutic 
efficacy and minimize the side effects, various drug delivery and targeted systems have 
been investigated, such as polymer conjugates, liposomes, micelles, and lipid nanoparticles 
[238, 251, 253, 257, 263, 268]. Nano-sized delivery systems could passively accumulate 
drugs in solid tumors by taking advantage of the EPR effect. Moreover, some of the 
delivery systems showed the ability to overcome MDR. Therefore, the combination of 
using EPF effect and overcoming MDR by drug delivery systems could provide a new 
strategy to solve the challenges of tumor chemotherapy.  
Doxorubicin is a P-gp substrate with a broad-spectrum anti-cancer activity. 
Although it continues to be used extensively in the treatment of different cancers, its 
clinical value is limited due to its acute myelotoxicity, development of cardiomyopathy 
and development of drug resistance. Two commercial formulations of doxorubicin are Dox 
Hydrochloride for Injection and liposomal Dox, Doxil®. Dox has two pKas, 7.8 and 10.7. 
Its free base at high pH (>10) is water-insoluble. However, at neutral pH, its salt form is 
water-soluble with a positive charge. Dox Hydrochloride for Injection was formulated by 
directly dissolving Dox·HCl salt into water. This formulation is not beneficial for targeting 
tumors. Thus, the selectivity of the formulation is low. The cationic charges of these salts 
may pose an obstacle for efficient drug incorporation into lipid particles or liposomes. To 
entrap Dox into liposomes, current liposomal Dox formulation uses a pH-gradient strategy. 
The pH outside of the liposomes is increased to allow formation of free Dox base. Due to 
water-insolubility of free Dox base, it could pass the hydrophobic bilayer of the liposomes. 
After getting into the core liposomes (hydrophilic and neutral pH), Dox returns to its salt 
form with a positive charge which can not pass through the hydrophobic bilayer of the 
liposomes, resulting in the incorporation of Dox into liposomes. Liposomal Dox 
formulations have been reported to significantly reduce cardiotoxicity in a phase III study 
as compared to free doxorubicin [39]. However, none of these commercial Dox 
formulations claims to overcome MDR. An ion-pair strategy has been used to entrap Dox 
into solid lipid nanoparticles [337]. Based on this strategy, counterions (ion-pair agents) 
with negative charges were used to form the ion-pair complex with Dox·HCl. Formed ion-
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pair complex could shield the positive charge of Dox and increase lipophilicity of Dox, 
leading to entrapping Dox into solid lipid nanoparticles. 
In this study, different ion-pair agents for Dox were screened in an attempt to form 
a stable ion-pair complex. We expected that the formation of stable ion-pair complex could 
enhance Dox loading and reduce the release of Dox from Dox-loaded nanoparticles. In 
following studies, Dox-loaded NPs were then tested to overcome P-gp-mediated drug 
resistance in-vitro.  
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6.3 Materials and Methods 
 
Materials 
 Doxorubicin hydrochloride, taurocholic acid sodium salt hydrate, (±)-α-Tocopherol 
phosphate disodium salt, sodium taurodeoxycholate (STDC), sodium lauryl sulfate (SDS), 
Niaproof 4 (7-Ethyl-2-methyl-4-undecyl sulfate sodium salt ), and sodium tetradecyl 
sulfate (STS) were purchased from Sigma-Aldrich (St. Louis, MO). Cellulose sulfate 
3500,000, Poly(vinylsulfonic acid) sodium salt, E. Wax and stearyl alcohol were purchased 
from Spectrum Chemicals (Gardena, CA). Brij 78 was obtained from Uniqema 
(Wilmington, DE). TPGS was purchased from Eastman Chemicals (Kingsport, TN). 
Dextran sulfate sodium salt 2500 was purchased from ABCR GmbH & Co. KG 
(Karlsruhe, Germany). Dextran sulfate sodium salt 5000, Dextran sulfate sodium salt 8000, 
and Dextran sulfate sodium salt 100,000 were purchased from Sigma-Aldrich (St. Louis, 
MO).   
 
Methods 
Preparation of doxorubicin-ion-pair complex 
 A titration method was used to select the suitable ion-pair agent with a negative 
charge to form stable Dox-loaded solid lipid nanoparticles. Doxorubicin hydrochloride was 
dissolved into D.I. water to make a Dox stock solution at the concentration of 1 mg/ml. 
Fifty microliters of Dox stock were titrated with various ion-pair agents which were 
dissolved in water, respectively, until red precipitates (ppts) appeared indicating the 
formation of Dox-ion-pair complex. The water was removed after centrifugation. One ml 
of PBS pH 7.4 was added to the red ppts and kept for 4 h at room temperature to test if 
ppts could dissolve in PBS.  
 
Preparation of doxorubicin-loaded solid lipid nanoparticles 
 Nanoparticles were prepared from warm o/w microemulsion precursors as 
previously described with some modification. Doxorubicin was first precipitated with the 
ion-pair agent in water to form the ion-pair complex. Then, the ion-pair complex was dried 
with N2 stream and dissolved into ethanol. Defined amounts of oil phases and surfactants 
were weighed into glass vials and melted at 65ºC. The Dox ion-pair complex/ethanol 
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solution was added into melted excipients and ethanol was removed using a N2 stream. 
One ml of D.I. water pre-heated at 65ºC was added into the mixture and stirred for 20 min 
at 65ºC. The mixture was then cooled to room temperature. The particle size of NPs was 
measured by photon correlation spectroscopy (PCS) using a Coulter N4 Plus Submicron 
Particle Sizer (Coulter) with scattering light at 90° at 25°C for 1 min. Zeta potentials were 
measured using the Zetasizer Nano ZEN2600 (Malvern Instruments, Worcs, U.K). 
 
Particle size stability of nanoparticles at 4ºC and 37ºC 
The physical stability of Dox-loaded NP suspension was tested over one month at 
4ºC by monitoring particle size of NPs. The size stability of NPs also was tested in PBS pH 
7.4 for 6 h at 37ºC. Four hundred microliters of Dox NPs were put into 10 ml PBS pH 7.4 
and incubated at 37ºC. At each time point, 1 ml of the NP suspension was taken out to 
measure particle size. Prior to particle size measurement, NP suspensions were allowed to 
equilibrate to room temperature. 
 
Quantitative measurement of Dox by Microplate reader and HPLC assay 
Quantitative assay methods were performed to measure concentration of 
doxorubicin. Doxorubicin standard solutions were prepared in water for injection and 
could be stored at -80ºC over six months without any changes on chemical properties. A 
Dox standard curve was developed using the Bio-Tek Synergy 2 Microplate Reader either 
at 487 nm or at fluorescence mode with 480 nm excitation and 550 nm emission. In 
addition, the concentration of Dox was quantified by HPLC using a Thermo Finnigan 
Surveyer HPLC System and an Inertsil ODS-3 column (4.6 × 150 mm) (GL Sciences Inc.) 
preceded by an Agilent guard column (Zorbax SB-C18, 4.6 × 12.5 mm). Separation was 
carried using a mobile phase consisting of 0.1 M ammonium formate containing 0.14 % 
triethylamine (adjusted pH to 2.4 by addition of formic acid)-acetonitrile-methanol-
tetrahydrofuran (60:25:17.5:2.5, v/v/v/v) at a flow rate of 1.0 ml/min. Dox was measured 
either with a fluorescence detector with an excitation wavelength of 480 nm and an 
emission wavelength of 550 nm, or a PDA detector at 487 nm. To measure Dox entrapped 
into NPs, 50 ul of Dox-loaded NPs were mixed with 150 ul of methanol prior to HPLC 
injection. The assay methods were compared using Dox-loaded NPs.  
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Determination of Dox loading and entrapment efficiency 
 Dox loading and entrapment efficiencies were determined by separating free Dox 
from Dox-loaded NPs using a Microcon Y-100 (MWCO 100 kDa, Millipore) at 4ºC, and 
then measuring Dox in supernatants and filtrates. Concentrations of Dox were measured 
using a microplate reader at 487 nm. The mass balance was then calculated. Drug loading 
and drug entrapment efficiencies were calculated as follows: 
 
% drug loading = [(drug entrapped in nanoparticles) / (weight of oil)] × 100% (w/w)  
% drug entrapment efficiency = [(drug entrapped in nanoparticles) / (total drug added into 
nanoparticle preparation)] × 100% (w/w) 
 
In-vitro release studies of Dox-loaded NPs 
Dox release studies from different Dox-loaded NPs (n=3 for each) were completed 
at 37ºC using the dialysis method. Two hundred microliters of Dox NPs were placed into a 
cellulose ester dialysis membrane (MWCO 100 kDa, Spectrum Lab) submerged in 6 ml 
PBS at pH 7.4 for 24 h. The release medium was then shaken in a water bath at a speed of 
150 rpm at 37ºC. At defined times, two hundred microliter aliquots were taken from 
outside the dialysis membrane, and fresh media were replaced. Dox was measured using 
the microplate reader in the fluorescence detection mode (480 nm excitation and 550 nm 
emission). Free Dox and Dox ion-pair complex (ppts) were used as controls.  
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6.4 Results 
Selection of the ion-pair agent for doxorubicin complex 
 NPs #2, composed of 2 mg/ml of E. wax, 2 mg/ml of Brij 78 and 2.6 mg/ml of 
TPGS in 1 ml of D.I. water, were used as the prototype of NPs to screen the suitable ion-
pair agent for Dox. The twelve tested ion-pair agents are listed on Table 6.1. The final 
optimized ion-pair agent for Dox was STS which quantitatively precipitated Dox at a mole 
ratio of 1:1.2 (Dox: STS) (Figure 6.1). Dox-STS complex had low solubility in PBS and 
also formed good NPs with the mean diameters less than 120 nm. The highest loading of 
Dox was 600 µg/ml by using STS as the ion-pair agent. Therefore, the rest of the studies in 
this section was focused on STS as the ion-pair agent for Dox.  
 
Quantitative measurement of Dox by a microplate reader and HPLC assays 
 Various quantitative assays were developed for doxorubicin, including a microplate 
reader assay and a HPLC assay with either UV-Vis or fluorescence detection (Table 6.2). 
Dox recovery in Dox NPs using the HPLC assay was 102.8%. To compare the 
measurement from the HPLC assay and microplate reader assay, the concentrations of Dox 
in Dox-loaded NPs were measured by both methods at 486 nm. The results did not show a 
significant difference: 124 µg/ml of Dox by the microplate reader assay versus 111 µg/ml 
of Dox by the HPLC assay. Thus, in the latter studies, the microplate reader assay was 
chosen as the major assay method for measuring either Dox concentration in Dox-loaded 
NPs or free Dox concentration.  
 
Optimization of compositions of NPs for Dox-STS-loaded NPs 
 To find the optimized NP formulation, two new Dox NPs, Dox NPs #3 composed 
of 2 mg/ml of E. wax and 4 mg/ml of Brij 78 and Dox NPs #4 composed of 2 mg/ml of 
stearyl alcohol and 4 mg/ml of Brij 78, were prepared using the Dox-STS complex. These 
Dox-loaded NPs were characterized in the rest studies and compared to identify the best 
NP formulation. 
 
Particle size stability of nanoparticles 
The physical stability of Dox-loaded NP suspension was monitored by measuring 
particle size of NPs over one month at 4ºC for the storage condition. All Dox-loaded NPs 
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increased their size over 45% from their initial starting point (Figure 6.2). However, 
particle size of Dox-loaded NPs did not change within 6 h at 37ºC in PBS, which simulated 
physiological conditions (Figure 6.3).  
 
Dox loading and entrapment efficiency 
 The Dox loading and entrapment efficiencies in three Dox-loaded NPs are shown 
in Table 6.3. The entrapment efficiencies of all Dox-loaded NPs were higher than 80%. 
The mass balance gave about 100% of Dox recovery. This indicated that the method for 
measuring entrapment efficiencies of Dox was reliable, and that STS was a good ion-pair 
agent. The formed Dox-STS ion-pair complex had very good solubility with oils and 
surfactants in NPs.  
 
In-vitro release studies of Dox-loaded NPs 
 The cumulative release of Dox from Dox-loaded NPs is shown in Figure 6.4. Over 
90% of free Dox were released from dialysis tubes within 4 h. This suggested that the 
dialysis method was suitable to make a sink condition and measure Dox release from Dox-
loaded NPs. At 8 h, about 70% of Dox were released from Dox-loaded NPs. This rapid 
release was observed in all Dox NPs with different compositions. A burst release was 
observed in all Dox NPs, with about 15% of Dox being released at the first 0-5 min. After 
the initial release, 50% of Dox was released in next 8 h and the rest of Dox (35% of Dox) 
was slowly released up to 24 h.   
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6.5 Discussion 
 Dox is a positively-charged drug and the hydrochloride salt has appreciable 
aqueous solubility. Thus, an ion-pairing strategy was utilized to neutralize the charge on 
Dox and increase its affinity for the melted oil phase. Various ion-pair agents were tested 
(Table 6.1). There are at least three criteria for the suitable ion-pair agent: 1) the most ideal 
agent should be able to quantitatively precipitate Dox from water, 2) the formed ion-pair 
complex should not be soluble in PBS, and 3) the formed ion-pair complex could be used 
to form stable NPs utilizing the method described herein. However, most of the ion-pairing 
complex of Dox either rapidly dissolved in PBS and/or were not soluble in the melted oil 
phases used to prepare the solid lipid nanoparticles. For example, STDC formed ion-pair 
complex with Dox quantitatively, and also gave good Dox-loaded NPs with a high drug 
loading efficiency. However, Dox-STDC complex is soluble in PBS, resulting in a very 
rapid release profile of Dox from Dox-STDC-loaded NPs. About 85% of Dox were 
released from Dox-STDC NPs within 15 min. The final optimized ion-pair agent for Dox 
was STS. All Dox NPs made from STS in the present work were reproducibly produced 
with mean diameters of particle sizes less than 120 nm, and had high drug loading and 
entrapment efficiency (Table 6.2). In addition, all NPs were stable over one month at 4°C, 
though particle size increased (Figure 6.2). By forming ion-pair complex, water-soluble 
and positive-charged Dox was successfully entrapped into solid lipid NPs. Ion-pair 
strategy may be a potential approach to entrap other ionic anti-cancer drugs into solid lipid 
nanoparticles. 
 The series of quantitative assays were developed for doxorubicin (Table 6.2). The 
assay method was chosen based on the concentration of samples in the experiment. The 
HPLC assay using a fluorescence detector could measure the concentration of Dox as low 
as 0.0023 µg/ml. Therefore, this method could be used as the assay method for future Dox 
uptake studies in cells or in-vivo biodistribution study. In the HPLC assay, Dox-loaded 
NPs were pre-destroyed by methanol to release free Dox. However, in the microplate 
assay, Dox-loaded NPs were directly measured at the microplate reader. The results from 
these two different assay methods did not show a significant difference. This also indicated 
that entrapping Dox into NPs did not influence the absorbance of Dox.  
 The release profile of Dox from Dox-loaded NPs consisted of a rapid release phase 
within 0-8 h and a slower release phase after 8 h (Figure 6.4). This indicated that some 
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Dox may locate near the surface of nanoparticles and readily diffuse out into the release 
medium. The reason for the rapid release may be related to the components in NPs which 
competed with Dox to bind with STS, so that the ion-pair complex partially dissociated 
during the process to make Dox-STS NPs. Thus, another two NPs with different 
compositions were studied. All Dox NPs gave high entrapment efficiency (Table 6.3). 
However, they showed similar release profiles. Moreover, Dox release from Dox-loaded 
NPs was similar with Dox release from Dox-STS complex (Figure 6.4). Actually, the 
current Dox release profiles are comparable with those reported in literature [337]. The 
unchanged particles sizes in PBS at 37ºC over time demonstrated that the physical stability 
of NPs was not the reason for the rapid release. It is possible that ions in PBS competed 
with Dox or STS to form new ion-pair complex, or the excipients competed with Dox to 
bind with hydrophobic STS during NP preparation. Thus, the major reason causing rapid 
release of Dox from Dox NPs within 8 h may be related to the stability of Dox-STS 
complex which could dissociate either in PBS over time or in the process of NP 
preparation.  
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Table 6.1.  Ion-pair agents screened for doxorubicin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 yesnoyesSTS (sodium tetradecyl sulfate)
yesnoyesNiaproof 4 (7-Ethyl-2-methyl-4-undecyl sulfate sodium salt )
noyesyesPoly(vinylsulfonic acid) sodium salt
nonoyesCellulose sulfate 3500,000
no or 
difficultnoyesDextran sulfate 100,000
yesnoyesDextran sulfate 8000
yesnoyesDextran sulfate 5000
yesnoyesDextran sulfate 2500
yesyesyesSDS (sodium lauryl sulfate)
yesyesyesSTDC (sodium taurodeoxycholate)
no(±)-α-Tocopherol phosphate disodium salt
noTaurocholic acid sodium salt hydrate
Form NPsppts dissolved in PBSPrecipitates (ppts)Ion-pair agents
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Table 6.2.  Standard curve of doxorubicin (N=3) 
 
 
 
 
 
 0.99930.00229-2.35y = 1000000xFluorescence
0.99921-100y = 116082x – 159253486 nm
HPLC assay
0.99990.282-4.69y = 504x – 87.7Fluorescence
0.99990.939-93.9y = 0.0111x486 nm
Microplate reader
R2Linear range (µg/ml)Standard curveDetectionAssay method
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Table 6.3.  Physiochemical properties of Dox-loaded nanoparticles (n=3) 
 
 
 
 
 
 
a The data are presented as the mean of the mean particle size of nanoparticles in 
different batches ± SD (n = 3).  
Formulations
Theoretical 
loading
(µg/ml)
Mean a 
diameter
(nm)
P.I.
Zeta 
potential
(mV)
% Drug 
loading
(w/w, drug/oil)
% Drug 
entrapment 
Dox NPs #2 300 0.284 ± 0.009 -27 15 86.2 ± 5.9
Dox NPs #3 300 0.313 ± 0.06 15 91.0 ± 5.9
Dox NPs #4 300 68.8 ± 2.5 0.064 ± 0.02 -26.6 15 91.8 ± 4.6
efficiency
(EE%)
-27.4 84.9 ± 3.3
103.3 ± 1.2
% Mass balance
for measuring EE% 
94.7 ± 0.6
108.8 ± 7.9
115.5 ± 1.8
 119
Figure 6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1:  Formation of Dox-ion-pair complex using STS as the ion-pair agent. Red 
precipitates (ppts) indicated that the ion-pair complex was formed in water when Dox 
solution was titrated with STS solution. At the specific ratio of STS to Dox (between 1.25 
to 1.5, mole/mole), over 95% of Dox formed the ion-pair complex.  
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Figure 6.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2:  Physical stability of Dox-loaded nanoparticles stored at 4ºC. Three 
different batches of Dox-loaded NPs with different compositions were monitored for 
particle size over one month. For all tested NPs, P.I. < 0.35. Data are presented as the mean 
particle size of three separate measurements for each batch.  
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Figure 6.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3:  Physical stability of Dox-loaded nanoparticles in PBS at 37ºC. Dox-loaded 
NPs were diluted with PBS and incubated at 37ºC. Particle size was monitored over time. 
For all tested NPs, P.I. < 0.35. Data are presented as the mean particle size of three 
separate measurements for each batch. 
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Figure 6.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4:  Release of Dox from Dox-loaded nanoparticles in PBS at 37ºC. Dox 
release was measured using the dialysis method in PBS. Data are presented as the mean ± 
SD (n=3). 
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Chapter 7 
 
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug 
resistance by inhibiting P-glycoprotein and ATP depletion 
 
7.1 Summary 
To test the ability of nanoparticle formulations to overcome P-gp-mediated 
multidrug resistance, several different doxorubicin and paclitaxel-loaded lipid NPs were 
prepared. Dox NPs showed 6-8-fold lower IC50 values in P-gp overexpressing human 
cancer cells than those of free Dox. The IC50 value of PX NPs was over 9-fold lower than 
that of Taxol in P-gp-overexpressing cells. A series of in-vitro cell assays were used 
including quantitative studies on uptake and efflux, inhibition of calcein 
acetoxymethylester (calcein AM) efflux, alteration of ATP levels, membrane integrity, 
mitochondrial membrane potential, apoptosis and cytotoxicity. Enhanced uptake and 
prolonged retention of Dox were observed with NP-based formulations in P-gp-
overexpressing cells. calcein AM and ATP assays confirmed that blank NPs inhibited P-gp 
and transiently depleted ATP. Intravenous injection of pegylated PX BTM NPs showed 
marked anti-cancer efficacy in nude mice bearing resistant NCI/ADR-RES tumors versus 
all control groups. NPs may be used to target both drug and biological mechanisms to 
overcome MDR via P-gp inhibition and ATP depletion. 
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7.2 Introduction 
Drug resistance is the major cause of failure of cancer chemotherapy. Multidrug 
resistance is a term used to describe the broad-spectrum resistance to chemotherapy in 
human cancer, which is a complex phenomenon that can result from several biochemical 
mechanisms that are still not fully understood [338]. A widely studied mechanism of MDR 
is that resulting from altered cell membrane transport. P-glycoprotein encoded by the mdr1 
gene is well-characterized and known to be a clinically important transporter protein 
belonging to the ATP-binding cassette family of membrane transporters [339]. It has been 
shown to pump substrates, including doxorubicin and paclitaxel, out of tumor cells through 
an ATP-dependent mechanism that reduces the effective drug concentrations and 
consequently decreases the cytotoxic activity. A large number of P-gp inhibitors have been 
developed. However, clinical trials have been disappointing due to the high inherent 
toxicities of P-gp inhibitors and/or changed pharmacokinetics and biodistribution 
properties of anti-cancer drugs co-administrated with P-gp inhibitors [340].  
Formulation strategies have been developed to potentially address P-gp-mediated 
resistance including colloidal delivery systems, polymer-drug conjugates, and polymeric-
micelles. Certain drug-loaded liposomes [235, 239] and solid lipid nanoparticles [251, 341] 
have been shown to decrease the resistance of P-gp-expressing cells in-vitro, which has 
been attributed to increased cellular accumulation of the drug. However, importantly, 
intracellular drug was still removed by P-gp efflux because formulations did not affect P-
gp function [256, 258]. Anti-cancer drugs conjugated to polymers such as pHPMA have 
been shown to effectively kill both sensitive and resistant cancer cells. Proposed 
mechanisms for these conjugates in resistant cells include internalization by endocytosis, 
partial inhibition of P-gp gene expression [342], and modification of caspase-dependent 
apoptosis signaling pathways [264]. Polymeric-micelles based on Pluronic, co-block 
polymers composed of poly(oxyethylene)-poly(oxypropylene), have been used to modulate 
P-gp in cancer cells [268, 276]. Pluronic micelles have been used to selectively inhibit the 
P-gp efflux system by ATP depletion in P-gp cells, as well as to reduce the GSH / GST 
detoxification system and to alter apoptotic signal transduction.  
Our laboratory has previously developed paclitaxel NPs wherein the drug was 
entrapped into NPs having E. wax as the oil phase and Brij 78 as the surfactant. These PX 
NPs were used to overcome P-gp-mediated resistance in-vitro in a human colon 
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adenocarcinoma cell line (HCT-15) [300] and in-vivo in a nude mouse HCT-15 xenograft 
model [319]. The purpose of the present study was to determine how improved PX NPs 
and new Dox NPs overcome P-gp-mediated resistance.  
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7.3 Materials and Methods 
 
Chemicals 
Doxorubicin hydrochloride, paclitaxel, sodium tetradecylsulfate (STS), sodium 
taurodeoxycholate (STDC), glyceryl tridodecanoate, calcein AM, Brij 700 and cyclosporin 
A were purchased from Sigma-Aldrich. E. Wax and stearyl alcohol were purchased from 
Spectrum Chemicals (Gardena, CA). Brij 78 was obtained from Uniqema (Wilmington, 
DE). TPGS was purchased from Eastman Chemicals. Polystyrene nanoparticles were 
purchased from Polysciences, Inc. 
 
Tumor cell lines and cell culture 
The P-gp-overexpressing human ovarian carcinoma cell line NCI/ADR-RES and 
sensitive cell line OVCAR-8 were both obtained from National Cancer Institute. The P-gp-
overexpressing human melanoma cell line MDA-MB-435/LCC6MDR1 and matching 
sensitive cell line MDA-MB-435/LCC6 were kindly provided by Dr. Robert Clarke 
(Georgetown University, Washington, DC). The sensitive human breast cancer cell line 
MDA-MB-468 was obtained from ATCC. All cells were maintained in exponential growth 
phase by periodic subcultivation. 
 
Preparation and characterization of Dox and PX nanoparticles 
Drug-loaded nanoparticles were prepared directly from warm o/w microemulsion 
precursors. PX NPs and Dox NPs were prepared and characterized as previously described 
in Chapter 4 and in Chapter 6, respectively. 
 
Preparation and characterization of concentrated pegylated PX BTM NPs 
To utilize PX BTM NPs for animal studies, PX BTM NPs containing a high 
concentration of PX were required to obtain the dose of 4.5 mg PX/kg with 200 µl of 
injection/mouse. PX BTM NPs were tested for their ability to be concentrated. Briefly, the 
concentrated NPs were prepared using 3-5 times of the amounts of all excipients and PX 
with the volume of water remaining unchanged. The resulting concentrated PX BTM NPs 
were measured for particle size. To test the ability of concentrated PX BTM NPs to pass 
0.2 µm sterile Millex-LG filters (Millipore), the light scattering counts of nanoparticles 
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were directly measured without any dilution. The concentration of PX in NPs was also 
measured by HPLC before and after passing through the 0.2 µm filters. To prepare 
concentrated pegylated PX BTM NPs for the in-vivo efficacy studies, 3-time concentrated 
PX BTM NPs containing 450 µg/ml of PX were chosen for pegylation using Brij 700 (8% 
w/w ratio of Brij 700 to Miglyol 812). To make an isotonic NP suspension and to avoid the 
generation of 7-epi isomer of PX, NPs were prepared in 10% lactose dissolved in water for 
injection. The pH value of the final 10% lactose solution was 5.4. Briefly, Brij 78 (2.8 
mg/ml), TPGS (1.5 mg/ml), and Miglyol 812 (2.5 mg/ml) were weighed out into a glass 
vial and heated to 70ºC. One (1) ml of 10% lactose solution pre-heated to 70ºC was added 
into the mixture of melted oils and surfactants. Spontaneously formed microemulsions 
were stirred for 15 min at 70ºC. Then, 200 µg Brij 700 dissolved in 10% lactose solution 
pre-heated to 70ºC were added to the warm microemulsions. The warm microemulsions 
were continually stirred for 10 min at 70ºC and then stirred for 4 h at room temperature to 
complete the insertion of Brij 700 into NPs. To prepare PX NPs, 450 µg of PX dissolved in 
ethanol were added directly to the melted oil and surfactant. After ethanol was evaporated 
using a nitrogen stream, the method described above was followed. The final NPs were 
passed through the sterile 0.2 µm filters. The concentrations of PX in NPs were measured 
before and after passing 0.2 µm filters, and PX entrapment efficiency was also measured 
after passing 0.2 µm filters using the HPLC assay.  
 
In-vitro cytotoxicity studies 
Cells were seeded into 96-well plates at 1.5 × 104 cells/well and allowed to attach 
overnight. Cells were incubated for 48 h with drug equivalent concentrations of all test 
articles ranging from 10,000 nM to 0.01 nM of free drug (corresponding to 5.45 µg/ml to 
5.45 pg/ml for Dox, and 8.54 µg/ml to 8.54 pg/ml for PX). The sulforhodamine B (SRB) 
assay was performed and IC50 values were calculated based on the percentage of treatment 
over control [324].  
 
Cellular uptake and efflux of Dox in cells 
Cells were seeded in 48-well plates at a density of 2 × 105 cells/well and incubated 
overnight. Confluent cell monolayers were washed with Earle’s balanced salt solution 
(EBSS) and treated with test articles. All samples were diluted with EBSS buffer and 
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adjusted to 5 µg Dox/ml or the Dox equivalent concentration. Cells were treated with 
samples at 37ºC for 0.5, 1 and 2 h. Cells were washed twice with ice-cold PBS pH 7.4 and 
lysed with PBS containing 1% Triton X-100 at 37ºC for 30 min. For efflux studies, cells 
were treated with each sample for 2 h, washed, and then cells were incubated with EBSS 
buffer at 37ºC for another 1, 2 and 4 h. Dox concentrations in cell lysates were measured 
by HPLC on an Inertsil ODS-3 column with a mobile phase consisting of 0.1 M 
ammonium formate containing 0.14 % triethylamine (adjusted pH to 2.4 by addition of 
formic acid)-acetonitrile-methanol-tetrahydrofuran (60:25:17.5:2.5, v/v/v/v) at a flow rate 
of 1.0 ml/min, and Dox was detected by fluorescence with 480/550 nm 
excitation/emission. Dox concentrations were normalized for protein content as measured 
with the BCA assay (Pierce) [343]. The cell efflux rate was calculated as: (uptake at 2 h – 
efflux at 4 h)/4.   
 
Calcein AM assay for P-gp function 
A calcein AM assay was performed using a modified method [344]. Briefly, cells 
were seeded in black 96-well plates at a density of 1 × 105 cells/well overnight and treated 
with 50 µl of various doses of test articles diluted in EBSS buffer. After 0.5 h at 37ºC, 50 
µl of 0.25 µM calcein AM (Sigma-Aldrich) were added into each well and the 
fluorescence of calcein was immediately measured every 5 min for 1 h using a microplate 
reader with 485/589 excitation/emission at room temperature. For pre-treatment 
experiments, cells were exposed to blank NPs #2 for 0.5 h and washed, and then 50 µl of 
fresh EBSS buffer was added before addition of calcein AM. The % relative fluorescence 
in the cells was expressed as: % Relative Fluorescence (FL) = [(FLtreatment – FLnontreatment)/ 
FLnontreatment] × 100%  
To assess cell membrane integrity, cells were treated with the same samples for 0.5 
h at 37ºC, and then incubated for 1 h at room temperature. Then, cells were trypsinized and 
50 µl of 0.4 % trypan blue solution was added. Membrane integrity was normalized to 
untreated control and expressed as (viable cells/total cells) × 100%.   
 
ATP and Apoptosis assays 
An ATP assay was performed as described previously [275]. Cells were seeded in 
48-well plates at a density of 2 × 105 cells/well and incubated overnight. Various doses of 
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test articles in EBSS buffer were added to cells and incubated at 37ºC for 2 h. After 
treatment, cells were washed twice with ice-cold PBS and lysed with PBS containing 1% 
Triton X-100 at 37ºC for 30 min. ATP in cell lysates was then measured using ATPlite 
1step Assay Kit (PerkinElmer) and normalized for protein content. Cell apoptosis under 
the tested conditions above was measured using the Annexin V-FITC Apoptosis Detection 
Kit I (BD Biosciences).  
To assess whether cells could recover from ATP depletion, cells were incubated 
with various concentrations of test articles for 2 h, washed, and then incubated for another 
4 h and 13 h, and then ATP levels and total proteins were measured.  
 
Histology studies by transmission electron microscopy (TEM) 
Cells were washed, scraped, and fixed in 4% buffered formalin, post-fixed in 2% 
osmium tetraoxide, and dehydrated in ascending concentrations of ethanol before 
embedded in Araldite 502. Blocks were sectioned at 1 µm and 800 Å for light and electron 
microscopy. Thin sections were stained with lead citrate and uranyl acetate before 
examined using a Philips 10 electron microscope operated at 60 kV.  
 
Mitochondrial potential measurement 
Cells were seeded in black 96-well plates at a density of 1 × 105 cells/well 
overnight and treated with test articles for 2 h at 37ºC. After washing, mitochondrial 
potential was detected using the JC-1 Mitochondrial Membrane Potential Detection Kit 
(Biotium). 1.5 or 0.15 µg/ml of PX BTM NPs and 6 µg/ml of cyclosporin A were used as 
positive and negative controls. Mitochondrial potential was expressed as (red FL/ green 
FL) treatment/ (red FL/ green FL) nontreatment × 100%.  
 
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay 
Resistant cells and their sensitive parental cells were seeded in 96-well plates as a 
density of 4 × 104 overnight and incubated with MTT and samples for 2 h at 37ºC. Two 
hundred microliters of reagent containing 20% SDS and 50% dimethyl formamide in water 
were added and incubated for 1 h at room temperature and plates were read at 570 nm 
(test) and 650 nm (reference). 
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In-vivo anti-cancer efficacy study using pegylated PX BTM NPs 
Female nude (nu/nu) mice, 4-5 weeks (Harlan Laboratories) were housed in a 
pathogen-free room. All experiments involving the mice were carried with an approved 
protocol by the University of North Carolina Animal Care and Use Committee. Two 
separate sets of in-vivo anti-cancer efficacy studies were performed.  
The first anti-cancer efficacy study: 
The mice were injected subcutaneously in the interscapular region with 4 × 106 
NCI/ADR-RES cells suspended in DMEM medium. When the tumors exhibited volume 
between 50 – 150 mm3 (Day -7), the mice were randomly assigned to different treatments 
at two different PX doses of 4.5 mg/kg and 2.25 mg/kg. Mice were injected with either 100 
or 200 μL of isotonic treatment article by intravenous injection. Tumors were measured in 
two perpendicular dimensions every two days for 12 days, and the tumor volume was 
calculated using the formula: V = (L × W2)/2, where L and W are the longest and shortest 
diameters, respectively.  
The second anti-cancer efficacy study 
Tumor models were set up as described above. When the tumors became a defined 
solid with the volume between 60 – 200 mm3 (Day -38), the mice were randomly assigned 
to different treatments at PX dose of 20 or 4.5 mg/kg. Mice were injected with 200 μL of 
isotonic treatment article by intravenous injection on day 0, 7, 14 and 21. On Day 30 after 
treatment, mice were sacrificed except the two Taxol groups and PX BTM NP group. On 
Day 31, mice in Taxol groups were treated with pegylated PX BTM NPs (4.5 mg PX/kg) 
every three days for a total of three times. Then, on Day 48, mice were retreated with 
pegylated PX BTM NPs (7.5 mg PX/kg) every three days for a total of three times. For PX 
BTM NP group, mice were monitored for tumor growth. On Day 48, mice were retreated 
with pegylated PX BTM NPs (7.5 mg PX/kg) every three days for a total of three times. 
Tumors were measured in two perpendicular dimensions and the tumor volume was 
calculated using the formula as above. 
 
Statistical analysis 
Statistical comparisons were made with ANOVA followed by pair-wise 
comparisons using Student’s t test using GraphPad Prism software. Results were 
considered significant at 95% confidence interval (p < 0.05). 
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7.4 Results  
Dox and PX nanoparticles 
The compositions and physicochemical properties of Dox and PX NPs are shown 
in Table 7.1.A and 7.1.B, respectively. PX could be entrapped directly into G78 NPs and 
BTM NPs. Dox ion-pair complexes with STDC were somewhat soluble in PBS that led to 
increased rates of Dox release from the NPs. In comparison, STS fully precipitated Dox at 
a mole ratio of 1:1.2 (Dox: STS) and resulted in an ion-pair complex that had both low 
solubility in PBS and high solubility in the melted oil phases. All NPs were stable over one 
month at 4°C (Figure 5.3 and Figure 6.2). 
 
Concentration and pegylation of PX BTM NPs for in-vivo efficacy studies 
 Blank BTM NPs and PX BTM NPs were concentrated to 3, 4 and 5 times of the 
original composition as presented in Chapter 4. The concentrated 3× NPs had particle sizes 
in the range between 170 nm and 200 nm, and the particle size 5× NPs was in the range 
between 200 to 230 nm. After passing through 0.2 µm filters, the light scattering counts for 
nanoparticle suspensions and the concentrations of PX changed less than 4%, indicating 
that concentrated blank BTM NPs and PX BTN NPs could pass 0.2 µm filters without the 
loss of nanoparticles (Table 7.2). Three-time (3×) concentrated PX BTM NPs containing 
450 µg/ml of PX were optimized to add Brij 700 for the in-vivo efficacy studies. The final 
optimized pegylated PX BTM NPs had particle sizes about 180 nm. Four batches of 
pegylated PX BTM NPs were prepared. The pegylated PX BTM NPs passed through 0.2 
µm filters without the loss of PX and the filtered pegylated PX BTM NPs had entrapment 
efficiency of PX higher than 95% (Table 7.3). 
 
In-vitro cytotoxicity studies 
Cytotoxicity data in two pairs of parental (sensitive) and P-gp cell lines are reported 
in Figure 7.1. As expected, in the tested Dox concentration range, free Dox showed no 
toxicity in NCI/ADR-RES cell line in the tested concentration range (IC50 > 5.45 µg/ml, 
corresponding to > 10,000 nM) and very low toxicity in MDA-MB-435/LCC6MDR1 cell 
line (IC50= 3.62 µg/ml, corresponding to 6643 nM) (Figure 7.1.A and 7.1.B). Dox-loaded 
NPs showed a clear dose-dependent cytotoxicity against all tested cell lines. In sensitive 
cell lines, the IC50 values of Dox-loaded NPs were comparable with those of free Dox. In 
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comparison, the IC50 values of Dox NPs #2 were 8-fold lower in NCI/ADR-RES cells 
(IC50s < 0.61 µg/ml, corresponding to 1111 nM) and in MDA-MB-435/LCC6MDR1 cells 
(IC50 < 0.45 µg/ml, corresponding to 821 nM) than those of free Dox. Blank NPs did not 
cause significant cytotoxicity against all cell lines up to a total NP dose of 30 µg/ml.  
Interestingly, the post-addition of Dox to blank NPs showed similar cytotoxicity to 
Dox NPs in both sensitive and resistant cell lines. Thus, to ascertain if this phenomenon 
was drug specific, PX G78 NPs and PX BTM NPs were tested for cytotoxicity in OVCAR-
8 and NCI/ADR-RES cells and compared with Taxol. As shown in Figure 7.1.C and 
Figure 7.1.D, the IC50 value of Taxol in NCI/ADR-RES cells was 495-fold greater (IC50= 
3.26 µg/ml, corresponding to 3814 nM) than that in sensitive cells (IC50= 0.00658 µg/ml, 
corresponding to 7.7 nM). Also, the IC50 value of both PX NPs was over 9-fold lower than 
that of Taxol in P-gp cells. Both blank NPs did not show significant cytotoxicity in these 
cell lines. Similar to when free Dox was post-added to blank NPs, the post-addition of free 
PX to blank G78 NPs or blank BTM NPs had comparable cytotoxicity to that of PX 
entrapped in NPs. The IC50 values of the post-addition were slightly lower than those of 
PX NPs in both cell lines; however, the difference was statistically significant (p < 0.05) 
only in the sensitive cells.  
 
Cellular uptake and efflux of Dox 
The uptake and efflux of Dox with various formulations containing 5 µg/ml of Dox 
was examined in both NCI/ADR-RES and MDA-MB-468 cells at different temperatures 
(Figure 7.2). Dox NPs #2 were chosen as the basic NP formulation for these studies. The 
uptake of Dox was time-dependent except when cells were pre-treated with blank NPs #2. 
In NCI/ADR-RES cell line at 37°C, NPs led to over a 2-fold increase in the extent of 
uptake compared with treatment with free Dox (Figure 7.2.A). Similarly, all treatments 
with NP formulations enhanced the retention of Dox. After cells were treated with Dox 
NPs #2, greater than 15-fold Dox remained in the P-gp cells and the efflux rate was 1.5-
fold lower compared with free Dox after 4 h of efflux. Importantly, the post-addition of 
Dox to blank NPs #2 also showed enhanced uptake and retention. To eliminate the 
possibility that Dox was quickly bound to the surface of blank NPs #2, cells were pre-
treated with blank NPs #2 and washed before the addition of free Dox. In this treatment, 
the uptake of Dox was very rapid and reached a maximum within 0.5 h and 7-fold greater 
 133
Dox was retained in cells compared with free Dox. However, the efflux rate of this 
treatment (0.19 [Dox](ng)/[protein](µg)/h) was significantly greater than that of free Dox 
(0.13 [Dox](ng)/[protein](µg)/h) (p < 0.05) (Figure 7.2.A). The uptake of Dox in 
NCI/ADR-RES cells at 4ºC with Dox NPs #2 and free Dox was 24-fold lower and 10-fold 
lower, respectively, than those at 37ºC. Unlike the uptake at 37°C that showed marked 
differences between NP groups and free Dox, the differences at 4°C were significantly 
reduced (Figure B.1). The extent of Dox uptake was also carried out in sensitive MDA-
MB-468 cells at 37°C. NP formulations showed greater uptake than free Dox as shown in 
Figure 7.2.B. In fact, the Dox NPs #2 very rapidly entered MDA-MB-468 cells and Dox 
from NPs quickly and extensively localized inside the nuclei of cells by fluorescence 
microscopy (Figure B.2).  
 To confirm that Brij 78 could also enhance Dox uptake and decrease efflux, 
NCI/ADR-RES cells were pre-treated with various concentrations of Brij 78 (Figure 
7.2.C). At the concentrations of Brij 78 that showed ATP depletion, pre-treatment of cells 
with Brij 78 led to comparable Dox uptake enhancement and efflux reduction compared 
with blank NPs #2 (Figure 7.2.A).   
 
Calcein AM assay 
The ability of blank NPs #2, and the Brij 78 and TPGS surfactants to inhibit P-gp 
was evaluated using the calcein AM assay in five resistant and sensitive cell lines (Figure 
7.3). Under all conditions tested, the trypan blue assay confirmed that there was no 
significant loss of cell membrane integrity (Figure B.3). In resistant cells, the fluorescence 
caused by intracellular calcein significantly increased in a dose-dependent manner either in 
the presence of blank BTM NPs (Figure B.4), blank NPs #2 (Figure 7.3.A and Figure 
7.3.B) or when cells were pre-treated with blank NPs #2 for 0.5 h (Figure B.5). Brij 78 and 
TPGS surfactants also led to a dose-dependent increase in calcein fluorescence over 1 h. In 
contrast, polystyrene NPs did not increase intracellular fluorescence. In stark contrast, no 
treatments led to increased intracellular fluorescence compared with calcein AM alone in 
the sensitive MDA-MB-468 cells (Figure B.6), OVCAR-8 cells (Figure 7.3.C) and MDA-
MB-435/LCC6 cells (Figure 7.3.D). However, the human melanoma MDA-MB-435/LCC6 
cells showed greater permeability as the uptake of calcein AM was higher in these cells.  
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ATP and Apoptosis Assays 
To further understand the mechanisms by which blank NPs and surfactants 
inhibited P-gp, intracellular ATP levels in cells were measured after exposure to various 
concentrations of blank NPs #2, Brij 78 and TPGS. In resistant NCI/ADR-RES and MDA-
MB-435/LCC6MDR1 cells, ATP levels decreased in a dose-dependent manner after 
treatment with blank BTM NPs (Figure B.7), blank NPs #2 and Brij 78 to 40%, 35% and 
20% of the initial value, respectively; however, there was no change in ATP levels after 
treatment with TPGS (Figure 7.4.A). Importantly, cyclosporin A and polystyrene NPs did 
not decrease ATP levels in the tested concentration range in NCI/ADR-RES cells. In 
contrast, over all tested concentrations in sensitive MDA-MB-468 and OVCAR-8 cells, 
only 0.5 and 1 µg/ml of Brij 78 and blank NPs #2 (Dox equivalent doses) decreased ATP 
levels to 86% and 65% of the initial value, respectively (Figure B.8). However, ATP levels 
decreased in MDA-MB-435/LCC6 cells, which had no significant difference with those in 
corresponding resistant cells (Figure B.8). Also, TPGS decreased ATP levels in this 
sensitive cell line (Figure B.8). In the presence of 17 µg/ml of cyclosporin A, ATP levels 
further decreased by an additional 20-40% at each concentration tested (Figure B.9). 
Finally, ATP recovery studies showed that after blank NPs #2 and Brij 78 were removed 
from NCI/ADR-RES cells, cellular ATP levels returned to 100% after 4 h for the lower 
concentrations tested and were completely restored after 13 h for all concentrations (Figure 
7.4.B).   
 Under the conditions analogous to the ATP depletion experiments, four 
concentrations of Dox-equivalent doses (0.5, 1, 2, and 5 μg/ml) for the Brij 78 and TPGS 
surfactants and blank NPs were tested for their ability to induce apoptosis versus control 
cells at 2 h in NCI/ADR-RES cells. Only blank NPs at 5 μg/ml showed significance versus 
control (p < 0.05), and these differences were modest (8% versus 6.7% for control).  
 
TEM 
MDA-MB-468, OVCAR-8 and NCI/ADR-RES cells are anchorage-dependent 
epitheloid cells. The effects of Dox on these cells seemed similar with the major changes in 
the degree of nuclear chromatin compaction. In NCI/ADR-RES and OVCAR-8 cells, Dox 
NPs #2 or blank NPs #2 treatment induced the most severe changes that included 
cytoplasmic accumulation of multivesicular bodies, chromatin condensation, and varying 
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degree of mitochondrial swelling. After 1 h of incubation, swollen mitochondria were 
frequently observed in the resistant cells treated with Dox NPs #2 or blank NPs #2 (Figure 
7.4.C). However, this effect was not observed in the sensitive MDA-MB-468 cells. In 
comparison, Brij 78 also produced mitochondrial swelling in NCI/ADR-RES and 
OVCAR-8 cells (Figure B.10). In human melanoma cells, MDA-MB-435/LCC6 and 
MDA-MB-435/LCC6MDR1, swollen mitochondria were also observed with the treatment 
of blank NPs #2 or Brij 78 (Figure B.10).  
 
Mitochondrial potential measurement 
Mitochondrial potential changed in all tested cells treated with blank NPs #2 and 
Brij 78 at the same concentrations that depleted ATP (Figure 7.4.D). TPGS did not change 
mitochondrial potential in all cell lines except in MDA-MDB-435/LCC6. All tested 
samples changed mitochondrial potential in MDA-MB-435/LCC6 cells except the 
treatment with 0.15 µg/ml of PX BTM NPs.  
 
MTT assay 
To a certain extent, all tested samples including blank NPs #2, Brij 78 and TPGS 
decreased MTT reduction in a dose-dependent manner, except at the lowest concentration 
of tested samples (0.05 µg/ml of Dox equivalent dose) (Figure B.11). The minimum value 
of MTT reduction at 1 µg/ml of Dox equivalent dose was 71 ± 8% (versus control) and 
observed in MDA-MB-435/LCC6 cells treated with blank NPs #2 (30 µg/ml).  
 
In-vivo anti-cancer efficacy study 
In the first study, tumor volume increased with control, Taxol and blank BTM NPs 
administration at the two PX or PX-equivalent doses tested. In comparison, a marked anti-
cancer effect of the pegylated PX BTM NPs was clearly observed (Figure 7.5). The tumor 
volume in the two tested pegylated PX BTM NPs groups almost did not change during the 
course of the study. A statistically significant difference of pegylated PX BTM NPs from 
all other treatments was observed from day 5 and continued to the end of the study. Blank 
BTM NPs did not show any clinical signs of toxicity even at the highest dose of 210 mg 
NPs/kg. 
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In the second study, tumor volume increased with control, blank BTM NPs, Taxol 
and the mixture of blank BTM NPs and Taxol administration. Taxol, at 20 mg PX/kg, is 
the maximum tolerate dose of Taxol in mice. However, only pegylated PX BTM NPs at 
the dose of 4.5 mg PX/kg, again, inhibited tumor growth (Figure 7.6.A). A statistically 
significant difference of pegylated PX BTM NPs from all other treatments was observed 
from day 7 and continued to the end of the study. After mice in Taxol groups were treated 
with pegylated PX BTM NPs, tumors became smaller (p < 0.05) (Figure 7.6.B). Although 
tumors continued growing after treatment ended, the second cycle of treatment with 
pegylated PX BTM NPs caused the tumors to shrink. The tumors in the PX BTM NP 
group started to grow after treatment (Figure 7.6.A). However, retreatment with pegylated 
PX BTM NPs in this group decreased tumor volume (Figure 7.6.C).  
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7.5 Discussion 
The objective of the present studies was to investigate the potential of drug-loaded 
lipid nanoparticles to overcome P-gp-mediated drug resistance, and to elucidate possible 
mechanisms. The results of the cytotoxicity studies indicate that all tested drug-loaded NPs 
significantly reduced IC50 values in P-gp-overexpressing ovarian and melanoma cell lines 
over free drug. Of interest was that the post-addition of free Dox to blank NPs also showed 
similar IC50 values compared to Dox-loaded NPs (Figure 7.1). This is a similar 
observation as reported by Némati and colleagues in which Dox-loaded 
polyalkylcyanoacrylate nanoparticles were used to treat sensitive and resistant leucemic 
murine cells [345]. This observation could be the result of two possibilities: 1) due to 
strong adhesive properties, Dox is adsorbed onto the surface of NPs [346], and 2) blank 
NPs could affect P-gp and therefore enhance the cytotoxicity of Dox. To test these two 
possibilities, PX was used because the neutral PX would be less likely to adhere to the 
slightly negatively charged NPs. In a similar manner as Dox NPs, free PX post-added to 
blank NPs showed comparable cytotoxicity as PX-loaded NPs. Temperature-dependent 
uptake of Dox NPs #2 in NCI/ADR-RES cells indicates an endocytosis pathway of NPs 
uptake. Obviously, nanoparticles not only enhanced the uptake of Dox but also improved 
the retention of Dox in resistant cell lines even if Dox was entrapped into NPs or 
physically present with blank NPs. More importantly, the uptake and retention of Dox 
increased when cells were pre-treated with blank NPs or free Brij 78 and then free Dox 
was added (Figure 7.2.A and Figure 7.2.C). These results are in contrast to a previous 
study that showed that the uptake and retention of Dox in MDA-MB-435/LCC6MDR1 
cells were not improved when free Dox was added to PLNs [256]. These contrasting 
studies seem to indicate a different and preferential mechanism of our NPs from the PLNs 
on P-gp. Taken as a whole, these studies prove that the lipid-based NPs described in the 
present studies inhibit the function of P-gp. Although a prior study suggested that an ion-
pair complex of Dox and polycyanoacrylic acid, a degradation product of 
polyalkylcyanoacrylate NPs, may increase the intracellular diffusion of Dox and result in 
increased efficacy of Dox NPs in resistant cells [347], the present study suggested that the 
ion-pairing agents likely did not affect P-gp directly since the IC50 of PX NPs prepared 
without ion-pair agents was also low (Figure 7.1.C and 7.1.D). According to the data, the 
factor that was the most influential was the inclusion of the surfactant Brij 78, but not 
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necessarily TPGS. In fact, it has been shown that some surfactants reverse the activity of 
P-gp and MRP2 [348]. In these studies, we showed that both Brij 78 and TPGS were able 
to increase calcein AM influx in P-g cells, but only Brij 78 was found to deplete ATP. 
Calcein AM is a non-fluorescent substrate of P-gp that, once in the cells, is irreversibly 
converted by cytosolic esterase to calcein, a non-permeable and fluorescent molecule. 
Thus, the increased intracellular fluorescence of calcein when P-gp cells were exposed to 
lipid-based NPs indicates the inhibition of P-gp function. Moreover, the integrity of 
membrane confirmed that the inhibition resulted from a selective interaction with P-gp 
rather than an unspecific membrane alteration which may increase doxorubicin transport in 
resistant cells. Additionally, the inhibition of P-gp by blank NPs was not related to 
nanoparticle size since polystyrene nanoparticles having the same particle size had no 
effect on the intracellular fluorescence (Figure 7.3.A). Since P-gp efflux is an energy-
dependent process, intracellular ATP levels were investigated. The results of the present 
studies demonstrate that exposure to blank NPs #2 induces a significant decrease in ATP 
levels in two resistant cells without inducing cell apoptosis. The effect of individual 
surfactant on ATP levels also was examined. It is clear that Brij 78, not TPGS, decreased 
ATP levels in resistant cell lines (Figure 7.4.A). Even at a very low actual concentration of 
4.5 µg/ml, which is well below the critical micelle concentration (CMC) of Brij 78 (860 
µg/ml), Brij 78 reduced the ATP levels after 2 h to 78% of the initial value. The ATP 
levels in sensitive cells responded differently to different cells. ATP levels only slightly 
changed in MDA-MB-468 and OVCAR-8 cells whereas ATP levels in MDA-MB-
435/LCC6 cells decreased to the same extent as with the corresponding resistant cells after 
treatment with either blank NPs #2 or Brij 78. Our findings on ATP depletion are in 
agreement with the previous reports from the Kabanov group that concluded that ATP 
depletion caused by Pluronic P85 block copolymer was one of the major reasons for 
reversal P-gp activity and dominant in P-gp cells [344, 349]. Moreover, Brij 78 had similar 
influence on enhanced Dox uptake and retention as compared to blank NPs #2 (Figure 
7.2.C). The results of the present study also suggested that reversal of P-gp function by 
ATP depletion caused by NPs was transient and reversible, based on ATP recovery studies 
(Figure 7.4.B) and uptake and efflux studies (Figure 7.2.A and Figure 7.2.C).  
Our previous studies suggested that Brij 78 could influence the activity of an 
alcohol dehydrogenase/NAD+ enzyme system in-vitro [318]. The mitochondria are 
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responsible for regulation of cellular metabolism, and also are the ATP factory in cells. 
Increase in matrix volume of mitochondria can be due to energetic stress inside cells [350, 
351]. It is important to note that the MTT reduction may not result from cell death because 
the apoptosis data and ATP recovery data showed that cells did not undergo apoptosis and 
that the ATP depletion was transient. Therefore, the MTT assay data more likely suggested 
a change in the cell metabolic activity or enzyme activity in the mitochondrial respiratory 
chain in treated cells [352, 353]. Therefore, it is likely that the metabolic activity was 
decreased in all cells treated with blank NPs #2 and Brij 78. Moreover, mitochondrial 
potential in resistant and sensitive cell lines changed at the same concentrations of blank 
NPs #2 or Brij 78 that depleted ATP. However, the change in mitochondrial potential and 
mitochondrial swelling did not destroy mitochondrial function as ATP levels returned to 
normal within 4-13 h depending on the dose (Figure 7.4.B). It is worthy to note that MDA 
MB-435/LCC6 cells showed both changes in ATP levels and mitochondrial potential. 
These effects may be related to the high permeability of the cell membrane as observed by 
the relatively high uptake of calcein AM (Figure 7.3.D). The change in the mitochondrial 
potential was correlated with mitochondrial swelling in all tested cells in these studies. 
Thus, it is possible that Brij 78 and NPs influence the enzymes involved in mitochondrial 
respiratory chain, and consequently produce energy stress in cells. As a consequence, the 
mitochondrial potential changes and the mitochondria swell to meet the energy 
requirement. These effects are likely pronounced in Pgp-overexpressing cells as they 
require more energy for P-gp expression and function.  
The current study suggested that there are at least two major reasons for enhanced 
cytotoxicity of Dox or PX-loaded lipid-based NPs in P-gp-mediated resistant cells: 1) 
increased extent of drug uptake by endocytosis of NPs which helps to partially bypass P-
gp; 2) decreased efflux rate of drug through inhibition of P-gp function and ATP depletion 
caused by Brij 78, a component of NPs. Both increase intracellular drug concentrations 
which is the key to overcome transporter mediated resistance.  
Pegylation is a common method to prepare “stealth” NPs to escape the RES 
system. Brij 700 containing a PEG moiety with a molecular weight 4400 was used to 
prepare pegylated PX BTM NPs. To achieve the high concentration of PX in NPs required 
for the in-vivo efficacy studies, PX BTM NPs were concentrated up to 5-times the original 
concentration. Pegylated PX BTM NPs containing 450 µg/ml of PX were successfully 
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prepared with the ability to pass through the 0.2 µm sterile filters. Two in-vivo anti-cancer 
efficacy studies in mice bearing resistant NCI/ADR-RES cell xenografts demonstrated that 
pegylated PX BTM NPs significantly inhibited tumor growth versus all tested controls. 
Taxol even at its maximum tolerate dose (20 mg PX/kg) did not inhibit tumor growth in 
current xenograft model. The blank BTM NPs also showed the ability to inhibit P-gp 
function and deplete ATP in-vitro. However, co-administration of blank BTM NPs and 
Taxol also did not inhibit tumor growth (Figure 7.6.A). Therefore, it is important to keep 
PX inside the NPs so that blank BTM NPs and PX could reach tumors at the same time for 
tumor inhibition, because ATP depletion caused by blank NPs is transient and reversible. 
For Taxol-failed groups, PX BTM NPs caused the tumors to shrink (Figure 7.6.B). It 
indicated that PX BTM NPs could be used to treat recurrent tumors. It was hypothesized 
that pegylated PX BTM NPs with a slow and sustained release profile of PX greatly took 
the advantage of the EPR effect to accumulate in tumors. By combining the benefit of 
blank BTM NPs to inhibit P-gp and deplete ATP, PX and P-gp inhibitors (blank BTM 
NPs) had synergized activity against tumor cells in order to overcome the resistance and 
inhibit tumor growth. Importantly, the BTM NPs were well tolerated by mice as mice did 
not show any clinical signs of toxicity even at the highest dose of 210 mg NPs/kg given 
weekly over four weeks and after several cycle treatments (Figure 7.6). This specific 
apparent lack of toxicity of BTM NPs distinguishes them from the common P-gp inhibitors 
which interact with drugs and have often resulted in additional side effects. Additional in-
vivo studies are on-going including pharmacokinetic and biodistribution studies, as well as 
additional efficacy studies in resistant and sensitive tumor mouse tumor models.  
In conclusion, both Dox and PX-loaded lipid-based NPs containing the Brij 78 
surfactant were shown to overcome P-gp-mediated drug resistance. The mechanism of P-
gp inhibition and ATP depletion distinguishes these Brij 78-based NPs from other known 
nanoparticles and liposome-based carrier systems. To the best of our knowledge, this is the 
first report on nanoparticles which can inhibit P-gp efflux and deplete ATP. Most 
importantly, NP-based carriers that effectively target both the drug and biological 
mechanisms to overcome MDR (P-gp inhibition and ATP depletion) appear to be a novel 
therapeutic strategy and additional in-vivo work is warranted. 
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Table 7.1 
Table 7.1.A. Compositions of Dox and PX NPs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final concentrations of Dox and PX in drug-loaded NPs were 300 µg/ml and 150 
µg/ml, respectively. 
 
Table 7.1.B. Summary of the physicochemical properties of Dox NPs and PX NPs 
 
 
 
 
 
 
 
 
 
 
 
 
Oil phases
(mg/ml)
Surfactants 
(mg/ml)
Formulations Ion-pair
E. wax Stearyl alcohol Glyceryltridodecanoate TPGS Brij 78
Dox NPs #1 STDC 2.0 - - 2.6 2.0
Dox NPs #2 STS 2.0 - - 2.6 2.0
Dox NPs #3 STS 2.0 - - - 4.0
Dox NPs #4 STS - 2.0 - - 4.0
PX G78 NPs none - - 1.7 - 4.0
PX BTM NPs none - - - 1.5 3.5
Miglyol 812
2.5
-
-
-
-
-
Formulations
Mean diameter
(nm)
% Drug loading 
(w/w, drug/oil)
% Drug entrapment 
efficiency
% Drug released 
in 2 h
Dox NPs #1 102.3 ± 3.9 10 87.2 77.0 ± 1.1
Dox NPs #2 103.3 ± 1.2 15 86.2 ± 5.9 45.5 ± 7.1
Dox NPs #3 84.9 ± 3.3 15 91.0 ± 5.9 56.9 ± 2.4
Dox NPs #4 68.8 ± 2.5 15 91.8 ± 4.6 52.8 ± 2.4
PX G78 NPs 138.7 ± 1.3 7.5 85.4 ± 3.3 5.5 ± 1.1
PX BTM NPs 177.3 ± 1.4 6 97.5 ± 2.6 8.7 ± 4.0
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Table 7.2 Characterization of concentrated PX BTM NPs  
before and after 0.2 µm filtration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulations
3x concentrated
Blank 
BTM NPs
Light 
scattering 
count (cps) 
before
4x concentrated 5x concentrated
PX     
BTM NPs
Blank 
BTM NPs
Blank 
BTM NPs
PX     
BTM NPs
PX     
BTM NPs
[% change 
before/after 
filtration]
[% change 
before/after 
filtration]
PX 
concentration 
(µg/ml) before
6.27 × 106 6.68 × 106 N.D 6.34 × 106 6.50 × 106 6.34 × 106
[-3.5%] [0%] [-0.3%] [-1.5%] [-3.9%]
504.5 ± 1.0 689.6 ± 1.5 773.7 ± 1.1
[-2.7%] [-0.3%] [-2.6%]
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Table 7.3 Characterization of 3× pegylated PX BTM NPs  
before and after 0.2 µm filtration 
 
 
 
 
 
 
 
 
 
 
a EE means entrapment efficiency. 
 
Formulations Batch #1
[% change 
before/after 
filtration]
PX 
concentration 
(µg/ml) before
449.3
[-1.7%] [-1.5%] [4.4%]
Batch #2 Batch #3 Batch #4
465.8 477.7 404.8
[-2.0%]
EE%  of PX 
in filtered 
pegylated PX 
BTM NPs
97 98 97 95
a
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Figure 7.1:  Dox and PX cytotoxicity studies at 48 h. IC50 values (µg/ml) of Dox and 
Dox NPs in (A) OVCAR-8 and NCI/ADR-RES cells, and (B) MDA-MB-435/LCC6 and 
MDA-MB-435/LCC6MDR1 cells. (C) IC50 values (µg/ml) of PX and PX G78 NPs in 
OVCAR-8 and NCI/ADR-RES cells. (D) IC50 values (µg/ml) of PX and PX BTM NPs in 
OVCAR-8 and NCI/ADR-RES cells. Data are presented as the mean ± SD of three 
independent experiments (N=3) with triplicate (n=3) measurements for each experiment. * 
p < 0.05; # and ## p > 0.05. “Drug equivalent dose” of NPs and excipients are calculated 
from the composition shown in Table 7.1. 
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Figure 7.2 
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Figure 7.2:  Cellular uptake and efflux of Dox in NCI/ADR-RES and MDA-MB-468 
cells.  (A) uptake and efflux in NCI/ADR-RES cells at 37ºC, and (B) uptake in MDA-MB-
468 cells at 37ºC. For pre-treatment experiments, cells were pre-treated with blank NPs #2 
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for 0.5 h before the next step. For efflux studies, cells were treated with samples for 2 h, 
and then re-incubated with fresh EBSS buffer for indicated time. (C) Dox uptake and 
efflux when cells were pre-treated with Brij 78 at concentrations of 45.3, 18.1, and 9.1 
µg/ml (corresponding to Dox-equivalent doses of 5, 2, and 1 µg/ml, respectively) for 0.5 h. 
Data are presented as the mean ± SD (n = 3). * p < 0.05 and # p > 0.05.  
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Figure 7.3 
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Figure 7.3:  Dose response of blank NPs #2 and surfactants in calcein AM assay in 
NCI/ADR-RES cells (A), MDA-MB-435/LCC6MDR1 cells (B), OVCAR-8 cells (C), 
and MDA-MB-435/LCC6 cells (D). Concentrations are presented as concentrations of 
blank NPs #2 (sum of mass of oils and surfactants) and as concentrations of free Brij 78 
and TPGS. Data are presented as the mean ± SD (n = 3).  
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Figure 7.4:  The effects of nanoparticles on ATP levels and mitochondria. (A) Effect 
of blank NPs #2 and surfactants on intracellular ATP level in NCI/ADR-RES cells and 
MDA-MB-435/LCC6MDR1 cells. (B) ATP recovery in NCI/ADR-RES cells for 4 h and 
13 h. Cells were treated with test samples for 2 h at 37ºC and then samples were removed 
from cells. Cellular ATP levels were measured after cells were continuously incubated in 
fresh medium for another 4 h and 13 h. Concentrations are presented as concentrations of 
blank NPs #2 (sum of mass of oils and surfactants) and as concentrations of free Brij 78 
and TPGS. Data are presented as the mean ± SD (n = 3). * p < 0.05 and # p > 0.05. (C) 
TEM analysis in NCI/ADR-RES, OVCAR-8 and MDA-MB-468cells treated with Dox NP 
#2, free Dox, and blank NP #2. Cells were treated for 1 h with samples containing Dox 
equivalent dose at 5 µg/ml. Treatment with Dox NPs #2 and blank NP #2 caused 
considerable mitochondria swelling in NCI/ADR-RES and OVCAR-8 cells, but not in 
MDA-MB-468 cells. The stars ( ) indicate multivesicular bodies, and the arrows (→) 
indicates mitochondria. Scale bar = 1 µm. (D) Mitochondrial potential measurement in 
NCI/ADR-RES cells and MDA-MB-435/LCC6MDR1 cells and their corresponding 
parental cells. Cells were treated with samples for 2 h at 37ºC. Mitochondrial potential 
detection was based on the ratio of red fluorescence caused by the accumulation of JC-1 in 
mitochondria and green fluorescence caused by the accumulation of JC-1 in the cytoplasm. 
The number before each label on x-axle indicates the concentration of tested samples 
(µg/ml). 
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Figure 7.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5:  The first in-vivo anti-cancer efficacy studies using pegylated PX BTM 
NPs in resistant mouse NCI/ADR-RES xenografts. On Day (-7), 18-19 g female nude 
mice (4 mice/group) received 4 x 106 cells by s.c. injection. Mice (n=4/group) were dosed 
i.v. with PX (4.5 or 2.25 mg/kg) by tail vein injection on day 0 and 7. The corresponding 
nanoparticle dose was 210 or 105 mg NPs/kg, respectively. Data are presented as the mean 
± SD. * p < 0.05 and # p > 0.05. 
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Figure 7.6 
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Figure 7.6:  The second in-vivo anti-cancer efficacy studies using pegylated PX BTM 
NPs in resistant mouse NCI/ADR-RES xenografts. (A) The anti-cancer efficacy study. 
On Day (-38), 18-19 g female nude mice (6-8 mice/group) received 4 x 106 cells by s.c. 
injection. Mice (n=6-8/group) were dosed i.v. with PX (20 or 4.5 mg/kg) by tail vein 
injection on day 0, 7, 14 and 21. (B) Retreatment of Taxol groups with PX BTM NPs. On 
Day 31, Taxol groups were retreated by i.v. injection with PX BTM NPs (7.5 or 4.5 mg 
PX/kg) for two cycles of treatments every three days for a total of three times per cycle. 
(C) Retreatment of the PX BTM NP group. On Day 48, PX NP group was retreated by i.v. 
injection with PX BTM NPs (7.5 mg PX/kg) every three days for a total of three times. 
“▲”indicates that mice were dosed i.v. with PX BTM NPs (4.5 mg PX/kg). “Δ” indicates 
that mice were dosed i.v. with PX BTM NPs (7.5 mg PX/kg). Data are presented as the 
mean ± SD. * p < 0.05 and # p > 0.05. 
 
 
*The contents of this chapter were published in Cancer Research, 69:3918-3926, 2009. X. 
Dong, C. A. Mattingly, M. T. Tseng, M. Cho, Y. Liu, V. R. Adams, and R. J. Mumper, 
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug 
resistance by inhibiting P-gp and depleting ATP.  
 
Copyright © Xiaowei Dong 2009 
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Chapter 8 
 
Summary and Conclusions 
 
 The overall goal of the studies presented herein was to investigate paclitaxel and 
doxorubicin-loaded nanoparticles to overcome P-gp-mediated drug resistance in solid 
tumors in-vivo after i.v. injection. The hypotheses driving this research were that: 1) the 
lipids used to form lipid nanoparticles could be metabolized in-vitro by alcohol 
dehydrogenase, 2) nanoparticles prepared from oil-in-water microemulsion precursors can 
be efficiently used to formulate paclitaxel and doxorubicin, 3) optimized nano-based 
paclitaxel and doxorubicin formulations will overcome P-gp-mediated tumor resistance in-
vitro, and 4) paclitaxel nanoparticles will have improved anti-tumor efficacy after i.v. 
injection compared to free PX solution in a nude mouse xenograft model bearing P-gp-
overexpressing cancer cells. 
 To test the metabolism of the lipids in NPs, an in-vitro study using horse liver 
alcohol dehydrogenase was carried out. The study demonstrated that the enzyme 
metabolized the lipids present in solid lipid nanoparticles. Over 80% of fatty alcohols in 
NPs were metabolized within 15 h in this in-vitro study. This result suggested that 
entrapping the lipids into solid nanoparticles did not hinder the reaction of the lipids with 
the enzyme. Moreover, the surfactant Brij 78 present in NPs influenced the activity of the 
enzyme.   
 In present studies, all NPs were prepared from oil-in-water microemulsion 
precursors. The water-insoluble drug PX was directly entrapped into lipid nanoparticles. 
The experimental design, a combination of Taguchi array and sequential simplex 
optimization, was efficiently used to develop Cremophor EL-free PX NPs. To our 
knowledge, this is the first report to use this combination method to optimize NP 
formulations via experimental design. Two injectable optimized PX NPs, including PX 
G78 NPs (with the solid oil glyceryl tridodecanoate) and PX BTM NPs (with the liquid oil 
Miglyol 812), were successfully developed. Both PX NPs had high drug loading and 
entrapment efficiencies with slow and sustained release profiles. Moreover, both PX NPs 
were physically stable at 4ºC and 37ºC. Further, both PX NPs showed similar in-vitro 
cytotoxicity compared to Taxol in human MDA-MB-231 breast cancer cells. Importantly, 
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PX BTM NPs showed unique features, such as, 1) the ability to be lyophilized without 
using cryoprotectants, 2) the ability to be easily sterilized by aseptic filtration with 0.2 µm 
filters, 3) the ability to potentially made “stealth” by adding 8% w/w/ Brij 700, and 4) good 
tolerability after i.v. injection in-vivo. Therefore, PX BTM NPs could be used as a novel 
PX formulation for i.v. injection to treat solid tumors. The water-soluble drug Dox was 
entrapped into lipid nanoparticles using an ion-pair complex. Several ion-pair agents were 
screened to quantitatively form the ion-pair complex with Dox. Finally, STS was identified 
as the most suitable ion-pair agent for Dox. Different compositions of NPs were developed 
for Dox NPs using STS as the ion-pair agent. All Dox NPs had high drug loading and 
entrapment efficiencies. However, relatively rapid release profiles of Dox were frequently 
observed in Dox NPs for all NP compositions. The variety of compositions of Dox NPs 
provided a number of samples to test the ability of NPs to overcome P-gp-mediated drug 
resistance in-vitro. These results support the hypothesis that NPs prepared from oil-in-
water microemulsion precursors can be efficiently used to formulate paclitaxel and 
doxorubicin. 
 In-vitro cytotoxicity studies were performed in two paired cancer cell lines 
including both sensitive and resistant cells. All developed PX and Dox NPs in the present 
studies were tested. In the sensitive cells, PX and Dox NPs showed the same or 
comparable cytotoxicity. In the P-gp-overexpressing resistant cancer cells, all of Dox NPs 
showed 6-8-fold lower IC50 values than those of free Dox, and PX NPs decreased IC50 
values up to 13-fold compared to free PX. Interestingly, even mixtures of blank NPs and 
free drugs showed similar cytotoxicity to drug-loaded NPs. To understand the mechanisms 
by which NPs could overcome P-gp-mediated resistance in-vitro, a series of in-vitro assays 
were carried out in both sensitive and resistant cells, including quantitative studies on 
uptake and efflux, inhibition of Calcein AM efflux, alteration of ATP levels, membrane 
integrity, mitochondrial membrane potential, apoptosis and MTT assay. Cellular uptake 
and efflux studies demonstrated that Dox NPs enhanced the uptake and prolonged the 
retention of the drug inside cells, and NPs entered cells by endocytosis pathways. Calcein 
AM and ATP studies demonstrated that blank NPs inhibited P-gp function and transiently 
depleted intracellular ATP. The surfactant Brij 78 could be the key component for ATP 
depletion. Further studies on apoptosis and mitochondria suggested that ATP depletion by 
blank NPs could be correlated to the enzyme activity in mitochondrial respiratory chain, 
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mitochondrial membrane potential, the observed swelling of the mitochondrial. The 
correlation was dominant in P-gp-overexpressing cancer cells. To the best of our 
knowledge, this is the first report on nanoparticles which can inhibit P-gp efflux and 
deplete ATP.   
In-vivo anti-cancer efficacy studies were performed in mice bearing NCI/ADR-
RES resistant tumors. To obtain “stealth” NPs which could escape the RES system, PX 
BTM NPs were pegylated with 8% w/w Brij 700 (based on the ratio of Brij 700 to the oil) 
using an optimized composition of PX BTM NPs. Two different doses of pegylated PX 
BTM NPs were used to treat these tumors after i.v. injection, and both of them 
significantly inhibited tumor growth compared to other control groups. Importantly, blank 
BTM NPs were well tolerated to mice. They did not show any clinical signs of toxicity 
even at the highest dose of 210 mg NPs/kg given weekly over three weeks. 
These in-vitro and in-vivo studies together support the hypotheses that optimized 
nano-based paclitaxel and doxorubicin formulations will overcome P-gp-mediated tumor 
resistance in-vitro, and paclitaxel nanoparticles will have improved anti-tumor efficacy 
after intravenous injection compared to free PX solution in a nude mouse xenograft model 
bearing P-gp-overexpressing cancer cells. It was demonstrated that blank NPs themselves 
were P-gp inhibitors. PX BTM NPs had a slow and sustained release profile. By 
combining the benefits of NPs, such as long circulation and ERP effect, the properties of 
these NPs to inhibit P-gp and deplete ATP provide significant potential and a novel 
strategy to the enhance anti-cancer efficacy of drugs in resistant tumors. Therefore, P-gp 
inhibitors (NPs) and the anti-cancer drug (PX) could reach tumor cells at the same time 
and work together. This unique property of PX NPs could greatly enhance the uptake and 
retention of the drug in these resistant tumors to improve the therapeutic responses.  
In conclusion, these studies highlight the potential application of PX and Dox-
loaded NPs prepared from oil-in-water microemulsion precursors for enhancing anti-
cancer efficacy of drug in P-gp-mediated resistant tumors. The combination of Taguchi 
array and sequential simplex optimization efficiently guided the development and 
optimizations of lipid-based PX NPs. Injectable PX NPs were successfully developed. 
Interestingly, PX BTM NPs could be lyophilized without cryoprotectants. Dox-loaded NPs 
were also prepared using an ion-pair strategy. PX and Dox-loaded NPs decreased IC50 
values in-vitro in resistant tumor cells compared to free drugs. Of significant importance is 
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the demonstration that blank NPs were P-gp inhibitors and depleted intracellular ATP 
levels, resulting in maintaining high intracellular drug levels in resistant cancer cells. The 
mechanism of P-gp inhibition and ATP depletion distinguishes these Brij 78-based NPs 
from other known nanoparticles and liposome-based carrier systems. In-vivo anti-cancer 
efficacy further demonstrated the potential of PX BTM NPs containing both an anti-cancer 
drug and a P-gp inhibitor to enhance therapeutic responses in resistant tumors. Therefore, 
the use of PX-loaded NPs could provide an excellent alternative and a novel therapeutic 
strategy to overcome P-gp-mediated drug resistance in solid tumors. 
The studies presented in the dissertation illustrate the potential application of drug-
loaded NPs for overcoming P-gp-mediated drug resistance and have established the 
underlying in-vitro mechanisms. However, additional experiments will be necessary to 
further characterize and optimize these systems. Although novel PX BTM NPs were 
developed, pegylation of PX BTM NPs was not well optimized in these studies, especially 
to make pegylated PX BTM NPs in 10% lactose for i.v. injection. Furthermore, the current 
mechanistic studies were based on in-vitro assays. It must be recognized that there are 
difference between in-vitro and in-vivo mechanisms. Additional in-vivo studies are needed 
to further understand why pegylated PX BTM NPs showed marked anti-cancer efficacy in 
resistant tumors. The answers discussed above, such as the utilization of EPR effect and 
synergetic action of blank NPs and drugs, are only hypotheses.  At this point, information 
on the biodistribution and pharmacokinetics of PX NPs are missing. In addition, other in-
vitro mechanistic studies are worthy of investigation. Besides inhibition of P-gp function, 
blank NPs may influence other biological responses such as GSH/GST detoxification 
system, cell apoptosis signaling and cellular defensive mechanisms (Table. 3.2). These 
further studies may provide new opportunities for NPs to overcome drug resistance caused 
by other mechanisms, not just P-gp-mediated resistance. Moreover, the present studies on 
the mechanism demonstrated that blank NPs depleted ATP. Most of transporters involved 
in MDR are ATP-dependent. Thus, it is worthy to test drug-loaded NPs in other 
transporter-mediated MDR, e.g. MRP-mediated resistance. NPs could overcome these 
MDR in term of the same mechanisms presented in the dissertation. These additional 
studies together could extend and reveal further improvements or alternative formulation 
approaches to overcome MDR.   
Copyright © Xiaowei Dong 2009 
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Appendices 
 
This section contains the following additional experiments:  
 
 
Appendix A: Development of TGF-α-coated nanoparticles to target EGF 
receptors in cancer cells 
Appendix B: Subset of figures in Chapter 7 
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Appendix A 
 
Development of TGF-α-coated nanoparticles to target  
EGF receptors on cancer cells 
 
A.1 Introduction 
EGFR is a cell surface transmembrane receptor overexpressed in various cancers 
and in many cases the extent of expression has been correlated with the stage of disease 
and poor prognosis. TGF-α, a biologically active polypeptide, is one of the ligands that 
bind to the EGF receptor. After TGF-α binding, the ligand-occupied EGFR is rapidly 
internalized in a process termed ligand-induced endocytosis, and TGF-α dissociates from 
EGFR very shortly after internalization. The recycling of EGFR to the cell surface will 
sustain the original ligand-binding ability of the cells.  
In previous sections, we developed new lipid-based BTM NPs. Pegylated PX-
loaded BTM NPs showed enhanced anti-cancer efficacy in mice bearing resistant 
xenograft tumors. To further improve the efficacy, this study investigated the active 
targeting delivery using TGF-α as a ligand attached on NP surface to target EGFR-
overexpressing cancer cells. BTM NPs were selected as the prototype NPs. TGF-α was 
first conjugated with tresylated Brij 700 (or Steareth-100) which contains a lipid chain and 
PEG moiety with molecular weight of 4400. Brij 700-TGF-α conjugate was coated on 
fluorescent-labeled BTM NPs by a post-insertion method. Cell uptake of targeted and non-
targeted fluorescent-labeled BTM NPs was quantitatively measured by a microplate reader 
and also evaluated by fluorescence microscopy.  
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A.2 Stability of TGF-α after exposure to different temperatures 
 TGF-α is a peptide with MW 5500 Da. Biological stability of TGF-α is a concern 
for the preparation and storage of TGF-α-coated NPs. To prepare TGF-α-coated NPs from 
microemulsion precursors, TGF-α needs to be heated at least for 10-20 min at 65ºC. Also, 
after TGF-α powder was reconstituted in an aqueous solution, the stability of TGF-α in the 
aqueous solution may become a problem. To understand the biological stability of TGF-α 
after exposure to different temperatures in the process of preparation of NPs, a competition 
binding assay of TGF-α was developed to evaluate binding activity of TGF-α to EGFR. 
The binding activity was used as an indicator for the biological stability of TGF-α for the 
targeting purpose.  
 The binding assay was performed in human epidermal carcinoma A431 cells which 
are known to overexpress EGFR (2×106 receptors/cell). A431 cells were seeded onto 96-
well plates at a density of 1×105 cells/well. The cells were incubated in 100 µl DMEM 
medium supplemented with 10% fetal bovine serum (FBS) at 37ºC for 24 h. The medium 
was removed and the cells were washed twice with binding buffer (DMEM containing 20 
mM HEPES, pH 7.4, and 0.1% BSA). TGF-α and EGF-Biotin samples were applied to 
cells in binding buffer. In saturation binding experiments, serial dilutions of EGF-Biotin 
were added into the wells. In competition binding experiments, mixtures of a fixed 
concentration of EGF-Biotin with different concentrations of TGF-α were added into the 
wells. A high concentration of EGF-Biotin was used to measure non-specific binding. 
After incubation for 2 h on ice, the cells were washed twice with binding buffer. A fixed 
concentration of HRP-conjugated streptavidin was added into each well and incubated for 
1 h at room temperature. The cells were then washed twice with ice-cold PBS 
supplemented with 0.1% BSA and twice with ice-cold PBS. One hundred microliters of 
TMB reagent were added to the wells and incubated for 15 min at room temperature, and 
then 100 µl of 2 M sulfuric acid were added to stop the reaction. The absorbance of each 
well was measured at 450 nm by a microplate reader. Each concentration was performed in 
duplicate. The binding constant (Kd) of EGF-Biotin was obtained using Prism by fitting the 
curve with non-linear regression and the inhibition constant (Ki) of TGF-α was calculated 
based on the competition binding assay using following equation: 
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where D is the concentration of EGF-Biotin, Kd is the binding constant of EGF-Biotin, and 
EC50 is the concentration of TGF-α at 50% of the maximum OD value. The saturation 
binding of EGF-Biotin and the competition binding of TGF-α are shown in Figure A.1.A 
and Figure A.1.B, respectively. The binding constant of EGF-Biotin to EGFR was 1.15 
nM. The inhibition constant of TGF-α was 15.6 nM. 
TGF-α was stored at room temperature and -4ºC for 24 h, -20ºC for one week, and 
was heated at 70ºC for 45 min, respectively. After these treatments, the competition 
binding was carried out for these treated TGF-α. The binding activities of TGF-α to EGFR 
were compared based on the binding constants of TGF-α.  Under all tested conditions, the 
results of the competition binding assays demonstrated that the inhibition constants of 
TGF-α had slight difference (Figure A.2). Therefore, the binding activity of TGF-α to 
EGFR remained the same after the treatments. 
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A.3 Conjugation of TGF-α with tresylated-Brij 700 
There are several ways to attach ligands on a NP surface. A common method called 
pre-insertion is to prepare activated NPs and then conjugate the ligand to the activated 
surface. This method sometime is problematic not only due to exposure of the 
functionalized NPs but also due to the possible reaction of the functional groups with other 
components on the NPs. A post-insertion method could avoid the problems from the pre-
insertion method. Thus, in these studies, the post-insertion method was utilized to attach 
TGF-α to the surface of NPs. First, the targeting ligand was conjugated to the 
functionalized terminus of PEG. Then, the lipid-PEG ligand conjugate was inserted into 
NPs using the lipid as an anchor. Generally, the ligand is covalently linked to a PEG, 
molecule that has been functionalized with a thiol-, amine-, or carboxyl- group.  However, 
the conjugation efficiency generally is not high. The hydroxyl group of PEG-sterol was 
activated with a tresyl group and reacted with the amine group on a protein [354]. After 12 
h, the conjugation of protein with the activated PEG-sterol was almost complete. In our 
lab, the hydroxyl group of the surfactant Brij 78 was functionalized using tresyl chloride. 
The tresylated Brij 78 further reacted with the primary amine of the model antigen 
ovalbumin (OVA) to yield Brij 78-OVA conjugate. Brij 700 containing a lipid chain and 
PEG moiety has a similar chemical structure with Brij 78 although the one difference 
between them is the length of PEG moiety which has molecular weight of 4400 in Brij 700 
and 880 in Brij 78. It was proposed that tresyl chemistry could be used to conjugate TGF-α 
to Brij 700, and that Brij 700 could improve the loading of TGF-α conjugate onto the 
surface of the BTM NPs. It has been reported that the A and C loops and the C-terminal 
tail of TGF-α contain residues that form the major binding interface with EGFR. To retain 
the activity of TGF-α, an N-terminal site-specific conjugation of TGF-α with PEG was 
desired. The competition binding assay was performed to evaluate the binding activity of 
TGF-α conjugate.  
Tresylated  Brij 700 (T-Brij 700) was synthesized as previously described with 
some modification [355]. Brij 700 (2.56 g) was dissolved in 20 ml of dichloromethane and 
incubated at 0ºC. One gram of tresyl chloride and 500 μl of pyridine were added to Brij 
700 solution by a drop-wise method. The reaction solution was stirred for 18 h at room 
temperature under nitrogen atmosphere. Then, the organic solvents were removed by a 
rotary evaporator and the precipitates were dissolved in 100 ml of ethanol acidized with 
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420 μl of HCl at room temperature. The solution was kept at -20ºC overnight. Reformed 
precipitates were centrifuged at -5ºC. After removing the supernatant, the precipitates were 
redissolved in 100 ml of acidic ethanol. The supernatant was tested for UV absorbance at 
255 nm for trace pyridine. The washing steps were repeated until the UV absorbance of 
pyridine was minimum and constant. The T-Brij 700 was dried over desiccators and stored 
at -20°C under nitrogen.   
To prepare Brij 700-TGF-α conjugate, 1.5 mg of T-Brij 700 and 180 µg of TGF-α 
(about 100:1 molar ratio, T-Brij 700: TGF-α) were mixed and dissolved into 600 µl of 0.1 
M HEPES buffer (pH 7.4). The reaction was kept for 18 h at room temperature. After 18 h 
reaction, the unreacted tresyl groups were blocked using 100 µl of 20 mM Tris-HCl buffer 
(pH 8.0) for 1 h. After reaction, free TGF-α and Brij 700-TGF-α conjugate were separated 
on a Sephedex G-100 column using 0.1M HEPES buffer pH 7.4 as the mobile phase. 
Thirty fractions (about 1 ml for each) were collected and tested using a Duoset ELISA kit 
for TGF-α (R&D System, Minneapolis, MN). In a separate experiment, 100 µg of free 
TGF-α were eluted from the same column to determine the fractions containing free TGF-
α. The chromatographs of free TGF-α and Brij 700-TGF-α conjugate were compared to 
estimate the conjugation efficiency. Fractions 1-8 containing the conjugate were 
concentrated using Centriplus YM-3 (MWCO 3000 Da) to 700 µl of the conjugate 
solution. The concentration of TGF-α in the conjugate solution was measured using a 
Duoset ELISA kit for TGF-α. The binding activity of the conjugate was tested using the 
competition binding assay so as to determine if the conjugate could compete with EGF-
Biotin for binding to the EGFR.  
Brij 700-TGF-α conjugate was successfully synthesized using tresyl chemistry as 
the band of Brij 700-TGF-α conjugate (MW 10 kDa) was clearly shown on the gel (Figure 
A.5). Very small fractions of free TGF-α in the solution of the conjugation were observed 
(Figure A.3). Moreover, on the gel, the band of free TGF-α was not detected in the solution 
of the conjugation (Figure A.5). These results indicated that the conjugation efficiency was 
high. Sixty seven (67) micrograms of TGF-α were detected in the 700 µl of final purified 
Brij 700-TGF-α conjugate. Therefore, the total conjugation yield was 29.3% (n=2). This 
low yield may be due to the lost of Brij 700-TGF-α conjugate during the process of the 
purification and concentration. The competition binding of Brij 700-TGF-α conjugate is 
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shown in Figure A.4. There was no difference in the inhibition constant of Brij 700-TGF-α 
conjugate compared to free TGF-α. 
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A.4 Preparation and characterization of TGF-α-coated BTM NPs containing 
BODIPY 558/568 C12 
 To efficiently load TGF-α on BTM NPs, the composition of the optimized BTM 
NP formulation for the in-vivo efficacy studies was used to make TGF-α-coated BTM 
NPs. To label BTM NPs with a fluorescent molecule, 50 µg/ml BODIPY 558/568 C12 
were entrapped into the BTM NPs. To prepare non-targeted BTM NPs containing 
BODIPY 558/568 C12, 2.5 mg of Miglyol 812, 1.5 mg of TPGS and 2.8 mg of Brij 78 
were weighed into a glass vial and heated to 65ºC. Fifty micrograms of BODIPY 558/568 
C12 dissolved in ethanol were added into the melted oil and surfactants. The ethanol was 
removed using a nitrogen stream. One (1) ml of filtered and D.I. water pre-heated at 65ºC 
was added into the mixture of melted oil and surfactants. The mixture were stirred for 20 
min at 65ºC and then cooled to room temperature. To prepare TGF-α-coated NPs, different 
volumes of water (950 µl, 900 µl or 800 µl) were, respectively, added into the melted 
excipients with BODIPY 558/568 C12 and stirred for 15 min at 65ºC, and then the Brij 
700-TGF-α conjugate at different volumes (50 µl, 100 µl or 200 µl) was added into the 
warm microemulsion to make a final volume of 1 ml TGF-α-coated NPs containing 
different concentrations of TGF-α. The warm microemulsion was continually stirred at 
65ºC for another 10 min before cooling to room temperature. After cooling, the NP 
suspension was stirred for 4 h at room temperature. The particle size and size distribution 
of NPs were measured using a N5 Coulter Submicron Particle Size Analyzer. To measure 
the entrapment efficiency of BODIPY 558/568 C12 in NPs, non-targeted BODIPY 
558/568 C12 BTM NPs were purified using a Centriplus Y-100 (MWCO 100 kDa). The 
non-purified and purified NPs were measured at 480 nm using a microplate reader to 
determine the entrapment efficiency of BODIPY 558/568 C12. To measure the loading 
efficiency of TGF-α in NPs, TGF-α-coated NPs were separated from the free Brij 700-
TGF-α conjugate using a Centriplus Y-100 and reconstituted to make a 1 ml suspension. 
The concentration of TGF-α in the filtrate was determined using the ELISA kit above and 
the loading efficiency of TGF-α was calculated. To evaluate the purification efficiency of 
the Brij 700-TGF-α conjugate and TGF-α-coated NPs, PAGE gel separation was 
performed using a tris-tricine natural gel. Defined amounts of free TGF-α, the reaction 
solution of the conjugation, purified Brij 700-TGF-α conjugate and 
 167
TGF-α-coated NPs were loaded into the well of Ready Gel 16.5% Tris Tricine gel (Bio-
rad, Hercules, CA). Also, TGF-α-coated NPs were heated for 30 min at 90ºC before loaded 
to the gel in order to release TGF-α from NPs and compared with non-heated TGF-α-
coated NPs. The gel was soaked into running buffer and a voltage of 100 v was applied for 
1.5 h. After separation, the gel was stained by SilverSNAP Stain kit (Pierce, Rockford, IL).  
All resulting NPs had particle sizes less than 220 nm. The entrapment efficiency of 
BODIPY 558/568 C12 in BTM NPs was 90%. Different concentrations of Brij 700-TGF-α 
conjugate were coated on BODIPY BTM NPs. The final concentrations of TGF-α and the 
loading efficiencies are shown on Table A.1. Up to 16.6 µg/ml of TGF-α were coated on 
the surface of BTM NPs with a loading efficiency higher than 80%. Also, gel 
electrophoresis showed that there was no free TGF-α or Brij 700-TGF-α conjugate in 
purified TGF-α-coated NP suspension (Figure A.5). After heating, TGF-α on TGF-α-
coated NP surface was released from Brij 700-TGF-α conjugate, or the Brij 700-TGF-α 
conjugate was released from NPs. Two clear bands, one for TGF-α (5.5 kDa) and the other 
for Brij 700-TGF-α conjugate (10 kDa), were shown on the gel for heated TGF-α-coated 
NPs.  
 168
A.5 Cellular uptake of TGF-α-coated BODIPY 558/568 C12 BTM NPs in 
NCI/ADR-RES and MDA-MB-468 cells 
NCI/ADR-RES or MDA-MB-468 cells were seeded in 48-well plates at a density 
of 2×105 cells/well overnight. After washing with PBS, cells were incubated with BTM 
NPs for 2 h. The NPs contained BODIPY 558/568 C12 (0.4 µg/ml) and had different 
concentrations of TGF-α on the surface. To test the influence of EGF on the targeting, EGF 
was added into TGF-α-coated NPs to compete with TGF-α in the uptake study. Then cells 
were washed with ice-cold PBS twice and lysed with PBS containing 1% Triton X-100. 
The fluorescence in the lysates was measured using a fluorescence microplate reader. The 
total proteins in cell lysates were measured by BCA assay. The uptake was normalized 
with protein content. Cellular uptake in NCI/ADR-RES cells was also measured using 
fluorescence microscopy.  
TGF-α-coated BTM NPs did not show enhanced uptake in both NCI/ADR-RES 
and MDA-MB-468 cells as shown in Figure A.6.A and Figure A.6.B as compared to non-
targeted BTM NPs (BL C12 BTM NPs) (p > 0.05). Actually, the uptake of TGF-α-coated 
BTM NP decreased when cells treated with the NPs containing the highest TGF-α 
concentration on the surface (p < 0.05) (Figure A.6.A). In the presence of EGF, the uptake 
also increased compared with non-targeted NPs. Moreover, TGF-α-coated NPs did not 
show stronger fluorescent density on the fluorescence images compared with non-targeted 
NPs (Figure A.7). Based on the uptake of non-targeted NPs in NCI/ADR-RES, the uptake 
of non-targeted BTM NPs was 27% of the total added NPs. This was a very high uptake 
ratio compared to other NPs in literature or even NPs #2 in Chapter 6 which normally had 
cellular uptake of about 5-10% of the total dose. Thus, it is possible that the reason for no 
difference between TGF-α-coated NPs and non-targeted NPs in the uptake study may be 
the high uptake of non-targeted NPs with no ligand.   
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A.6 Conclusions 
These studies demonstrated that the Brij 700-TGF-α conjugate could be 
synthesized using tresylated Brij 700. The Brij 700-TGF-α conjugate could be successfully 
coated on the surface of optimized BTM NPs with different concentrations of TGF-α. 
Moreover, BODIPY 558/568 C12 could be a suitable fluorescent molecule to label BTM 
NPs with very high entrapment efficiency. The cellular uptake studies indicated that uptake 
of TGF-α-coated BTM NPs was similar as that of non-targeted BTM NPs, probably due to 
the intrinsic high uptake of non-targeted BTM NPs.   
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Table A.1.  Characterization of TGF-α-coated BTM NPs containing different 
concentrations of TGF-α on the NP surface. 
(BT stands for Brij 700-TGF-α conjugate) 
 
 
 
 
 
 
Added BT into NPs (µl) 50 100 200
TGF-α on NPs (µg/ml) 4.3 7.6 16.6
Coating % 87.9 79.3 86.5
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Figure A.1 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure A.1:  The binding assays of EGF-Biotin and TGF-α in EGFR-overexpressing 
A431 cells. (A) Saturation binding of EGF-Biotin. (B) Competition binding studies 
between TGF-α and EGF-Biotin. Each experiment was done in duplicate.  
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Figure A.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TGF-α -20ºC TGF-α 4ºC TGF-α RT TGF-α 70ºC
Ki (× 10-8 M) 6.94 5.02 6.19 4.00 
 
 
Figure A.2:  Stability of TGF-α after exposure to various temperatures. The stability 
of TGF-α was indicated by the binding activity of TGF-α to EGFR measured by the 
competition binding assay. TGF-α was incubated at -20ºC for one week, 4ºC and room 
temperature overnight and at 70ºC for 45 min (to simulate NP preparation conditions). 
Each experiment was done in duplicate.  
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Figure A.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.3:  Separation of the Brij 700-TGF-α conjugate and free TGF-α on a 
Sephedex G-100 column. The mobile phase was 0.1 M HEPES buffer (pH 7.4). Free 
TGF-α started to be eluted after fraction 10. Fractions 1-8 were collected as the purified 
conjugate to prepare TGF-α-coated NPs.  
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Figure A.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.4:  Competition binding assay for the Brij 700-TGF-α conjugate compared 
with free TGF-α. The synthesized Brij 700-TGF-α conjugate shows similar binding 
activity as free TGF-α. Data are presented as the mean ± SD (n = 3). 
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Figure A.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.5:  PAGE gel separation of free TGF-α, the reaction solution of the 
conjugation, purified Brij 700-TGF-α conjugate and TGF-α-coated NPs. Separation 
was performed on a tris-tricine gel in a natural condition. The mixture of blank NPs and 
TGF-α was used as the control. TGF-α-coated NPs (purified and non-purified) were also 
heated for 30 min at 90ºC before loaded on the gel to release TGF-α or Brij 700-TGF-α 
conjugate from NPs.  
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Figure A.6 
A. 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
Figure A.6:  Uptake of TGF-α-coated BTM nanoparticles containing BODIPY 
558/568 C12 in NCI/ADR-RES cells (A) and MDA-MB-468 cells (B). Cells were seeded 
in a density of 2 × 105 cells/well on 48-well plates overnight. After washing with PBS, 
cells were incubated with BTM NPs containing different concentrations of TGF-α on the 
surface for 2 h. Then cells were washed with ice-cold PBS twice and lysed with PBS 
containing 1% Triton X-100. The fluorescence in the lysates was measured by a 
fluorescence microplate reader. The total proteins in cell lyses were measured by BCA 
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assay. The uptake was normalized with protein content. Data are presented as the mean ± 
SD (n = 3). # p > 0.05 and * p < 0.05. BT stands for Brij 700-TGF-α conjugate. 
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Figure A.7 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.7:  Uptake of TGF-α-coated BTM NPs and blank BTM NPs in NCI/ADR-
RES at 2 h. NPs contained BODIPY 558/568 C12 (yellow color). Cell nuclei were stained 
with 4', 6-diamidino-2-phenylindole dihydrochloride (Dapi, 0.17 µl/ml in PBS) (blue 
color).  
TGF-α-coated BTM NPs BL BTM NPs
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Appendix B 
 
Subset of figures in Chapter 7 
 
Figure B.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.1:  Cellular uptake of Dox in NCI/ADR-RES cells at 4ºC for 2 h. Cells were 
incubated with samples at 5 µg/ml of Dox equivalent doses for 2 h. The uptake of Dox at 
4ºC with Dox NPs #2 and free Dox was 24-fold lower and 10-fold lower than those at 
37ºC, respectively. The differences between NP groups and free Dox were significantly 
reduced at 4ºC. Temperature-dependent uptake of Dox NPs #2 in NCI/ADR-RES cells 
indicates an endocytosis pathway of NP uptake. Data are presented as the mean ± SD (n = 
3). 
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Figure B.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.2:  Uptake of Dox NPs #2 and free Dox in MDA-MB-468 cells after 15 min 
of incubation as observed by Cytoviva fluorescence microscopy. MDA-MB-468 cells 
(1 × 105 cells/well) in medium were plated onto glass coverslips and incubated overnight. 
After the coverslips were washed once with EBSS buffer, Dox NPs #2 and free Dox (5 
µg/ml of Dox equivalent doses) were added on the coverslips corresponding to a Dox 
weight of 20 µg. Images were obtained at room temperature after 15 min using 
fluorescence microscopy (Cytoviva). The results show that the Dox NPs #2 very rapidly 
entered MDA-MB-468 cells and Dox localized quickly and extensively inside the nuclei of 
cells.  
Dox NPs #2 Dox
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Figure B.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.3:  Membrane integrity of NCI/ADR-RES cells treated with blank NPs #2, 
Brij 78 and TPGS. The integrity of the cell membrane under the conditions of the Calcein 
AM assay was determined using the trypan blue exclusion assay. Cells were trypsinized 
and plated onto 96-well plates at a density of 1 × 105 cells/well in EBSS buffer. After cells 
were treated with the samples under the conditions of the Calcein AM assay, 0.4% trypan 
blue solution were added to evaluate the membrane integrity. Each sample was measured 
in triplicate. Concentrations of blank NPs #2, Brij 78 and TPGS were calculated based on 
Dox equivalent doses. 
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Figure B.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.4:  Dose response of blank G78 NPs and blank BTM NPs in Calcein AM 
assay in NCI/ADR-RES cells. Concentrations of blank G78 NPs and BTM NPs were 
calculated based on PX equivalent doses. Data are presented as the mean of triplicate 
measurements.  
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Figure B.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.5:  Dose response of blank NPs in Calcein AM assay in NCI/ADR-RES cells 
in pre-treatment conditions. Cells were pretreated with blank NPs #2, blank G78 NPs 
and blank BTM NPs for 0.5 h, respectively. Then blank NPs were removed and Calcein 
AM assays were performed. Concentrations of samples were calculated based on drug 
equivalent doses. Data are presented as the mean of triplicate measurements.  
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Figure B.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.6:  Dose response of blank NPs #2 and surfactants in calcein AM assay in 
MDA-MB-468 cells. Concentrations of blank NPs #2, Brij 78 and TPGS were calculated 
based on Dox equivalent doses. Data are presented as the mean of triplicate measurements.  
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Figure B.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.7:  The effects of blank G78 NPs and blank BTM NPs on ATP levels in 
NCI/ADR-RES cells. Concentrations of blank G78 NPs and blank BTM NPs were 
calculated based on PX equivalent doses. The ATP levels in NCI/ADR-RES cells 
decreased in a dose-dependent manner. These results demonstrate that blank G78 NPs and 
BTM NPs also had the ability to deplete ATP in P-gp-overexpressing cancer cells. Data are 
presented as the mean ± SD (n = 3). 
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Figure B.8 
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Figure B.8:  The effects of nanoparticles on ATP levels in sensitive human cancer cells 
including, (A) MDA-MB-468 cells, (B) OVCAR-8 cells and (C) MDA-MB-435/LCC6 
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cells. Concentrations of blank NPs #2, Brij 78 and TPGS were calculated based on Dox 
equivalent doses. The ATP levels in sensitive cells responded differently to different cells. 
ATP levels only slightly changed in MDA-MB-468 and OVCAR-8 cells whereas ATP 
levels in MDA-MB-435/LCC6 cells decreased to the same extent as with the 
corresponding resistant cells after treatment with either blank NPs #2 or Brij 78. Even 
TPGS, which had no influence in other sensitive cells, decreased ATP levels in MDA-MB-
435/LCC6 cells. Data are presented as the mean ± SD (n = 3). 
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Figure B.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.9:  The effects of blank NPs and Brij 78 on ATP levels in the present of P-gp 
inhibitor cyclosporin A in NCI/ADR-RES cells. In the presence of 17 µg/ml of 
cyclosporin A, ATP levels further decreased by an additional 20-40% at each 
concentration tested compared to the ATP levels tested without cyclosporin A. 
Concentrations of blank NPs #2 and Brij 78 were calculated based on Dox equivalent 
doses. 
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Figure B.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.10:  The effects of Brij 78 on mitochondria analyzed by TEM. OVCAR-8, 
MDA-MB-435/LCC6MDR1 and MDA-MB-435/LCC6 were treated with Brij 78 at 5 
µg/ml of Dox equivalent doses for 1 h at 37ºC. Brij 78 caused mitochondria swelling in all 
treated cells. Scale bar = 1 µm. 
OVCAR-8 MDA-MB-435/LCC6 MDA-MB-435/LCC6MDR1
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Figure B.11 
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Figure B.11:  The effects of blank NPs #2, Brij 78 and TPGS on MTT reduction in 
human cancer cells. MTT assays were performed in NIC/ADR-RES (A), MDA-MB-
435/LCC6MDR1 (B), OVCAR-8 (C) and MDA-MB-435/LCC6 (D) cells treated with 
blank NPs #2 and surfactants for 2 h. MTT reduction requires catalysis of the enzymes in 
mitochondrial respiratory chain. Blank NPs and surfactants dramatically decreased MTT 
reduction within 2 h treatments, indicating the influence of blank NPs #2 and surfactants 
on the enzyme activity involved in the mitochondrial respiratory chain. Concentrations of 
blank NPs #2, Brij 78 and TPGS were calculated based on Dox equivalent doses. 
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